hD54 polynucleotides

ABSTRACT

The present invention relates to a novel member of the D52 gene family, hD54. The genes and gene fragments of the present invention are themselves useful as DNA and RNA probes for gene mapping by in situ hybridization with chromosomes and for detecting gene expression in human tissues by Northern blot analysis and for the diagnosis and prognosis of breast cancer.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority benefit to U.S. Appl. No. 60/074,961, filed Feb. 17, 1998, which disclosure is herein incorporated by reference.

FIELD OF THE INVENTION

The present invention relates to genes expressed in breast carcinoma. In particular, the invention relates to a murine homolog and a novel isoform of a human gene expressed in breast carcinoma, and a novel member of the D52 gene family, hD54.

BACKGROUND OF THE INVENTION

D52 Gene Family

The human D52 (hD52) cDNA was initially cloned during a differential screening of a breast carcinoma cDNA library (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995)), and a hD52 cDNA (termed N8) was subsequently identified by differential display of mRNA from normal and tumor-derived lung cell lines (Chen, S-L., et al., Oncogene 12:741-751 (1996)). The hD52 gene was found to be overexpressed in approximately 40% of breast carcinomas, specifically in the cancer cells (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995)). Cloning of hD52 orthologues in other species has indicated that D52 proteins may participate in the calcium signaling cascade (Parente (Jr) et al., J. Biol. Chem. 271:20096-20101 (1996)) and the control of cell proliferation (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)).

Orthologues ofthe hD52 gene have been cloned from mouse (Byrne, J. A., et al., Genomics 35:523-532 (1996)), rabbit (Parente (Jr) et al., J. Biol. Chem. 271:20096-20101 (1996)), and Japanese quail (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)), and in situ hybridization mapping has indicated that the human and mouse D52 loci are syntenically conserved, having been localized to human chromosome 8q21 (Byrne, J. A. , et al., Cancer Res. 55:2896-2903 (1995)), and mouse chromosome 3A1-3A2 (Byrne, J. A. , et al., Genomics 35:523-532 (1996)), respectively.

The rabbit D52 homologue CSPP28 (calcium sensitive phosphoprotein of 28 kDa) was identified as being one of several proteins known to be phosphorylated in response to cholinergic stimulation of gastric parietal cells, and it was postulated that CSPP28 may participate in the calcium signaling cascade in a variety of rabbit tissues (Parente (Jr), J. A. , et al., J. Biol. Chem. 271:20096-20101 (1996)). In the Japanese quail (Coturnix coturnix japonica), a D52 homologue R10 was identified as the cellular sequence to which retroviral sequences were joined in chimeric transcripts amplified from in vitro cultures of proliferating neuroretinal cells infected with RAY-1 (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)). Thus, D52 may a represent signaling molecule of a calcium-sensitive signaling pathway mediating or associated with aspects of cellular proliferation. A role for both hD52 and hD53 in, or as markers of cell proliferation was also suggested by the observation that hD52 and hD53 transcript levels were decreased in HL60 and K562 leukemic cell lines, respectively, when these were cultured in the presence of 12-O-tetradecanoylphorbol-13-acetate (Byrne, J. A. , et al., Genomics 35:523-532 (1996)).

While the sequences of D52 proteins are highly conserved between species (Byrne, J. A. , et al., Genomics 35:523-532 (1996); Parente (Jr), J A., et al., J. Biol. Chem. 271:20096-20101 (1996); Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)), they exhibit insufficient homology with proteins of known function as to permit their inclusion in an existing protein family. That D52 represents the first member of a novel protein family was confirmed by the identification of the hD53 gene, whose predicted product is 52% identical/66% conserved with respect to hD52 (Byrne, J. A. , et al., Genomics 35:523-532 (1996)). The existence of hD53 was first indicated by several expressed sequence tags (ESTs) which showed significant levels of identity with regions of hD52 (Byrne, J. A. , et al., Genomics 35:523-532 (1996)). The corresponding cDNA clones were obtained, and one was used to isolate full-length cDNAs from the same breast carcinoma cDNA library used for the identification of the original hD52 cDNA (Byrne, J. A. , et al., Cancer Res. 55:2896-2903 (1995)). That hD53 transcripts derive from a separate gene was demonstrated by the distinct chromosomal localizations for the hD52 and hD53 loci, on human chromosomes 8q21 (Byrne, J. A. , et al., Cancer Res. 55:2896-2903 (1995)) and 6q22-q23 (Byrne, J. A. , et al., Genomics 35:523-532 (1996)), respectively.

The existence of a coiled-coil domain in D52-like molecules was predicted (Byrne, J. A. , et al., Genomics 35:523-532 (1996); Chen, S-L., et al., Oncogene 12:741-751 (1996) and; Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)), which in turn suggests that their functions involve protein-protein interactions. The coiled-coil domains of D52-like proteins are highly conserved both with respect to their sequences, lengths, and locations within D52-like proteins. That a functional relationship may exist between hD52 and hD53 gene products was indicated by examples of similar regulation of hD52 and hD53 transcript levels in both breast carcinoma and leukemic cell lines, despite the fact that hD52 and hD53 transcripts derive from separate genes located on independent chromosomes (Byrne, J. A. , et al., Genomics 35:523-532 (1996)). This suggestion of a functional relationship between hD52 and hD53, combined with the degree of conservation between their coiled-coil domains, and the fact that hD52 and hD53 could be either co- or independently expressed, led to the hypothesis that hD52 and hD53 proteins may be capable of both homo- and heteromer formation (Byrne, J. A. , et al., Genomics 35:523-532 (1996)).

Breast Cancer

Despite earlier detection and a lower size of the primary tumors at the time of diagnosis (Nyström, L. et al, Lancet 341:973-978 (1993); Fletcher, S. W. et al., J. Natl. Cancer Inst. 85:1644-1656 (1993)), associated metastases remain the major cause of breast cancer mortality (Frost, P. & Levin, R., Lancet 339:1458-1461 (1992)). The initial steps of transformation characterized by the malignant cell escape from normal cell cycle controls are driven by the expression of dominant oncogenes and/or the loss of tumor suppressor genes (Hunter, T. & Pines, J., Cell 79:573-582 (1994)).

Tumor progression can be considered as the ability of the malignant cells to leave the primary tumoral site and, after migration through lymphatic or blood vessels, to grow at a distance in host tissue and form a secondary tumor (Fidler, I. J., Cancer Res. 50:6130-6138 (1990); Liotta, L. et al., Cell 64:327-336 (1991)). Progression to metastasis is dependent not only upon transformation but also upon the outcome of a cascade of interactions between the malignant cells and the host cells/tissues. These interactions may reflect molecular modification of synthesis and/or of activity of different gene products both in malignant and host cells. Several genes involved in the control of tumoral progression have been identified and shown to be implicated in cell adhesion, extracellular matrix degradation, immune surveillance, growth factor synthesis and/or angiogenesis (reviewed in, Hart, I. R. & Saini, A., Lancet 339:1453-1461 (1992); Ponta, H. et al., B.B.A. 1198:1-10 (1994); Bernstein, L. R. & Liotta, L. A., Curr. Opin. Oncol. 6:106-113 (1994); Brattain, M. G. et al., Curr. Opin. Oncol. 6:77-81 (1994); and Fidler, I. J. & Ellis, L. M., Cell 79:185-188 (1994)).

However, defining the mechanisms involved in the formation and growth of metastases is still a major challenge in breast cancer research (Rusciano, D. & Burger, M. M., BioEssays 14:185-194 (1992); Hoskins, K. & Weber, B. L., Current Opinion in Oncology 6:554-559 (1994)). The processes leading to the formation of metastases are complex (Fidler, I. J., Cancer Res. 50:6130-6138 (1990); Liotta, L. et al., Cell 64:327-336 (1991)), and identifying the related molecular events is thus critical for the selection of optimal treatments.

SUMMARY OF THE INVENTION

The present inventors have identified a novel isoform of hD53, +5 hD53; the murine homolog of hD53, mD53; and a novel member ofthe D52 gene family, hD54.+5hD53, mD53, and hD54 are useful as breast cancer prognosticators.

Accordingly, the present invention provides isolated nucleic acid molecules encoding the +5 hD53, murine (m) D53, or hD54 polypeptides whose amino acid sequences are shown in FIGS. 1, 3, and 16, respectively. Further embodiments of the invention include isolated nucleic acid molecules that are at least 90% and preferably at least 95%, 96%, 97%, 98% or 99% identical the above-described isolated nucleic acid molecules of the present invention.

The present invention also relates to vectors which contain the above-described isolated nucleic acid molecules, host cells transformed with the vectors and the production of+5 hD53, mD53, or hD54 polypeptides or fragments thereof by recombinant techniques.

The present invention further provides an isolated +5 hD53, mD53 or HD54 polypeptide having the amino acid sequence as shown in FIG. 1, 3, or 16, respectively.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. FIG. 1 shows the cDNA (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO:2) of +5 hD53.

FIG. 2. FIG. 2 shows a comparison of the amino acid sequences of +5 hD53 (SEQ ID NO:2) and hD53 (SEQ ID NO:9).

FIG. 3. FIG. 3 shows the cDNA (SEQ ID NO:3) and deduced amino acids sequence (SEQ ID NO:4) of mD53.

FIG. 4. FIG. 4 shows a comparison of the amino acid sequences of mD53 (SEQ ID NO:4) and hD53 (SEQ ID NO:9).

FIG. 5. FIG. 5 shows the global alignment of D52-like sequences tested in the yeast two-hybrid system, as produced by the program CLUSTAL (Thompson, J. D., et al., Nucleic Acids Res. 22:4673-4680 (1994)): mD52 (SEQ ID NO:11), hD52 (SEQ ID NO:13), hD53 (SEQ ID NO:9), hD54+ins2 (SEQ ID NO:6), hD54−ins2 (SEQ ID NO:15) and hD54T (SEQ ID NO:17). The coiled-coil domain predicted in each D52-like protein is shown in bold. Two alternatively-spliced regions, ins2 and ins3, are indicated, and the hD54T amino acid sequence which shows no similarity to other D52-like sequences (due to a frame-shift in the corresponding cDNA sequence) is underlined. Numbers refer to sequence positions of the first and last amino acids shown in each line.

FIGS. 6A-6E. FIGS. 6A-6E show the interactions between GST-niD52 and in vitro-translated D52-like proteins in GST pull-down assays, as demonstrated by Coomassie Brilliant Blue staining (B, D) and autoradiographic exposure (C, E) of proteins eluted from glutathione-agarose. In vitro translation reactions included pTL1 constructs bearing no insert (lane 1), or mD52 (lane 2), hD52 (lane 3) or hD54−ins2 (lane 4) coding sequences. (A) ³⁵S-labelled protein resulting from in vitro translation of pTL1 constructs. In vitro translation of mD52 and hD52 coding sequences gave single 28 kDa ³⁵S-labelled proteins (lanes 2 and 3), whereas in vitro translation of the hD54−ins2 coding sequence gave a single 31 kDa ³⁵S-labelled protein (lane 4). (B) Coomassie blue-stained GST protein (26 kDa) eluted from glutathione agarose. (C) Autoradiographic exposure (10 days) of the same gel indicate that in-vitro translated D52-like proteins were not retained on glutathione-agarose to which GST had been bound. (D) Coomassie blue-stained GST-mD52 protein (47 kDa) eluted from glutathione agarose. (E) Autoradiographic exposure (10 days) of the same gel indicated that it-vitro translated D52-like proteins were retained on glutathione-agarose to which GST-mD52 had been bound.

FIG. 7. FIG. 7 shows an idiogram of the WMP mouse Rb (Taylor, B. A., et al., Mamm. Genome 6:S190-S200 (1996)) chromosome indicating the distribution of labeled sites on chromosome 10 using the mD53 cDNA probe. In the 100 metaphase cells examined, there were 204 silver grains associated with chromosomes and 47 of these (23%) were located on chromosome 10. The distribution of grains on chromosome 10 was not random, 37/47 (78.7%) of them mapping to the A4-B2 region.

FIGS. 8A-8B. Global alignment of hD52 (SEQ ID NO:13), R10 (SEQ ID NO:19) (Proux, V., et al, J. Biol Chem. 271:30790-30797 (1996)), hD53 (SEQ ID NO:9), 192334 (SEQ ID NO:8), hD54+ins2/H11/L12 (SEQ ID NO:6), hD54−ins2/G11 (SEQ ID NO:15), hD54T/D12/D1A (SEQ ID NO: 17) amino acid sequences. Four insertions of 4 or more residues are shown in bold and labeled ins1, ins2, ins3 and ins4. The coiled-coil domain of hD54 is boxed. The C-terminal 42 amino acids of the hD54T/D12/Db1A sequence which shows no homology with the other D52-like sequences aligned is shown in italics.

FIG. 9. Variation within hD54+ins2, hD54−ins2, hD54T nucleotide (SEQ ID NOs:5, 14, and 16, respectively) and deduced amino acid sequences (SEQ ID NO:6, 15, and 17, respectively). Arrows border nucleotide sequences that are present in hD54+ins2 but not in hD54−ins2 or hD54T. The 3 nucleotides before and after alternative coding sequences are shown in bold with a line above or below the sequence.

FIG. 10. Alignment of the D52 motifs present in the sequences of D52-like proteins: hD52 (SEQ ID NO:13), mD52 (SEQ ID NO:11), CSPP28 (SEQ ID NO:20)(Parente (Jr), J A., et al., J. Biol. Chem. 271:20096-20101 (1996)), R10 (SEQ ID NO:19) (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)), hD53 (SEQ ID NO:9), mD53 (SEQ ID NO:4), hD54−ins2 (SEQ ID NO: 15) and hD54+ins2 (SEQ ID NO:6). The consensus sequence (SEQ ID NO:21) is shown below these sequences, and residues which are conserved in accordance with this consensus are shown in bold. hD54+ins2 (1) and hD54+ins2 (2) refer to the more N- and C-terminal D52 motifs respectively, created by the presence of ins2.

FIG. 11. Mapping of the hD54 locus to chromosome 20ql3.2-ql3.3. Idiogram of human chromosome 20 illustrating the distribution of labeled sites obtained with the 192334 cDNA.

FIGS. 12A-12C. RT-PCR analysis of D54 coding sequence heterogeneity. PCR products obtained by amplification of rat D54 regions flanking sequences encoding (A) ins1, (B) ins2 and (C) ins3&4. Letters above each lane in panel A refer to the tissue used in reverse transcriptase cDNA synthesis reactions (b, brain and l liver). Results obtained in brain or liver were representative of those obtained in skeletal muscle, cardiac atrium, stomach, testis and kidney samples, at the respective developmental time-points examined. Plus symbols appear above lanes where the template for PCR reactions was hD54 cDNA (hD54+ins2/H11, panels A, B and C, and additional lane, hD54−ins2/G11, panel B). PCR control reactions where cDNA template was emitted are indicated by a minus symbol. Size markers and PCR product sizes are indicated in bp to the left and right of each panel, respectively. Alignments of PCR product sequences with hD54 (SEQ ID NO:5) or 192334 (SEQ ID.NO:7) sequence regions are shown below each panel. Ins1, ins2 and ins3 sequences, and the nucleotide sequences encoding these, are shown in bold. Nucleotide sequences of PCR products are translated below each sequence, with residues underlined being predicted by all nucleotide sequences in each alignment.

FIGS. 13A-13C-1. RT-PCR analysis of D52 coding sequence heterogeneity. PCR products obtained by amplification ofrat D52 regions flanking sequences encoding (A) ins 1, (B) ins2 and (C, C-1) ins3&4. Letters above each lane in panel A refer to the tissue used in reverse transcriptase cDNA synthesis reactions (b, brain and 1, liver). Results obtained in liver represent those obtained in skelet al muscle, cardiac atrium, stomach, testis and kidney samples, at the respective developmental time-points examined. A plus symbol appears above lanes where the template for PCR reactions was mD52 cDNA. PCR control reactions where cDNA template was omitted are indicated by a minus symbol. Size markers and PCR product sizes are indicated in bp to the left and right of each panel, respectively. Alignment of PCR product sequences with mD52 sequence (SEQ ID NO:10) and R10 (SEQ ID NO:18) regions are shown below each panel. Ins3 sequences, and the nucleotide sequences encoding these, are shown in bold. Nucleotide sequences of PCR products are translated below each sequence, with residues underlined being predicted by all nucleotide sequences in each alignment.

FIGS. 14A-14B-1. RT-PCR analysis of D53 coding sequence heterogeneity. (A) PCR products obtained by amplification of rat D53 regions flanking sequences encoding ins1, ins2 and ins3&4. Letters above each lane refer to the adult rat tissue used in reverse transcriptase cDNA synthesis reactions (a, cardiac atrium, s, stomach, l liver and k, kidney). A plus symbol appears above lanes where the template for PCR reactions was mD53 cDNA. PCR control reactions where cDNA template was omitted are indicated by a minus symbol. Size markers and PCR product sizes are indicated in bp to the left and right of each panel, respectively. (B, B-1) Alignments of PCR product sequences with mD53 (SEQ ID NO:3) sequence regions. Ins3 and ins4 sequences, and the nucleotide sequences encoding these, are shown in bold. Translated amino acid sequences appear above or below their corresponding nucleotide sequences, with residues underlined being predicted by all nucleotide sequences in each alignment.

FIG. 15. The hD52 EST W25876. Alignment of hD52 (SEQ ID NO:12) (Byrne, J. A. , et al., Cancer Res. 55:2896-2903 (1995)), W25876 (SEQ ID NO:38) and R10 (SEQ ID NO:18) (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)) nucleotide sequences. The translated R10 amino acid sequence (SEQ ID NO:19) appears below the alignment, with residues underlined being also predicted by hD52 and W25876 sequences. Sequence insertions present in W25876 with respect to the hD52 sequence (nucleotides 82-151 and 254-419) are labeled above the alignment. Ins3 sequences and the nucleotide sequences encoding these, are shown in bold.

FIGS. 16A-16B. The nucleotide (SEQ ID NO: 5) and deduced amino acid (SEQ ID NO:6) sequence of hD54.

FIGS. 17A-17C. ESTs with homology to D53: AA182908 (SEQ ID NO:63), W93489 (SEQ ID NO:64), AA240722 (SEQ ID NO:65), AA278103 (SEQ ID NO:66), AA066421(SEQ ID NO:67), T89899 (SEQ ID NO:68), T93647 (SEQ ID NO:69), W69680 (SEQ ID NO:70), AA055718 (SEQ ID NO:71), T68402(SEQ ID NO:72), W11611 (SEQ ID NO:73), W14257 (SEQ ID NO:74), and N99206 (SEQ ID NO:75).

FIGS. 18A-18G. ESTs with homology to D54: AA004043 (SEQ ID NO:76), AA008731 (SEQ ID NO:77), AA031903 (SEQ ID NO:78), AA103819 (SEQ ID NO:79), AA124904 (SEQ ID NO:80), W10501 (SEQ ID NO:81), W20813 (SEQ ID NO:82), W54810 (SEQ ID NO:83), W66669 (SEQ ID NO:84), W82290 (SEQ ID NO:85), W91446 (SEQ ID NO:86), W97219 (SEQ ID NO:87), AA218395 (SEQ ID NO:88), AA268015 (SEQ ID NO:89), AA266320 (SEQ ID NO:90), AA255184 (SEQ ID NO:91), W75292 (SEQ ID NO:92), AA048792 (SEQ ID NO:93), H31879 (SEQ ID NO:94), AA277778 (SEQ ID NO:95), W13944 (SEQ ID NO:96), H39077 (SEQ ID NO:97), AA411964 (SEQ ID NO:98), AA124922 (SEQ ID NO:99), AA 16313 (SEQ ID NO:100), W75408 (SEQ ID NO:101), and AA436748 (SEQ ID NO:102).

DETAILED DESCRIPTION OF THE INVENTION

+5 hD53, mD53, and hD54 Nucleic Acid Molecules, Polypeptides and Fragments Thereof

The present inventors have identified an isoform of hD53, termed +5 hD53, from a human breast carcinoma cDNA library. D53 was described in WO97/06256, which is herein incorporated by reference.

The present inventors have also identified a mouse cDNA exhibiting a high level of homology to the hD53 cDNA. The mouse D53 (mD53) cDNA was isolated from an embryonic stem cell cDNA library using an 842 bp hD53 cDNA as a probe (Byrne, J. A. , et al., Genomics 35:523-532 (1996)). The 1307 bp mD53 cDNA (SEQ ID NO:3) includes a 615 bp coding region which predicts a 204 amino acid protein (SEQ ID NO:4). The hD53 and mD53 proteins are predicted to be 91% identical/93% conserved, and as such are more highly conserved than the majority of orthologous mouse and human proteins (Makalowski, W., et al., Genome Res. 8:846-857 (1996)).

The present inventors have also identified a novel member of the D52 family, D54. The 2302 bp hD54 cDNA (SEQ ID NO:4) includes a 621 bp coding region which predicts a 206 amino acid protein (SEQ ID NO:5). The polypeptide sequence of hD54 is 56% and 51% identical/67% and 60% similar to those of hD52 and hD53, respectively.

+5hD53, mD53 and hD54 are useful as breast cancer prognosticators, as described for D52 family members in WO97/06256, which is herein incorporated by reference.

Using the information provided herein, such as the nucleotide sequences of +5 hD53, mD53 or hD54 as set out in FIGS. 1, 3, and 16, respectively (SEQ ID NOS:1, 3, and 5), an isolated nucleic acid molecule of the present invention may be obtained using standard cloning and screening procedures, such as those for cloning cDNAs using mRNA as starting material.

By “isolated” nucleic acid molecules(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a vector are considered isolated for purposes of the invention as are recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vitro RNA transcripts of the DNA molecules of the present invention. By “isolated” polypeptide or protein is intended a polypeptide or protein removed from its native environment. For example, recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for purposes of the invention, as are native or recombinant polypeptides which have been partially or substantially purified by any suitable technique such as, for example, the single-step purification method disclosed in Smith and Johnson, Gene 67:31-40 (1988). Isolated nucleic acid molecules and polypeptides also include such compounds produced synthetically.

As indicated, nucleic acid molecules ofthe present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double- or single-stranded. Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be the noncoding strand, also referred to as the antisense strand.

+5 hD53

The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding the +5 hD53 polypeptide whose amino acid sequence is shown FIG. 1 (SEQ ID NO:2) or a fragment thereof Such isolated nucleic acid molecules include DNA molecules comprising an open reading frame (ORF) starting at position 1 of the nucleotide sequence of FIG. 1 (SEQ ID NO:1) and further include DNA molecules which comprise a sequence substantially different than all or part of the ORF starting at position 1 of the nucleotide sequence of, FIG. 1 (SEQ ID NO:1) but which, due to the degeneracy of the genetic code, still encode the +5 hD53 polypeptide or a fragment thereof. Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate the degenerate DNA molecules above.

The invention further provides an isolated nucleic acid molecule having the nucleotide sequence shown in FIG. 1 (SEQ ID NO:1) or a fragment thereof Such isolated DNA molecules and fragments thereofare useful as DNA probes for gene mapping by in situ hybridization with chromosomes and for detecting expression of the D53 gene in human tissue (including breast and lymph node tissues) by Northern blot analysis.

mD53

The present invention also provides isolated nucleic acid molecules comprising a polynucleotide encoding the mD53 polypeptide whose amino acid sequence is shown FIG. 3 (SEQ ID NO:4) or a fragment thereof. Such isolated nucleic acid molecules include DNA molecules comprising an open reading frame (ORF) whose initiation codon is at position 192-194 of the nucleotide sequence of FIG. 3 (SEQ ID NO:3) and further include DNA molecules which comprise a sequence substantially different than all or part of the ORF whose initiation codon is at position 192-194 of the nucleotide sequence of FIG. 3 (SEQ ID NO:3) but which, due to the degeneracy of the genetic code, still encode the mD53 polypeptide or a fragment thereof. Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate the degenerate DNA molecules above.

The invention also provides an isolated nucleic acid molecule encoding the mD53 polypeptide as shown in SEQ ID NO:4, but lacking the N-terminal methionine.

The invention further provides an isolated DNA molecule having the nucleotide sequence shown in FIG. 3 (SEQ ID NO:3) or a fragment thereof. Such isolated DNA molecules and fragments thereof are useful as DNA probes for gene mapping by in situ hybridization with chromosomes and for detecting expression of the murine or human D53 gene in mouse or human tissue (including breast and lymph node tissues) by Northern blot analysis. Of course, as discussed above, if a DNA molecule includes the ORF whose initiation codon is at position 192-194 of FIG. 3 (SEQ ID NO:3), then it is also useful for expressing the murine D53 polypeptide or a fragment thereof.

hD54

The present invention also provides isolated nucleic acid molecules comprising a polynucleotide encoding the hD54 polypeptide whose amino acid sequence is shown FIG. 16 (SEQ ID NO:6) or a fragment thereof. Such isolated nucleic acid molecules include DNA molecules comprising an open reading frame (ORF) whose initiation codon is at position 77-79 of the nucleotide sequence of FIG. 16 (SEQ ID NO:5) and further include DNA molecules which comprise a sequence substantially different than all or part of the ORF whose initiation codon is at position 77-79 of the nucleotide sequence of FIG. 16 (SEQ ID NO:5) but which, due to the degeneracy of the genetic code, still encode the hD54 polypeptide or a fragment thereof Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate the degenerate DNA molecules above.

The invention also provides an isolated nucleic acid molecule encoding the hD54 polypeptide as shown in SEQ ID NO:6, but lacking the N-terminal methionine.

The invention further provides an isolated DNA molecule having the nucleotide sequence shown in FIG. 16 (SEQ ID NO:5) or a fragment thereof. Such isolated DNA molecules and fragments thereof are useful as DNA probes for gene mapping by in situ hybridization with chromosomes and for detecting expression of the murine or human D54 gene in mouse or human tissue (including breast and lymph node tissues) by Northern blot analysis. Of course, as discussed above, if a DNA molecule includes the ORF whose initiation codon is at position 77-79 of FIG. 16 (SEQ ID NO: 5), then it is also useful for expressing the hD54 polypeptide or a fragment thereof

Fragments, Derivatives and Variants of the Isolated Nucleic Acid Molecules of the Invention

By “fragments” of an isolated DNA molecule having the nucleotide sequence shown in FIG. 1, 3, or 16 (SEQ ID NO:1, 3, or 5 respectively) are intended DNA fragments at least 15 bp, preferably at least 20 bp, and more preferably at least 30 bp in length which are useful as DNA probes as discussed above. Of course, larger DNA fragments of about 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, or 1050-2000 bp in length are also useful as DNA probes according to the present invention as are DNA fragments corresponding to most, if not all, of the nucleotide sequence shown in FIG. 1, 3, or 16 (SEQ ID NO:1, 3, or 5 respectively). By a fragment at least 20 bp in length, for example, is intended fragments which include 20 or more contiguous bases from the nucleotide sequence shown in FIG. 1, 3, or 16 (SEQ ID NO:1, 3, or 5 respectively). As indicated, such fragments are useful diagnostically either as a probe according to conventional DNA hybridization techniques or as primers for amplification of a target sequence by the polymerase chain reaction (PCR).

Since the +5 hD53, mD53, and hD54 genes are shown in FIGS. 1, 3, and 16 respectively (SEQ ID NO:1, 3, and 5 respectively) are provided, generating such DNA fragments of the present invention would be routine to the skilled artisan. For example, restriction endonuclease cleavage or shearing by sonication could easily be used to generate fragments of various sizes. Alternatively, the DNA fragments of the present invention could be generated synthetically according to known techniques.

Preferred nucleic acid molecules of the present invention will encode the mature form of the +5 mD53, mD53, or hD54 protein and/or additional sequences, such as those encoding a leader sequence, or the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with additional, noncoding sequences, including for example, but not limited to introns and noncoding 5′ and 3′ sequences such as the transcribed, nontranslated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding, and mRNA stability; and additional coding sequence which codes for additional amino acids, such as those which provide additional functionalities. Thus, for instance, the polypeptide may be fused to a marker sequence, such as a peptide, which facilitates purification of the fused polypeptide. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86: 821-824 (1989), for example, hexa-histidine provides for convenient purification of the fusion protein. The HA tag corresponds to an epitope derived of influenza hemagglutinin protein, which has been described by Wilson et al., Cell 37:767 (1984).

The present invention further relates to variants ofthe isolated nucleic acid molecules of the present invention, which encode fragments, analogs or derivatives of the +5 hD53, mD53, or hD54 protein. Variants may occur naturally, such as an allelic variant. Non-naturally occurring variants may be produced using art-known mutagenesis techniques, which include those produced by nucleotide substitutions, deletions or additions. Especially preferred among these are silent or conservative substitutions, additions and deletions, which do not alter the properties and activities of the +5 hD53, mD53, or hD54 protein or fragment thereof.

Further embodiments of the invention include isolated nucleic acid molecules that are at least 90% identical, and more preferably at least 95%, 96%, 97%, 98% or 99% identical to the above-described isolated nucleic acid molecules of the present invention. In particular, the invention is directed to isolated nucleic acid molecules at least 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequences contained in FIGS. 1, 3 or 16 (SEQ ID NO: 1, 3, or 5, respectively).

By the invention, “% identity” between two nucleic acid sequences can be determined using the “fastA” computer algorithm (Pearson, W. R. & Lipman, D. J., Proc. Natl. Acad. Sci. USA 85:2444 (1988)) with the default parameters. Uses of such 95%, 97%, 98%, or 99% identical nucleic acid molecules of the present invention include, inter alia, (1) isolating the hD53, +5 hD53, mD53, or hD54 gene or allelic variants thereof in a cDNA library; (2) in situ hybridization (FISH) to metaphase chromosomal spreads to provide precise chromosomal location of the hD53, mD53, or hD54 gene as described in Verma et al., Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, N.Y., 1988); and (3) Northern Blot analysis for detecting hD53, +5 hD53, mD3, or hD54 mRNA expression in specific tissues.

Guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main approaches for studying the tolerance of an amino acid sequence to change. The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection. The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selections or screens to identify sequences that maintain functionality. As the authors state, these studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described in Bowie, J. U., et al., Science 247: 1306-1310 (1990), and the references cited therein.

The invention is further related to nucleic acid molecules capable of hybridizing to a nucleic acid molecule having a sequence complementary to or hybridizing directly to the nucleic acid sequence shown in FIG. 1, 3, or 16 (SEQ ID NO:1, 3, or 5 respectively) under stringent conditions. By “stringent conditions” is intended overnight incubation at 42° C. in a solution comprising 50% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA (ssDNA), followed by washing the filters in 0.1×SSC at about 65° C.

In a further aspect, the present invention is directed to polynucleotides having a nucleotide sequence complementary to the nucleotide sequence of any of the polynucleotides discussed above.

Expressed Sequence Tags

An expressed sequence tag (EST) is a segment of a sequence from a randomly selected cDNA clone that corresponds to a mRNA (Adams, M. D. et al., Science 252:1651-1656(1991); Adams, M. D. et al., Nature 355:632-634(1992); Adams, M. D. et al., Nat. Genet. 4:373-380 (1993)).

The present inventors have identified the following ESTs with homology to portions of AA182908 (SEQ ID NO:63), W93489 (SEQ ID NO:64), AA240722 (SEQ ID NO:65), AA278103 (SEQ ID NO:66), AA066421 (SEQ ID NO:67), T89899 (SEQ ID NO:68), T93647 (SEQ ID NO:69), W69680 (SEQ ID NO:70), AA055718(SEQ ID NO:71), T68402(SEQ ID NO:72), W11611 (SEQ ID NO:73), W14257 (SEQ ID NO:74), and N99206 (SEQ ID NO:75).

The present inventors have also identified the following ESTs with homology to portions of hD54 AA004043 (SEQ ID NO:76), AA008731 (SEQ ID NO:77), AA031903 (SEQ ID NO:78), AA103819 (SEQ ID NO:79), AA124904 (SEQ ID NO:80), W10501 (SEQ ID NO:81), W20813 (SEQ ID NO:82), W54810 (SEQ ID NO:83), W66669 (SEQ ID NO:84), W82290 (SEQ ID NO:85), W91446 (SEQ ID NO:86), W97219 (SEQ ID NO:87), AA218395 (SEQ ID NO:88), AA268015 (SEQ ID NO:89), AA266320 (SEQ ID NO:90), AA255184 (SEQ ID NO:91), W75292 (SEQ ID NO:92), AA048792 (SEQ ID NO:93), H31879 (SEQ ID NO:94), AA277778 (SEQ ID NO:95), W13944 (SEQ ID NO:96), H39077 (SEQ ID NO:97), AA411964(SEQ ID NO98), AA124922 (SEQ ID NO:99), AA116313 (SEQ ID NO:100), W75408 (SEQ ID NO 101), and AA436748 (SEQ ID NO:102). The invention includes polynucleotide fragments which do not comprise these ESTs.

Isolated RNA Molecules

The present invention further provides isolated RNA molecules which are in vitro transcripts of a nucleic acid sequence shown in FIG. 1, 3 or 16 (SEQ ID NO:1, 3, or 5, respectively) or a fragment thereof Such RNA molecules are useful as antisense RNA probes for detecting hD53 or mD53 gene expression by in situ hybridization.

Polypeptides and Fragments Thereof

+5 hD53

The invention further provides an isolated +5 hD53 polypeptide having an amino acid sequence as shown in FIG. 1 (SEQ ID NO:2), or a fragment thereof +5 hD53 is a member of the hD52 family of proteins. hD52-like proteins all contain coiled-coil domains near the N-terminus. The present inventors have shown that the hD52 family of proteins interact in homo- and heteromeric fashions both in vivo and in vitro. Indications that hD52 and hD53 coiled-coil domains were also mediating homo- and heteromeric interactions between these proteins derive from the results of yeast two-hybrid screenings, where all hD52 and hD53 interactors identified contained sequences encoding entire coiled-coil domains.

The cloning of an alternatively-spliced form of hD53 during a yeast two-hybrid screening using the hD53 bait has also provided further evidence that multiple protein isoforms may be produced from D52-like genes (Proux, V., et al., J. Biol Chem. 271:30790-30797 (1996)). The +5 hD53 cDNA identified in the present study predicts a C-terminally truncated hD53 protein as a result of a 100 bp out-of-frame deletion. The resulting truncation occurs three residues after residue 128 (SEQ ID NO:2), which represents the first residue of an alternatively-spliced 13 amino acid region (residues 128-140 of SEQ ID NO:2) referred to as ins3.

mD53

The invention further provides an isolated mD53 polypeptide having an amino acid sequence as shown in FIG. 3 (SEQ ID NO:3) or a fragment thereof The present invention also provides isolated polypeptides having an amino acid sequence of mD53 as shown in SEQ ID NO:4, but lacking the N-terminal methionine. The present inventors have discovered that the mD53 polypeptide is an about 204 amino acid residue protein having a coiled-coiled domain at the N-terminus. Interactions between mD52 and hD53 fusion proteins were found to be mediated via mD52 residues 1-95 of SEQ ID NO:4, which include the predicted coiled-coil domain at residues 29-71 of SEQ ID NO:4.

hD54

The invention further provides an isolated hD54 polypeptide having an amino acid sequence as shown in FIG. 16 (SEQ ID NO:5) or a fragment thereof. The present invention also provides isolated polypeptides having an amino acid sequence of hD54 as shown in SEQ ID NO:6, but lacking the N-terminal methionine. The present inventors have discovered that the hD54 polypeptide is an about 206 amino acid residue protein having a coiled-coiled domain at the N-terminus.

Polypeptide Fragments and Variants

Fragments of +5 hD53, mD53, or hD54 other than those described above capable of raising both monoclonal and polyclonal antibodies will be readily apparent to one of skill in the art and will generally be at least 10 amino acids, and preferably at least 15 amino acids, in length. For example, the “good antigen” criteria set forth in Van Regenmortel et al., Immunol. Letters 17:95-108 (1988), could be used for selecting fragments of the hD53, mD53, or hD54 protein capable of raising monoclonal and polyclonal antibodies.

It will be recognized in the art that some amino acid sequences of +5 hD53, mD53, or hD54 can be varied without significant effect on the structure or function ofthe protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity. Such areas will usually comprise residues which make up the binding site, or which form tertiary structures which affect the binding site. In general, it is possible to replace residues which form the tertiary structure, provided that residues performing a similar function are used. In other instances, the type of residue may be completely unimportant if the alteration occurs at a noncritical region of the protein.

Thus, the present invention further includes variations of the +5 hD53, mD53, or hD54 protein which show substantial protein activity or which include regions of the +5 hD53, mD53, or hD54 protein such as the protein fragments discussed above capable of raising antibodies useful in immunohistochemical or RIA assays. Such mutants include deletions, insertions, inversions, repeats and type-substitutions (e.g., substituting one hydrophilic residue for another, but not strongly hydrophilic for strongly hydrophobic as a rule). Small changes or such “neutral” amino acid substitutions will generally have little effect on activity.

Typically seen as conservative substitutions are as follows: the replacements, one for another, among the aliphatic amino acids, Ala, Val, Leu and Ile; interchange of the hydroxyl residues, Ser and Thr; exchange of the acidic residues, Asp and Glu; substitution between the amide residues, Asn and Gln; exchange of the basic residues, Lys and Arg; and replacements among the aromatic residues, Phe, Tyr. As indicated in detail above, further guidance concerning which amino acid changes are likely to be phenotypically silent (i.e., are not likely to have a significant deleterious effect on a function) can be found in Bowie, J. U. et al., Science 247:1306-1310 (1990).

Preferably, such variants will be at least 90%, 95%, 96%, 97%, 98% or 99% identical to the +5 hD53, mD53, or hD54 polypeptides described above and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids. By the invention, “% identity” between two polypeptides can be determined using the “fastA” computer algorithm with the default parameters (Pearson, W. R. & Lipman, D. J., Proc. Natl. Acad. Sci. USA 85:2444 (1988)).

The isolated hD53, mD53, or hD54 polypeptide, or a fragment thereof, are preferably provided in an isolated form, and preferably are substantially purified. Of course, purification methods are known in the art. In preferred embodiment, a recombinantly produced version of the hD53, mD53, or hD54 polypeptide is substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). The hD53, mD53, or hD54 protein can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography (“HPLC”) is employed for purification. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides ofthe present invention may be glycosylated or may be nonglycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, and in some cases as a result of host-mediated processes.

Vectors and Hosts

The present invention also relates to vectors which include an isolated DNA molecule(s) of the present invention, host cells which are genetically engineered with the vectors, and the production of +5 hD53, mD53, or hD54 polypeptide(s), or fragments thereof, by recombinant techniques.

A DNA molecule, preferably a cDNA, encoding the +5 hD53, mD53, or hD4 polypeptide or a fragment thereof, may easily be inserted into a suitable vector. Ideally, the vector has suitable restriction sites for ease of insertion, but blunt-end ligation, for example, may also be used, although this may lead to uncertainty over reading frame and direction of insertion.

The +5 hD53, mD53, or hD54 polypeptide(s), or fragments thereof, can be expressed in any suitable host cell. The extent of expression may be analyzed by SDS polyacrylamide gel electrophoresis (Laemmelli. el al., Nature 227:680-685 (1970)). Cultures useful for production of such polypeptides include prokaryotic, eukaryotic and yeast expression systems. Preferred systems include E. coli, Streptomyces and Salmonella typhimurium and yeast, mammalian or plant cells. Mammalian hosts include HeLa, COS, and Chinese Hamster Ovary (CHO) cells. Yeast hosts include S. cerevisiae. Insect cells include Drosophila S2 and Spodoptera Sf9 cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art. Vectors capable of directing expression in the above-mentioned host cells are also known in the art.

hD54 as a Breast Cancer Prognosticator

The hD54 gene of the present invention encodes a polypeptide which is useful as a prognostic marker for breast cancer. It is known in the art that prognostic markers provide important information in the management of breast cancer patients (Elias et al., J Histotechnol. 15(4):315-320(1992)). For example, for application of systemic adjuvant therapy in primary breast cancer, identification of high- and low-risk patients is a major issue (McGuire, W. L., N. Engl. J. Med. 320:525-527 (1989)). Several classical (tumor size, lymph node status, histopathology, steroid receptor status) and second-generation prognostic factors (proliferation rate, DNA ploidy, oncogenes, growth factor receptors and some glycoproteins) are currently available for making therapeutic decisions (McGuire, W. L., Prognostic Factors for Recurrence and Survival, in Educational Booklet American Society of Clinical Oncology, 25th Annual Meeting, 89-92 (1989); Contesso et al., Eur. J Clin. Oncol. 25:403-409 (1989)). Although no group ofthe art-known prognosticators completely fulfills the objective to fully distinguish high- and low-risk patients, combinations ofthe prognostic factors can improve the prediction of a patient's prognosis (McGuire, W. L., N. Engl. J. Med 320:525-527 (1989)). Thus, by the invention, a further prognostic marker is provided which can be added to the population of art-known prognosticators to more particularly distinguish between high- and low-risk breast cancer patients.

The present inventors have discovered that, in many instances, cells obtained from breast tumors contain significantly greater copy number of hD54 and express significantly enhanced levels of hD54 mRNA and/or protein when compared to cells obtained from “normal” breast tissue, i.e., non-tumorigenic breast tissue. Thus, the invention provides a method useful during breast cancer prognosis, which involves assaying a first hD54 gene expression level or gene copy number in breast tissue and comparing the gene expression level or gene copy number with a second hD54 gene expression level or gene copy number, whereby the relative levels of said first gene expression level or gene copy number over said second is a prognostic marker for breast cancer.

By the invention, gene amplification and enhanced gene expression over the standard is clinically relevant for breast cancer prognosis as independent studies have shown an association between the presence of amplification and an increased risk of relapse (Slamon et al., Science 235:177 (1987); Ravdin & Chamness, Gene 159:19 (1995)).

The methods of the invention can be used alone or together with other markers known in the art for breast cancer prognosis, including those discussed above. By “assaying hD54 gene expression level” is intended qualitatively or quantitatively measuring or estimating the hD54 protein level or hD54 mRNA level in a first biological sample either directly or relatively by comparing to the hD54 protein level or mRNA level in a second biological sample. By “assaying hDS4 gene copy number” is intended qualitatively or quantitatively measuring or estimating hD54 gene copy number in a first biological sample either directly or relatively by comparing to the hD54 gene copy number in a second biological sample.

Preferably, the hD54 protein level, mRNA level, or gene copy number in the first biological sample is measured or estimated and compared to a second standard hD54 protein level, mRNA level, or gene copy number, the standard being taken from a second biological sample obtained from an individual not having breast cancer. As will be appreciated in the art, once a standard hD54 protein level, mRNA level, or gene copy number is known, it can be used repeatedly as a standard for comparison. It will also be appreciated in the art, however, that the first and second biological samples can both be obtained from individuals having breast cancer. In such a scenario, the relative hD54 protein levels, mRNA levels or gene copy numbers will provide a relative prognosis between the individuals.

By “biological sample” is intended any biological sample obtained from an individual, cell line, tissue culture, or other source which contains hD54 protein, mRNA, or gene. Preferably, the biological sample includes tumorigenic or non-tumorigenic breast tissue. Methods for obtaining tissue biopsies are well known in the art.

The present invention is useful as a prognostic indicator for breast cancer in mammals. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Assaying hD54 gene copy number can occur according to any known technique such as, for example, by visualizing extrachromosomal double minutes (dmin) or integrated homogeneously staining regions (hsrs) (Gebhart et al., Breast Cancer Res. Treat. 8:125 (1986); Dutrillaux et al., Cancer Genet. Cytogenet. 49:203 (1990)). Other techniques such as comparative genomic hybridization (CGH) and a strategy based on chromosome microdissection and fluorescence in situ hybridization can also be used to search for regions of increased DNA copy number in tumor cells (Guan et al, Nature Genet. 8:155 (1994); Muleris et al., Genes Chrom. Cancer 10:160 (1994)). DNA probes that hybridize to the hD54 can be prepared as described below.

Total cellular RNA can be isolated from normal and tumorigenic breast tissue using any suitable technique such as the single-step guanidinium-thiocyanate-phenol-chloroform method described in Chomczynski and Sacchi, Anal. Biochem. 162:156-159(1987). The LiCL/urea method described in Auffray and Rougeon, Eur. J. Biochem. 107:303 (1980) can also be used. hD54 mRNA levels are then assayed using any appropriate method. These include Northern blot analysis, S1 nuclease mapping, the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR), and reverse transcription in combination with the ligase chain reaction (RT-LCR).

Northern blot analysis can be performed as described in Harada et al., Cell 63:303-312 (1990). Briefly, total RNA is prepared from a biological sample as described above. For the Northern blot, the RNA is denatured in an appropriate buffer (such as glyoxal/dimethyl, sulfoxide/sodium phosphate buffer), subjected to agarose gel electrophoresis, and transferred onto a nitrocellulose or nylon filter. hD54 DNA labeled according to any appropriate method (such as the ³²P-multiprimed DNA labeling system (Amersham)) is used as probe. After hybridization, the filter is washed and exposed to x-ray film.

hD54 DNA for use as probes according to the present invention are described below. Where a fragment is used, the DNA probe will be at least about 15-30 nucleotides in length, and preferably, at least about 50 nucleotides in length.

S1 mapping can be performed as described in Fujita et al., Cell 49:357-367 (1987). To prepare probe DNA for use in S1 mapping, the sense strand of hD54 cDNA is used as a template to synthesize labeled antisense DNA. The antisense DNA can then be digested using an appropriate restriction endonuclease to generate further DNA probes of a desired length. Such antisense probes are useful for visualizing protected bands corresponding to hD54 mRNA. Northern blot analysis can be performed as described above.

Alternatively, hD54 mRNA levels are assayed using the RT-PCR method described in Makino et al, Technique 2:295-301 (1990). By this method, the radioactivities of the amplification products in the polyacrylamide gel bands are linearly related to the initial concentration of the target mRNA. Briefly, this method involves adding total RNA isolated from a biological sample in a reaction mixture containing a RT primer and appropriate buffer. After incubating for primer annealing, the mixture can be supplemented with a RT buffer, dNTPs, DTT, RNase inhibitor and reverse transcriptase. After incubation to achieve reverse transcription of the RNA, the RT products are then subject to PCR using labeled primers. Alternatively, rather than labeling the primers, a labeled dNTP can be included in the PCR reaction mixture. PCR amplification can be performed in a DNA thermal cycler according to conventional techniques. After a suitable number of rounds to achieve amplification, the PCR reaction mixture is electrophoresed on a polyacrylamide gel. After drying the gel, the radioactivity of the appropriate bands (corresponding to the hD54 mRNA) is quantified using an imaging analyzer. RT and PCR reaction ingredients and conditions, reagent and gel concentrations, and labeling methods are well known in the art. Variations on the RT-PCR method will be apparent to the skilled artisan.

Any set of oligonucleotide primers which will amplify reverse transcribed hD54 mRNA can be used and can be designed by reference to the hD54 DNA sequence provided below.

Assaying hD54 protein levels in a biological sample can occur using any art-known method. Preferred are antibody-based techniques. For example, hD54 protein expression in tissues can be studied with classical immunohistological methods. In these, the specific recognition is provided by the primary antibody (polyclonal or monoclonal) but the secondary detection system can utilize fluorescent, enzyme, or other conjugated secondary antibodies. As a result, an immunohistological staining of tissue section for pathological examination is obtained. Tissues can also be extracted, e.g., with urea and neutral detergent, for the liberation of hD54 protein for Western-blot or dot/slot assay (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol 105:3087-3096 (1987)). In this technique, which is based on the use of cationic solid phases, quantitation of hD54 protein can be accomplished using isolated hD54 as a standard. This technique can also be applied to body fluids. With these samples, a molar concentration of hD54 protein will aid to set standard values of hD54 protein content for different body fluids, like serum, plasma, urine, spinal fluid, etc. The normal appearance of hD54 amounts can then be set using values from healthy individuals, which can be compared to those obtained from a test subject.

Other antibody-based methods useful for detecting hD54 gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). For example, a monoclonal antibody can be used both as an immunoabsorbent and as an enzyme-labeled probe to detect and quantify the hD54 protein. The amount of hD54 protein present in the sample can be calculated by reference to the amount present in a standard preparation using a linear regression computer algorithm. Such an ELISA for detecting a tumor antigen is described in lacobelli et al., Breast Cancer Research and Treatment 11:19-30 (1988). In another ELISA assay, two distinct monoclonal antibodies can be used to detect hD54 protein in a body fluid. In this assay, one of the antibodies is used as the immunoabsorbent and the other as the enzyme-labeled probe.

The above techniques may be conducted essentially as a “one-step” or “two-step” assay. The “one-step” assay involves contacting hD54 protein with immobilized antibody and, without washing, contacting the mixture with the labeled antibody. The “two-step” assay involves washing before contacting the mixture with the labeled antibody. Other conventional methods may also be employed as suitable. It is usually desirable to immobilize one component of the assay system on a support, thereby allowing other components of the system to be brought into contact with the component and readily removed from the sample.

Suitable enzyme labels include, for example, those from the oxidase group, which catalyze the production of hydrogen peroxide by reacting with substrate. Glucose oxidase is particularly preferred as it has good stability and its substrate (glucose) is readily available. Activity of an oxidase label may be assayed by measuring the concentration of hydrogen peroxide formed by the enzyme-labeled antibody/substrate reaction. Besides enzymes, other suitable labels include radioisotopes, such as iodine (¹²⁵I, ¹²¹I), carbon (¹⁴C), salphee (³⁵S), tritium (³H), indium (¹¹²In), and technetium (^(99m)Tc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying hD54 protein levels in a biological sample obtained from an individual, hD54 protein can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of hD54 protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or caesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

An antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ¹³¹I, ¹¹²In, ^(99m)Tc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously or intraperitoneally) into the mammal to be examined for breast cancer. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of ^(99m)Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the protein. In vivo tumor imaging is described in S. W. Burchiel et al., Immunopharmacokinetics of Radiolabelled Antibodies and Their Fragments, in Tumor Imaging: the Radiochemical Detection of Cancer (S. W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

Antibodies for use in the present invention can be raised against the intact hD54 protein or an antigenic polypeptide fragment thereof, which may presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. As used herein, the term “antibody” (Ab) or “monoclonal antibody” (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab′)₂ fragments) which are capable of specifically binding to the hD54 protein. Fab and F(ab′)₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., J. Nucl. Med. 24:316-325 (1983)). Thus, these fragments are preferred.

The antibodies ofthe present invention may be prepared by any of a variety of methods. For example, cells expressing the hD54 protein or an antigenic fragment thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of hD54 is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or hD54-binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology (Kohler et al, Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al, Monaclonai Antibodies and T-cell Hyrbridomas, 563-681 (Elsevier, N.Y., 1981)). In general, such procedures involve immunizing an animal (preferably a mouse) with a hD54 antigen or, more preferably, with a cell expressing the antigen. Suitable cells can be recognized by their capacity to bind anti-hD54 antibody. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earne's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56° C.), and supplemented with about 10 μg/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 μg/ml of streptomycin. The splenocytes of such mice are extracted and fised with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP₂O), available from the American Type Culture Collection, Rockville, Md. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al., Gastroenterology 80:225-232 (1981). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the hD54 antigen.

It will be appreciated that Fab and F(ab′)₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab′)₂ fragments). Alternatively, antigen binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

Where in vivo imaging is used to detect levels of hD54 protein in humans, it may be preferable to use “humanized” chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. See, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al, U.S. Pat. No. 4,816,567, Taniguchi et al, EP 171496, Morrison etal., EP 173494; Neuberger et al, WO 8601533; Robinson et al, WO 8702671; Boulianne et al, Nature 312:643 (1984); Neuberger et al, Nature 314.268 (1985).

Having generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration and are not intended to be limiting.

It will be appreciated to those skilled in the art that the invention can be performed within a wide range of equivalent parameters of composition, concentrations, modes of administration, and conditions without departing from the spirit or scope of the invention or any embodiment thereof.

The disclosure of all references, patent applications and patents recited herein are hereby incorporated by reference.

EXAMPLES Example 1

Characterization of D52-like Proteins

D52-like Proteins Interact Homo- and Heteromerically within the Yeast Two-hybrid System

In order to test whether D52-like proteins interact within the yeast two-hybrid system, the relevant coding sequences (or portions thereof) were subcloned into the yeast two-hybrid vectors pACT2 and/or pAS2-1, such that these sequences were in-frame with those encoding the GAL4 transcriptional activation domain (GAL4-AD), or the DNA-binding domain (GAL4-DB), respectively. Proteins fused with the GAL4-AD were referred to as interactors, whereas those fused with the GAL4-DB were referred to as baits. The D52-like proteins tested represent the human and mouse homologues of D52 (hD52 and mD52), hD53, and 3 hD54 isoforms (FIG. 5). The existence of multiple hD54 isoforms was predicted from coding sequence differences identified in hD54 cDNAs, with hD54 sequences differing with respect to a region encoding a 20 amino acid insertion, ins2 (FIG. 5). Whereas 2 hD54 cDNA clones contained the 60 bp sequence encoding ins2 (nucleotides 391-450 of SEQ ID NO:5), this was absent from another cDNA clone. A further variation was noted where a 71 bp deletion (nucleotides 380-450 of SEQ ID NO:5) was predicted to remove ins2, plus an additional 4 residues from the translated sequence. This deletion was not produced in-frame, and a truncated product was predicted to result after 42 amino acids (FIG. 5). We refer to the 3 isomeric forms of hD54 thus predicted as hD54+ins2, hD54-ins2, and hD54t.

Before proceeding with a testing of interactions, D52-like baits and interactors were individually tested for their inability to activate Y190 reporter gene expression.

Y 190 yeast strains which had been transfected with individual constructs were grown on either solid SD/-Trp media (for baits) or SD/-Leu media (for interactors) incorporating 0.07 M potassium phosphate pH 7, and 40 μg/ml 5-bromo-4-chloro-3 -indoyl-β-D-galactopyranoside (X-gal). After 4 days incubation at 30° C., colony phenotypes were compared with that of Y190 yeast transfected with the corresponding vector as a negative control. Excepting the case of Y190 yeast transfected with the hD54t bait, a white colony phenotype was obtained for all Y190 strains tested, indicating that these D52-like baits and interactors were unable to activate the Y 190 lacZ reporter gene. However, Y 190 yeast transfected with the hD54t bait gave a blue colony phenotype after 2 days incubation at 30° C. on solid SD/-Trp media containing X-gal, indicating that this hD54 isoform was unsuitable for further use in the yeast two-hybrid system.

For direct testing of interactions between D52-like fusion proteins, each bait plasmid (pAS2-1hD52, pAS2-1mD52, pAS2-1hD53, pAS2-1hD54+ins2, pAS2-1hD54−ins2, and pAS2-1 as a negative control), was paired with each interactor plasmid (pAD-GAL4hD52, pACT2mD52(₁₋₁₆₃₎, pACT2hD53, pACT2hD54+ins2, pACT2hD54−ins2, and pACT2 as a negative control), and co-transfected into Y 190. Interactions between baits and interactors were assessed by qualitatively and/or quantitatively determining HIS3 and/or lacZ reporter gene activity in Y190 co-transfectants. All D52-like fusion proteins tested were found to be capable of both homo- and heteromer formation in the yeast two-hybrid system (Table 1). However, the results of both qualitative and quantitative β-galactosidase assays indicated that interactions between different pairs of D52-like fusion proteins occurred with different strengths. In Y190 co-transfectants bearing hD53-encoding constructs, the highest β-galactosidase activity level was obtained for the interaction between hD53 fusion proteins (Table 1), indicating that homomeric interactions were preferred. However, in Y190 co-transfectants bearing mD52- or hD52-encoding constructs, homomeric interactions were indicated to be significantly weaker than heteromeric interactions between D52 and hD53 fusion proteins (Table 1). In the cases of Y 190 co-transfectants bearing hD54+ins2 or hD54−ins2 constructs, the highest levels of β-galactosidase activity were also noted for heteromeric interactions with hD53 fusion proteins (Table 1).

TABLE 1 Interactions between D52-like proteins within the yeast two-hybrid system, as measured by quantitative β-galactosidase assays. Bait constructs (or the pAS2-1 vector as a negative control) were paired with interactor constructs (or the pACT2 vector as a negative control), and co- transfected into Y190 cells. Three (or two*) colonies from each co-transfected Y190 strain were cultured in the absence of histidine, and assayed separately for β-galactosidase activity (see Methods). The mean number of β-galactosidase activity units obtained for each co-transfection is presented, ± the standard error. To permit comparisons between assays, all values have been related to a mean number of β-galactosidase activity units obtained for three simultaneously- performed, positive control assays, which was set to 1000 units. Baits → Interactors Vector ↓ (pAS2-1) hD52 mD52 hD53 hD54+ins2 hD54−ins2 Vector 0 ± 0 0 ± 0 0 ± 0 0.14 ± 0.14 0 ± 0 0 ± 0 (pACT2) hD52 0.17 ± 0.02 0.87 ± 0.30 0.16 ± 0.02 3.02 ± 0.43 0.85 ± 0.14 1.74 ± 0.09 mD52₍₁₋₁₆₃₎ 0 ± 0 1.30 ± 0.41 0.42 + 0.26 5.71 ± 0.26 4.25 ± 0.63 2.37 ± 0.29 hD53 0 ± 0 15.18 ± 1.30  6.07 ± 0.37 18.11 ± 0.93  11.74 ± 0.09  17.58 ± 6.47  hD54+ins2 0 ± 0 2.03 ± 0.27 0.48 ± 0.02 6.01 ± 1.31 5.98 ± 1.10 3.51 ± 1.15 hD54−ins2 0.45 ± 0.06 1.15 ± 0.06 0.44 ± 0.02 2.26 ± 0.24 2.03 ± 0.28 1.07 ± 0.11

Interactions Between D52-like Proteins Occur Via Their Coiled-coil Domains

In order to test whether the interactions observed between D52-like proteins occurred via their coiled-coil domains as predicted, we employed two bait constructs, pAS2-1mD52(₁₋₉₅) and pAS2-1D52(₉₅₋₁₈₅). These encode fusion proteins between the GAL4-DB and the N-terminal half of mD52 (which includes the predicted coiled-coil domain at residues 29-71 of SEQ ID NO:4), or the C-terminal half of mD52, respectively. These bait constructs, or pAS2-1mD52 as a positive control, were paired with the interactor plasmid pACT2hD53, or pACT2 as a negative control, and co-transfected into Y 190 cells, and interactions were qualitatively and/or quantitatively assessed by determining HIS3 and lacZ reporter gene activity (Table 2). Similar levels of β-galactosidase activity were obtained in Y 190 cells co-transfected with the hD53 interactor and full-length mD52 or mD52₁₋₉₅ baits, whereas negligible β-galactosidase activity was detected in Y190 co-transfectants bearing the hD53 interactor and mD52₉₅₋₁₈₅ bait (Table 2). This indicated that the first 95 amino acids of mD52, which include the coiled-coil domain, were responsible for mediating the interaction observed between the mD52 bait and hD53 (Tables 1 and 2).

TABLE 2 Interactions between wild-type or truncated mD52 baits and hD53 within the yeast two-hybrid system, as measured by quantitative β- galactosidase assays. Bait constructs were paired with the interactor construct pACT2hD53 (or pACT2 as a negative control), and co-transfected into Y190 cells. Three colonies from each co-transfected Y190 strain were cultured in the absence of histidine, and assayed separately for β-galactosidase activity (see Methods). The mean number of β-galactosidase activity units is presented, ± the standard error. Presented values have, in all cases, been standardized to the mean number of β-galactosidase activity units obtained for three simultaneously-performed positive control assays, which was to 1000 units. Baits → Interactors ↓ mD52 mD52₍₁₋₉₅₎ mD52₍₉₅₋₁₈₅₎ Vector 0.34 ± 0.08 0.36 ± 0.07 0.23 ± 0.15 (pACT2) hD53 5.44 ± 1.45 6.95 ± 1.32 0.52 ± 0.20

hD52 and hD53 Proteins were Identified as Potential Interactors for hD52 and hD53 Baits Using Yeast Two-hybrid Screening

We chose to construct and screen an expression library using the same human breast carcinoma from which the hD52, hD53 and hD54 cDNAs had been isolated (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995); and Byrne, J. A., et al., Genomics 35:523-532 (1996)). In this way, interacting proteins identified through library screening would be more likely to be co-expressed with D52-like proteins, and thus to represent biological partners for these proteins (Allen J. B., et al., Trends Biochem. Sci., 20:511-516 (1995)).

Screening approximately 772,200 colony forming units (cfu) of the breast carcinoma cDNA expression library in Y190 cells using the full-length hD53 bait resulted in the identification of 8 Y190 colonies which were His+ and lacZ+. Of these, 6 colonies contained pAD-GAL4 constructs encoding hD53, and one colony contained a pAD-GAL4 construct encoding hD52 (pAD-GAL4hD52) (Table 3). The remaining colony contained a pAD-GAL4 construct encoding suilisol (GenBank accession no. L26247), but retransfection of Y190 cells with this construct and the hD53 bait did not reproduce the His+ lacZ+ phenotype. All hD53 and hD52 cDNAs included sequence encoding the entire predicted coiled-coil domain (Table 3).

TABLE 3 Interactors identified through yeast two-hybrid screening of a human breast carcinoma cDNA expression library with D52-like baits Interactor 5′ (N-term) Coiled-coil Bait/Strain identity sequence extent included? hD53/Y190 hD53 nt 111^(a)(<Met¹) yes hD53/Y190 hD53 nt 111 (<Met¹) yes hD53/Y190 hD53 nt 1^(b)(Ser¹) yes hD53/Y190 hD53 nt 204 (Leu⁹) yes hD53/Y190 hD53 nt 81 (<Met¹) yes hD53/Y190 hD53 nt 81 (<Met¹) yes hD53/Y190 hD52^(c) nt 46 (<Met¹) yes hD52/Hf7c hD53 nt 204 (Leu⁹) yes hD52/Hf7c hD52 nt 60 (<Met¹) yes ^(a)Sequence co-ordinates refer to those specified in GenBank accession nos. U44427 and U18914 for hD53 and hD52 cDNAs, respectively, unless otherwise indicated. ^(b)The −5 hD53 cDNA predicts a novel hD53 isoform, and sequence co-ordinates refer to those specified in SEQ ID NO:1. ^(c)This pAD-GAL4hD52 interactor was used in the direct testing of interactions in the yeast two hybrid system.

Screening approximately 1,350,000 cfu of the same expression library in Y 190 cells using the full-length hD52 bait resulted in the identification of only one His+lacZ+Y190 colony. This contained a pAD-GAL4 construct encoding fte-1 (GenBank accession no. M84711), for which the interaction with the hD53 bait was not reproducible. Since this approach did not identify any reproducible interactor for the hD52 bait, we elected to perform a more sensitive screening in Hf7c cells. The Hf7c HIS3 reporter is less “leaky” than the Y 190 HIS3 reporter (Feilotter, H. E., et al., Nucleic Acids Res. 22:1502-1503 (1994) and; Durfee, T., et al., Genes Dev. 7:555-569 (1993)), and the HIS3 competitor 3-amino- 1, 2, 4-triazole is therefore not required to be added to selective media to suppress a basal level of HIS3 expression (Feilotter, H. E., et al., Nucleic Acids Res. 22:1502-1503 (1994)). Thus, weaker interactions with bait proteins are more likely to be detected (Allen J. B., et al, Trends Biochem. Sci., 20:511-516 (1995)). In addition, to increase the chance of identifying interactors binding D52 regions other than the coiled-coil domain, we elected to use both full-length hD52 and mD52₉₅₋₁₈₅ baits. Screening approximately 44,000 cfu of the breast carcinoma cDNA expression library in Hf7c cells resulted in a total of 10 His+ colonies. Of these, single colonies contained pAD-GAL4 constructs encoding hD53 and hD52 interactors with complete coiled-coil domains (Table 3). The remaining colonies contained pAD-GAL4 constructs encoding eukaryotic initiation factor 4AII (DNA Database of Japan accession no. D30655), histidyl t-RNA synthetase (EBML accession no. Z 11518), NADH dehydrogenase 3 (identified twice, EMBL accession no. X62996), collagen type 1 α-2 chain (GenBank accession no. J03464), RING10 proteasome subunit (GenBank accession no. X62598) and novel cDNAs of 10 kb (GenBank accession no. AA036831) and 1.7 kb (no database match). However, retransfection of Hf7c with these interactors and the individual D52 baits used in screening did not reproduce a His+ phenotype.

Identification of a Novel hD53 Isoform Using Yeast Two-hybrid Screening

Of the 7 hD53 cDNAs identified in this study using D52-like baits, the sequence of one (+5) differed significantly from those of the remaining 6 hD53 cDNAs, and from previously identified D53 cDNA sequences (Byrne, J. A., et al., Genomics 35:523-532 (1996)). The most 5′ 59 bp of the +5 cDNA could not be aligned with any other D53 sequence, and predicted a 20 amino acid stretch which showed no similarity to hD53 (FIG. 2). However, the coding sequences and reading frames of +5 and hD53 subsequently became identical for 365 bp, at which point a 100 bp deletion was noted in the +5 cDNA sequence with respect to hD53 (nts 567-666, GenBank accession no. U44427). Since the deletion does not occur in-frame, a truncated product is predicted to result (FIG. 2). The +5 cDNA does not appear to be full-length, since there is no Met residue in a favorable context for translation initiation within the novel sequence (FIG. 2, SEQ ID NO: 1). Thus while it is difficult to predict the size of the novel hD53 isoform, it is predicted to be greater than 144 amino acids in length.

Glutathione S-transferase (GST) Pull-down Assays Indicate Homo- and Heteromeric Interactions Between Recombinant GST-mD52 Protein and in Vitro-translated D52-like Proteins

In order to examine whether D52-like proteins are able to interact homo-and heteromerically in vitro as well as in vivo, we analyzed binding between GST-tagged mD52 protein and in vitro-translated D52-like proteins using a GST pull--down assay system. In vitro translation of mD52 and hD52 coding sequences gave rise to single 28 kDa ³⁵S-labelled proteins, whereas in vitro translation of the hD54-ins2 coding sequence gave rise to a 31 kDa ³⁵S-labelled protein (FIG. 6A). While larger than might be predicted from amino acid sequence data alone, these protein sizes are in agreement with that reported for CSPP28 (Parente (Jr), J. A., et al, J. Biol. Chem. 271:20096-20101 (1996)). Recombinant GST-mD52, or GST alone, were produced in the BL21 E. coli strain, and soluble post-induction extracts were incubated with glutathione-agarose. The subsequently bound GST-mD52 or GST was then incubated with in-vitro translated proteins, and a large excess of soluble BL21 extract as a complex binding competitor. Following washing of matrices and the elution of bound material, the binding characteristics of in vitro-translated D52-like proteins to GST (FIGS. 6B and 6C) or GST-mD52 (FIGS. 6D and 6E) could be compared. Autoradiographs (FIG. 6D and 6E) of Coomassie Brilliant Blue-stained gels (FIG. 6B and 6D) indicated that ³⁵S-labelled D52-like proteins were only retained on matrices to which GST-mD52 was bound. In vitro-translated proteins were not retained on glutathione-agarose to which GST had been bound, indicating that ³⁵S-labelled D52-like proteins were unable to bind to either GST or glutathione-agarose.

Discussion

The hypothesis that D52-like proteins are capable of interacting both homo- and heteromerically was initially advanced on the basis of several lines of evidence (Byrne, J. A., et al., Genomics 3:5:523-532 (1996)). Similar coiled-coil domains were predicted in both hD52 and hD53 proteins, and the corresponding genes were observed to be either co- or independently expressed in human cell lines. Moreover, examples of similar regulation of hD52 and hD53 transcript levels in both breast carcinoma and leukemic cell lines suggested the existence of a functional relationship between hD52 and hD53 (Byrne, J. A., et al, Genomics 35:523-532 (1996)). The present study has permitted both the confirmation of this hypothesis, and its extension to include a third member of the D52 protein family, hD54, in that D52-like proteins were found to interact in homo- and heteromeric fashions both in vivo (Tables 1 and 2) and in vitro (FIGS. 6A-6E). Using the yeast two-hybrid system, we were able to demonstrate interactions between all D52-like fusion proteins tested which, in most cases, were independent of whether a given D52-like protein was present as a bait or an interactor (Table 1). Similarly, screening a human breast carcinoma expression library using both hD53 and hD52 baits identified both homo- and heteromeric interactions between these proteins (Table 3). Interactions between mD52 and hD53 fusion proteins were found to be mediated via mD52 residues 1-95, which include the predicted coiled-coil domain at Glu²⁹ -Leu⁷¹(Table 2). Indications that hD52 and hD53 coiled-coil domains were also mediating homo- and heteromeric interactions between these proteins derive from the results of yeast two-hybrid screenings, where all hD52 and hD53 interactors identified contained sequences encoding entire coiled-coil domains (Table 3).

Results from both direct testing of interactions between D52-like fusion proteins and yeast two-hybrid screenings have indicated that not all interactions between D52-like proteins occur with the same strengths. In particular, homomeric interactions were indicated to be preferred by the hD53 bait (Tables 1 and 3), whereas heteromeric interactions with hD53 fusion proteins were preferred by the D52 and hD54 proteins tested (Table 1). However, a comparison of interactions between D52-like proteins and the hD54 isoforms hD54+ins2 or hD54−ins2 indicated that the presence or absence of ins2 did not significantly affect the interaction preferences of hD54 baits or interactors (Table 1). Thus, the presence or absence of ins2 24 amino acids C-terminal of the hD54 coiled-coil domain does not appear to obviously affect this domain's function. The significance of ins2 in hD54 proteins is however unclear, as no homology can be identified between the 20 amino acids comprising ins2, and sequence regions of other known proteins.

The cloning of an alternatively-spliced form of hD53 during a yeast two-hybrid screening using the hD53 bait has also provided further evidence that multiple protein isoforms may be produced from D52-like genes (Proux, V., et al, J. Biol. Chem. 271:30790-30797 (1996)). The +5 hD53 cDNA identified in the present study predicts a C-terminally truncated hD53 protein as a result of a 100 bp out-of-frame deletion removing hD53 nts 567-666 (GenBank accession no. U44427). The resulting truncation occurs three residues after Met¹²⁸, which represents the first residue of an alternatively-spliced 13 amino acid region (Met¹²⁸-Ala¹⁴⁰) referred to as ins3 (FIG. 2). A 23 amino acid ins3-like sequence is also predicted in a quail D52 homologue, RIO (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)). We had previously sequenced a partial hD53 cDNA (clone 83289; GenBank accession nos. T68402 and U44429) isolated by the IMAGE consortium (Lennon G., et al., Genomics 33:151-152 (1996)) which contained the same 100 bp deletion now noted in the +5 cDNA (Byrne, J. A., et al, Genomics 35:523-532 (1996)). As this deletion was only observed in a single cDNA at this time, we could not exclude the possibility that it had arisen through a cloning artifact. However, 4 additional expressed sequence tags (ESTs) now also show identical 100 bp deletions (GenBank accession nos. AA055718, AA066421, W11611, and W14257), and another EST (GenBank accession no. W69680) shows a smaller deletion of 61 bp (hD53 nts 606-666, GenBank accession no. U44427) which predicts a similar truncation occurring three residues after Met¹⁴¹, immediately after ins3 (FIG. 2). That alternative splicing mechanisms appear to regulate the presence or absence of the C-terminal portion of hD53 (and particularly, the presence or absence of ins3) suggests that these regions have roles in modulating D53 function.

While single putative D52 homologues have thus far been indicated in C. elegans (EMBL Accession No. Z68105; Wilson, R., et al., Nature 368:32-38 (1994)), and D. melanogaster (GenBank Accession Nos. AA263893, AA390326, and AA392910), three human D52-like genes have been identified, and analyses of mammalian expressed sequence tags identify sequences (GenBank Accession Nos. W50222, W49042 and AA 130196) which predict the existence of additional mammalian D52-like genes. Since RNAs deriving from those D52-like genes thus far cloned appear to be alternatively spliced (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)), a significant number of D52-like proteins may thus exist. This, combined with the fact that in the present study, each D52-like protein tested could interact with every other D52-like protein examined, indicates a potentially rich array of interactions between D52-like proteins, depending up the number of individual D52-like genes and isoforms expressed in a particular cell type. However, despite extensive screening of a human breast carcinoma yeast two-hybrid expression library in both Y 190 and Hf7c yeast strains using different full-length and/or truncated D52-like baits, no other partners were identified for D52-like proteins. While nonetheless indicating that interactions between D52-like proteins are highly specific, additional factors may have contributed towards this result. Firstly, technical limitations associated with the yeast two-hybrid system (Allen J. B., et al., Trends Biochem. Sci., 20:511-516 (1995)) may have prevented the demonstration of interactions between D52-like baits and other interactor types. Secondly, it may be that interactions between D52-like proteins and other partners are too weak and/or transient to be detected using the two-hybrid system. In the present study, screening sensitivity was maximized by performing two-hybrid screenings in both Hf7c and Y190 strains with the hD52 bait. That the screening in Hf7c cells was more sensitive was indicated by the fact that interactions between the hD52 bait and hD52 or hD53 interactors were only identified in Hf7c cells, despite the fact that a significantly greater proportion of the breast carcinoma library was screened in Y190 cells.

Similarly, the number of false-positives obtained in Hf7c cells compared with that obtained in Y190 cells also attests to the sensitivity of the Hf7c HIS3 reporter (Feilotter, H. E., et al., Nucleic Acids Res. 22:1502-1503 (1994)). However, since two-hybrid systems have been reported to be inherently more sensitive than other methods of identifying protein-protein interactions (Allen J. B., et al., Trends Biochem. Sci., 20:511-516 (1995)), proteins which interact either more weakly and/or transiently with D52-like proteins than D52-like proteins themselves may be difficult to identify using other methodologies. Finally, it is possible that additional partners exist for D52-like proteins in other tissues, but that these are either of low abundance, or not expressed, in breast carcinoma.

The CSPP28 and R10 molecules, which represent D52 homologues in rabbit and quail, respectively, have been implicated in calcium-mediated signal transduction processes (Parente (Jr), J. A., et al., J. Biol. Chem. 271:20096-20101 (1996)) and the control of cellular proliferation (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)). The interactions between D52-like molecules demonstrated in the present study may be integral to the roles of D52-like proteins in these cellular processes, Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996) having also demonstrated homomeric interactions between epitope-tagged and untagged R10 proteins. The functional importance of interactions between D52-like molecules is further supported by the prediction that increased expression of D52-like genes, such as reported for hD52 in a proportion of human breast carcinomas (Byrne, J. A., et al, Cancer Res. 55:2896-2903 (1995)), might be predicted to increase cellular concentrations of the corresponding protein, and thus the proportion of that protein found in homo- and/or heteromeric complexes. Thus, if increased hD52 gene expression promotes breast cancer cell proliferation, it might be predicted that the (more) active form of hD52 in this process is that which is bound to hD52, or other D52-like proteins.

Yeast Strains and Media

Yeast cultures were grown at 30° C. in standard liquid or solid media, based upon either rich YPD media (2% bacto-peptone, 1% yeast extract, 2% dextrose), or minimal SD medium (0.67% yeast nitrogen base without amino acids, 2% dextrose, with appropriate amino acid supplements). The Saccharomyces cerevisiae strain Y190 (genotype: MATa,ura3-52, his2-200, lys2-801, ade2-101, trp1-901, leu2-3, 112, gal4Δ, gal80Δ, cyh^(r)2, LYS2::GAL1_(UAS)-HIS3_(TATA)-HIS3, URA3::GAL1_(UAS)-GAL1_(TATA)-lacZ) (Clontech) was used for direct testing of interactions, whereas Y190 and Hf7c strains (Hf7c genotype: MATa, ura3-52, his3-200, lys2-801, ade2-101, trp1-901, leu2-3, 112, gal4-542, gal80-538, LYS2:: GAL1_(UAS)-GAL1_(TATA)-HIS3, URA3::(GAL1 17 mers)3-CyCl_(TATA)-lacZ) were used for expression library screenings.

Plasmid Constructions for the Yeast Two-hybrid System

Constructs for use in the yeast two-hybrid system were made using the pAS2-1 and pACT2 vectors (Clontech). The pAS2-1 vector contains the selectable marker TRPI, and permits the expression of fusion proteins with the GAL4₁₋₄₇ DNA-binding domain, whereas pACT2 contains the selectable marker LEU2, and permits the expression of fusion proteins with the GAL4₍₇₆₈₋₈₈₁₎ activation domain. The following pAS2-1 and pACT2 constructs were made by subcloning hD52-like coding sequences (or portions thereof) in-frame using internal restriction sites, and in some cases, those ofthe original pBS SK- multiple cloning sites: pAS2-1hD52, a Pst I-Nsi I fragment comprising nts 64-719 of hD52 and thus including the entire hD52 coding region (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995)), was subcloned into the Pst I site of pAS2-1; pAS2-1mD52, a Pst I-Pst I fragment including nts 1-832 of mD52 and thus the entire mD52 coding region (Byrne, J. A., et al., Genomics 35:523-532 (1996)), was subcloned into the Pst I site of pAS2-1; pAS2-1hD53, an Nco I-Sal I fragment including nts 180-1347 of hD53, and thus the entire hD53 coding region (Byrne, J. A., et al., Genomics 35:523-532 (1996)), was subcloned into the Nco I and Sal I sites of pAS2-1; pAS2-1mD52₉₅₋₁₈₅, a Pst I-Nsi I fragment including nts 1-306 of mD52, and thus the region encoding amino acids 1-95 of mD52 was subcloned into the Pst I site of pAS2-1; pAS2-1mD52₉₅₋₁₈₅, a Nsi I-Nsi I fragment including nts 307-787 of mD52, and thus the region encoding amino acids 95-185 of nD52 was subcloned into the Pst I site of pAS2-1; pACT2mD52₁₋₁₆₃, an EcoR I-EcoR I fragment including nts 1-507 of mD52, and thus the region encoding amino acids 1-163 of mD52 was subcloned into the EcoR I site of pACT2; and pACT2hD53, an Nco I-Xho I fragment including nts 180-1347 of hD53, and thus the entire hD53 coding region was subcloned into the Nco I and Xho I sites of pACT2. In the case of the hD52 cDNA (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995)), suitable restriction sites for use with the pACT2 vector were absent, and thus a pAD-GAL4hD52 plasmid isolated through yeast two-hybrid screening (see below, Table 1) was used for the direct testing of interactions. In the case of hD54 cDNAs encoding the 3 hD54 isoforms hD54+ins2, hD54—ins2 and hD54t (GenBank accession no. AF004430), suitable internal restriction sites for both pAS2-1 and pACT2 vectors were absent, and thus coding sequences were PCR-amplified using the primers 5′-CG CAT GCC ATG GAC TCC GCC GGC-3′(SEQ ID NO:103) and 5′-TCC CCC GGG GGA TTA GAA AGG TGC GGG ATC-3′ (SEQ ID NO:104). For hD54 cDNAs encoding all 3 hD54 isoforms, these PCR primers permitted amplification of sequences including full-length hD54 coding regions, the conversion of a 5′ cryptic Nco I site to a fill Nco I site, and the introduction of a 3′ Sma I site. Resulting PCR products were digested with Nco I and Sma I, and subcloned into the corresponding restriction sites of pACT2 and/or pAS2-1 vectors. This approach resulted in the pAS2-1hD54+ins2, pAS2-1hD54−ins9, pAS2-1hD54t, pACT2hD54+ins2, pACT2hD54−ins2 constructs. The reading frame of each fusion protein between GAL4 and D52-like sequences was verified by automated sequencing (see below).

Expression cDNA Library construction

A human breast carcinoma cDNA library was constructed in the HybriZAP vector using reagents and instructions supplied by the manufacturer (Stratagene). This vector permits the construction of λ bacteriophage cDNA libraries which can be converted to plasmid libraries in the pAD-GAL4 vector by in vivo excision. The pAD-GAL4 vector contains the selectable LEU marker and permits the expression of GAL4₇₆₁₋₈₈₁ activation domain fusion proteins. Briefly, 5 μg polyA+RNA from a primary infiltrating ductal breast carcinoma (Byrne, J. A., et al, Cancer Res. 55:2896-2903 (1995)) was primed using an oligodT linker-primer incorporating a Xho I site, and reverse-transcribed using MMLV-RT. EcoR I adaptors were ligated and the resulting Xho I-digested inserts were ligated into prepared HybriZAP vector arms. This resulted in approximately 5×10⁶ plaque forming units (pfu) which were amplified once on an XLI Blue MRF′ host. An aliquot of the λ bacteriophage library (5×10⁹ pfu) was rescued using in vivo excision in the form of pAD-GAL4 phagemids in a SOLR host, according to the manufacturer's instructions (Stratagene). Plasmid DNA for library screenings was directly isolated from approximately 50×10⁶ cfu grown on 128 large LB agar plates incorporating 100 μg/ml ampicillin, and purified using Qiagen 500 columns. Over 90% of pAD-GAL4 plasmids were found to contain inserts, with the average insert length being 1.1 kb.

Yeast Two-hybrid System

For the direct testing of interactions, paired baits (pAS2-1 constructs) and interactors (pACT2 or pAD-GAL4 constructs) were transfected into the Y190 yeast strain according to the supplier's instructions (Clontech), with co-transfectants being initially selected on solid SD media lacking Trp and Leu. Interactions between baits and interactors were assessed by qualitatively and/or quantitatively determining HIS3 and lacZ reporter gene activity in Y190 co-transfectants. Reporter gene activities were assessed qualitatively by observing the growth and color development of Y190 co-transfectants on solid SD media lacking His, Trp and Leu (SD/-His-Trp-Leu), and incorporating 0.07 M potassium phosphate pH 7, 35 mM 3-AT, and 40 μg/ml X-gal. For quantitative assessment of interactions, β-galactosidase activity was measured using the substrate o-nitrophenyl β-D-galactopyranoside (ONPG) in liquid cultures (SD/-His-Trp-Leu +35 mM 3-AT) of Y190 co-transfectants. As a positive control for each assay, and to permit the comparison of results obtained in different assays, μ-galactosidase activity was also measured in liquid cultures (SD/-Leu) of Y190 transfected with the GAL4-encoding construct pCL1 (Clontech). For both qualitative and quantitative assays, negative controls were supplied by Y190 co-transfectants in which each bait or interactor had been paired with the opposing empty vector.

Yeast Two-hybrid Screening

Bait (pAS2-1hD53, or pAS2-1hD52 with or without pAS2-1 mD52₉₅₋₁₈₅) and human breast carcinoma pAD-GAL4 library plasmids were transfected either sequentially or simultaneously into Y190 or Hf7c strains. Transformants were plated onto solid SD/-His-Trp-Leu (incorporating 35 mM 3-AT in the case of Y190 transformants) and incubated for up to 14 days at 30° C. After 3 initial days of growth, plates were inspected daily, and His+ colonies were transferred to SD/-His-Trp-Leu +0.07 M potassium phosphate pH 7+40 μg/ml X-gal plates which incorporated 35 mM 3-AT in the case of Y190 co-transformants. Colonies which remained His+, and in the case of Y190 co-transformants, were also lacZ+, were re-streaked onto fresh plates to check that all colonies were of uniform phenotype. After 6 days incubation at 30° C., yeast colonies were directly harvested, and plasmid DNA was isolated and used to transfect XL1 Blue. Mini-preparations of plasmid DNA were performed for at least 5 XL1 Blue colonies per transfection, with the results of restriction digests differentiating potential interactors from bait plasmids. Potential interactors were identified by DNA sequencing (see below) and re-transfected into the yeast strain used in library screening, with the relevant bait, or the pAS2-1 vector as a negative control. Phenotypes of resulting co-transfectants were assayed quantitatively and/or qualitatively as described above. Where re-transfection of an interactor did not reproduce the phenotype originally observed during library screening, the interactor was termed a “false-positive”.

Plasmid Constructions for in Vitro Transcription/Translation and GST-pull Down Assays

Constructs for in vitro transcription/translation were made using the pTL 1 vector, a derivative of pSG5 (Green, S., et al, Nucleic Acids Res. 16:369 (1988)), which permits in vitro transcription from the T7 promoter. The following pTL1 constructs were made by subcloning hD52-like coding sequences with flanking 5′-and 3′-UTR regions using internal restriction sites, and in some cases, those of the original pBS SK- multiple cloning sites: pTL1hD52, a BamH I-Bgl II fragment including nts 25-972 of hD52 was subcloned into the BamH I site of PTL1; pTL1mD52, a Pst I fragment including nts 1-832 ofmD52 was subcloned into the Pst I site of pTL1 ; and pTL1hD54−ins2, a Xho I-Pst I fragment including nts 51-662 of hD54−ins2 was subcloned into the Xho I and Pst I sites of pTL1. All pTL1 constructs were verified using automated sequencing (see below). A construct allowing prokaryotic expression of N-terminally GST-tagged mD52 protein was made using the pGEX3X-6His vector, representing a modified form of pGEX3X (Pharmacia) which also permits the incorporation of a C-terminal 6-histidine tag. Nhe I and Xba I restriction sites were introduced into the mD52 coding sequence using site-directed mutagenesis (Kunkel, T. A., et al, Methods Enzymol 154:367-382 (1987) and; Ausubel, F. M., et al, Current Protocols in Molecular Biology Vol. 1 (1997)) and the oligonucleotide primers 5′-G CGG GAG CGA GGT GGC GCT AGC ATG GAC CGC GGC GAG C-3′ (SEQ ID NO: 105) and 5′-G ATG ACA GAG AGC CCC TCT AGA GCC GAC CTG TGT CCT G-3′ (SEQ ID NO: 106), which permitted subcloning of the full-length mD52 coding sequence. Prior to subcloning into pGEX3X-6His, the mD52 insert subjected to mutagenesis was verified by automated sequencing (see below), as was the reading frame between sequences encoding GST and mD52 in the subsequently-generated pGEX3XrnD52-6His construct.

In vitro Transcription/translation

Coupled in vitro transcription and translation of D52-like proteins was performed using the TNT T7 wheat germ lysate system (Promega Corp.) according to the manufacturer's instructions. Briefly, 0.5 μg linearized plasmid DNA was included in a 25 μg l reaction volume with 2 μl translation grade ³⁵S-Methionine (Amersham Corp.) and incubated at 30° C. for 90 min. Protein product sizes were verified by electrophoresing 2.5 μl of each reaction through a 10% denaturing polyacrylamide gel which was then fixed, dried, and exposed to autoradiographic film (BioMax, Kodak) for 3 days at −80° C.

GST-pull Down Assays

Recombinant GST-mD52, and GST protein, were produced in the BL21 E. coli strain following the induction of log-phase cultures with 250 μg/ml IPTG for 2 h at 37° C. Proteins were isolated by incubating E. coli samples in isotonic lysis buffer (10 mM potassium phosphate pH 8.0, 140 mM KCl, 3 mM MgCl₂, 1 mM DTT, 0.5% Nonidet P-40, 0.5 mM PMSF) for 15 min on wet ice, followed by brief sonication. Protein product sizes were verified by electrophoresing pre- and post-induction protein samples on 10% SDS-polyacrylamide gels, followed by Coomassie Brilliant Blue staining. Post-induction protein extracts were incubated with glutathione-agarose (Sigma) which had been previously saturated in 0.5% (w/v) BSA (fraction V, Boehringer-Mannheim). Recombinant proteins (2-5 μg) bound to 30 μl glutathione agarose were then incubated with 7 μl of each in vitro translation reaction, and 2.6 mg soluble BL21 protein extract, prepared as described in Ausubel, F. M., el al., Current Protocols in Molecular Biology Vol. 3 (1996), for 2 h at 4° C. Matrixes were washed 3 times with 1 ml cold buffer (50 mM potassium phosphate pH 7.5, 150 mM KCl, 10 mM MgCl₂, 10% (v/v) glycerol, 1% Triton X-100, 0.5 mM PMSF), and bound proteins were eluted in 12 μl SDS-loading buffer (50 mM Tris pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 10% (v/v) 2-mercaptoethanol) by boiling for 5 min. Eluted proteins (6 μl) were separated on 10% SDS-polyacrylamide gels, which were stained with Coomassie Brilliant Blue, dried, and exposed to autoradiographic film (BioMax, Kodak) for 10 days at −80° C.

DNA Sequencing

Mini-preparations of plasmid DNA were further purified by NaCl and polyethyleneglycol 6000 precipitation, and sequenced with Taq polymerase and dye-labeled ddNTPs for detection on an Applied Biosystems 373A automated sequencer. The oligonucleotide primers 5′-TCATCGGAAGAGAGTAG-3′ (SEQ ID NO:107) (for pAS2-1 constructs) and 5′-TACCACTACAATGGATG-3′ (SEQ ID NO:108) (for pACT2 or pAD-GAL4 constructs) were used to permit sequencing of junctions between GAL4 and D52-like sequences. The T7 universal primer was used to determine 3′ insert sequences of pAD-GAL4 constructs, and to verify the orientations of inserts in pTL1 constructs. Complete insert sequences of pAD-GAL4 constructs were verified when required using internal hD52 or hD53 primers, and internal mD52 primers were used to verify the mD52 coding sequence subjected to site-directed mutagenesis, and the subsequently-derived pGEX3XmD52-6His construct.

Sequence Analyses

Searches of nucleotide databases (updated daily) were performed using BLASTN and TBLASTN programs (Altschul, S. F., et al., J. Mol. Biol. 215:403-410 (1990)). Multiple amino acid sequences were aligned using CLUSTAL (Thompson, J. D., et al., Nucleic Acids Res. 22:4673-4680(1994)), with coiled-coil domains being predicted using Pepcoil (Lupas, A., et al., Science 252:1162-1164(1991)).

Example 2

Identification of mD53

The mD53 cDNA was isolated from an embryonic stem cell cDNA library using an 842 bp hD53 cDNA as a probe (Byrne, J. A., et al., Genomics 35:523-532 (1996)). The 1307 bp mD53 cDNA (SEQ ID NO:3) includes a 615 bp coding region which predicts a 204 amino acid protein (SEQ ID NO:4). The hD53 and mD53 proteins are predicted to be 91% identical/93% conserved, and as such are more highly conserved than the majority of orthologous mouse and human proteins (Makalowski, W., et al., Genome Res. 8:846-857 (1996)).

In situ chromosomal mapping of the mD53 locus was performed, in order to determine whether the human and mouse loci are syntenically conserved. We elected to use a radioactively-labeled mDS3 cDNA for this purpose, because of the greater sensitivity afforded by this labeling technique for shorter DNA probes. The mD53 cDNA was tritium labeled by nick-translation to a specific activity of 1×10⁸ dpm/μg, and then hybridized to metaphase spreads at a final concentration of 100 ng/ml hybridization solution, as previously described (Mattei, M. G., et al., Hum. Genet. 69:268-271(1985)). This approach identified a single mD53 locus at the 10A4-10B2 region of the murine genome (FIG. 7). This region is within a larger syntenic group spanning 27-33 cM on the mouse chromosome 10 genetic map where the corresponding human loci have been localized to human chromosome 6q (Lyon, M. F., et al., Mouse Genome 95:29-77 (1997), and Taylor, B. A., et al., Mamm. Genome 6:S190-S200 (1996)). Since the hD53 gene has been previously mapped to human chromosome 6q22-q23 using the same method (Byrne, J. A., et al., Genomics 35:523-532 (1996)), the human and mouse D53 loci appear to be syntenically conserved.

The mammalian D52 gene family is thus emerging as being represented by genes found on different chromosomes (Byrne, J. A., et al., Genomics 35:523-532 (1996); and Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995)), Mourse et al., manuscript in preparation) whose loci are syntenically conserved between the human and mouse. The existence of multiple D52-like genes in mouse and human compared with a single D52-like gene in Caenorhabditis elegans (Byrne, J. A., et al., Genomics 35:523-532 (1996)) indicates that the former arose from a common ancestor through gene duplication events. Thus, syntenic conservation of D52-like loci between human and mouse indicates that both the derivation of D52-like genes and their dispersal over different chromosomes predate the evolutionary separation of primates and rodents some 80 million years ago (Byrne, J. A., et al., Genomics 35:523-532 (1996)).

Example 3

Identification of hD54

The present example outlines the identification of a novel human gene hD54, which represents a third D52 gene family member. In situ mapping placed the hD54 gene on human chromosome 20q13.2q13.3, a localization distinct from those of both hD52 and hD53 genes. The identification of hD54 cDNAs predicting 3 isomeric forms of hD54 suggested that alternatively-spliced transcripts may be produced from the 3 D52-like genes. RT-PCR amplification of D52-like transcripts from developing and adult rat tissues was performed to investigate coding sequence heterogeneity within D52-like transcripts. Direct sequencing of PCR products, and analyses ofthe expressed sequence tag divisions of nucleotide databases, indicated that alternatively-spliced transcripts predicting multiple protein isoforms are produced from all 3 D52-like genes. Differential regulation of the use of alternative coding sequence regions was indicated, with particular alternative splicing events being regulated in tissue-specific and temporal fashions.

Isolation of Human D54 cDNAs

A cDNA 192334 (GenBank Accession No. H39077), whose translated 5 ′-25 EST sequence showed 41.3% identity with amino acids 111-155 of hD52, and 62.3% identity with amino acids 129-180 of hD53, was obtained (Genome Systems Inc., St Louis, Mo.), and its insert sequenced on both strands. An open reading frame extending from the 5′-end was predicted to encode 67 amino acids, the sequence of which could be aligned with C-terminal portions of hD52 and hD53 (FIG. 8). The remainder of the nucleotide sequence represented a 1596 bp 3′-UTR, including an AATAAA polyadenylation signal. Since 192334 was thus likely a partial-length cDNA, a breast carcinoma cDNA library was screened with the most 5′ 193 bp of the 192334 cDNA insert in order to isolate full-length cDNAs.

Five cDNAs thus identified showed additional sequences at their 5′ ends with respect to the 192334 sequence, and the insert of one, H11, was sequenced on both strands. The presence of an ATG codon in a favourable context for translation initiation preceded by a stop codon indicated that the H11 cDNA consisted of a 76 bp 5′-UTR, a 621 bp coding sequence, and a 1605 bp 3′-UTR which was virtually identical to that of the 192334 cDNA. The translated H11 coding sequence was predicted to be 56% and 51% identical/67% and 60% similar to those of hD52 and hD53, respectively. Four gaps or insertions comprising 4 or more amino acids were however required for an optimal global alignment between these sequences (FIGS. 8A and B). We decided to term the novel human gene corresponding to the H11 cDNA, hD54, which is predicted to encode a protein of 206 amino acids with a molecular mass of approximately 22.2 kDa. Analysis of the hD54 sequence with the program Pepcoil (Lupas, A., et al., Science 252:1162-1164 (1991)) revealed the likely presence of a single coiled-coil domain from residues 37-81 (FIGS. 8A and B), which shows strong similarity in both its sequence, length and position to the predicted coiled-coil domains of hD52 and hD53 (Byrne, J. A., et al., Genomics 35:523-532 (1996)).

Somewhat unexpectedly, it was noted that the amino acid sequences predicted by the H11 and 192334 sequences were not identical. While residues 19-67 of 192334 were predicted to be identical to residues 158-206 of H11, residues 1-18 of 192334 could not be aligned with any H11 region (FIGS. 8A and B). However, residues 1-18 of 192334 were 83% identical to residues 178-197 of the quail D52 orthologue R10 (Proux, V., et al., .J. Biol. Chem. 271:30790-30797 (1996) and FIGS. 8A and B). In addition, residues 8-20 of 192234 were identical to residues 130-142 of hD53 (FIG. 8). Residues 175-197 of R10 and 130-142 of hD53 are present as insertions with respect to the global sequence alignment (FIGS. 8A and B), and as such, are not present in hD52 or H11 sequences. In order to further investigate the possibility of hD54 coding sequence heterogeneity, the coding sequences of 4 other breast carcinoma-derived hD54 cDNAs were determined on one strand. In all cases, sequences homologous to those encoding hD53, R10 or 192334 sequence insertions were not present, as in the H11 cDNA sequence (FIGS. 8A and B). However, the breast carcinoma-derived hD54 sequences were found to differ in the region predicted to encode amino acids 106-125 of H11 (FIGS. 8A and B and 9). These 20 residues are absent from D52 and hD53 sequences, and as such form another insertion (termed ins2) with respect to the global alignment (FIGS. 8A and B). In total., 2/5 cDNAs (H11 and L12) contained the 60 bp sequence encoding ins2 (FIG. 9). This region was absent from the G11 cDNA (FIGS. 8A and 9 and 9) and a further variation was noted in the identical cDNAs D12 and D1A, in which a 71 bp deletion (FIG. 9) was predicted to remove sequences encoding ins2, and an additional 4 residues. This deletion is not produced in-frame (FIG. 9), and a truncated product is predicted after 42 amino acids (FIGS. 8A and B). We refer to the 3 isomeric forms of hD54 thus predicted as hD54+ins2 (from the H11 and L12 cDNAs), hD54-ins2 (from the G11 cDNA), and hD54T (from the D12 and D1A cDNAs). Alignment of D52-like sequences also identified a 10 amino acid insert in all hD54 sequences, but not in any D52 or D53 sequences, which we termed ins1 (FIGS. 8A and B, encoded by nucleotides 137-166).

Visual inspection of sequence alignments identified a 14 residue motif (V,M)(T,Q)X(T,S)XAYKKTXETL (SEQ ID NO:44), found in all D52-like sequences except hD54T (FIG. 10), which will be termed hereafter the D52 motif The hD52, mD52, CSPP28, R10, hD53, mD53 (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995); Byrne, J. A., et al., Genomics 35:523-532 (1996); Parente (Jr), J A., et al., J. Biol. Chem. 271:20096-20101 (1996), Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)), and hD54−ins2 sequences bear a single D52 motif which crosses the ins2 insertion point in the global sequence alignment (FIGS. 8A and B). Thus the presence of ins2 in hD54+ins2 divides the D52 motif as this occurs in hD54−ins2 (FIGS. 8A and B). However, rather than removing the D52 motif, the presence of ins2 appears to create 2 closely-spaced D52 motifs in hD54+ins2, since the first 8 and last 6 amino acids of ins2 are in accordance with the last 8 and first 6 residues of the D52 motif consensus, respectively (FIGS. 8A and B and 10).

Chromosomal Localization of the hD54 Gene

In order to determine the chromosomal location of the hD54 gene, we performed in situ mapping on human metaphase spreads using the 192334 cDNA as a probe. In the 100 metaphase spreads examined after in situ hybridization, there were 191 silver grains associated with chromosomes and 53 of these (27.7%) were located on chromosome 20. The distribution of grains on this chromosome was not random, with 45/53 (84.9%) mapping to the q13.2-q13.3 region of the chromosome 20 long arm. These results allowed us to map the hD54 locus to the 20q13.2-13.3 region of the human genome (FIG. 11), a localization which is independent of these previously demonstrated for the hD52 and hD53 genes on chromosomes 8q21 and 6q22-q23, respectively (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995)).

Analysis of Transcribed D52-like Sequence Heterogeneity

As coding sequence heterogeneity had been indicated within hD54 transcripts, Northern blot analyses were performed to assess D54 transcript lengths and levels in a panel of adult rat tissues (brain, kidney, liver, testis, stomach and skeletal muscle). A 2.3 kb D54 transcript was detected very weakly in brain and kidney after 7 days of autoradiographic exposure, whereas D54 transcripts were undetectable in liver, testis, stomach and skeletal muscle. The finding of a single D54 transcript was however in accordance with the hD54 cDNA sequence variations observed (FIGS. 8A and B and 9), which would be predicted to alter the hD54 transcript length by at most 71 bp. In order to more reliably examine potential variations in transcribed D54 sequences, PCR primers were designed to permit RT-PCR amplification of D54 coding sequences (Table 4).

The sequences targeted by RT-PCR were those encompassing 4 insertions identified in the global alignment of D52-like sequences, since cDNA cloning had indicated that sequence heterogeneity involved D54 sequences encoding 2 such insertions, namely ins2 and ins3 (FIGS. 8A and B). Furthermore, since the levels of conservation between D52, D53 and D54 coding sequences might be predicted to reflect similarities in their respective gene structures, PCR primers were also designed for the amplification of the homologous coding regions of D52 and D53 genes (Table 4). Potential variations in transcribed DS2-like sequences were thus investigated in 6 adult rat tissues (brain, kidney, liver, testis, stomach and cardiac atrium), in brain and liver from 12.5 dpc rat fetuses, and in brain, skeletal muscle and liver samples from 5 additional developmental time-points (14.5 dpc and 16.5 dpc, birth, and 3 and 6 weeks of age).

TABLE 4 Primer sequences used in RT-PCR analysis of D52-like transcripts with their corresponding predicted PCR product sizes. PCR Primers Gene Insert Name Sequence Predicted Sizes of PCR Products (bp) D52 1 5′D52INS1 ATGGACCGCGGCGAGCAAGG (SEQ ID NO:45) −ins1 +ins1 3′D52INS1 TGGGACAGAGTCTGGATTTC (SEQ ID NO:46) 164 194 2 5′D52INS2 GCCAAAGGGTGGCAAGACG (SEQ ID NO:47) −ins2 +ins2 3′D52INS2 TTTGGTGATGACTGAGCC (SEQ ID NO:48) 120 180 3&4 5′D52INS3 GTCATCACCAAAAAGCTGG (SEQ ID NO:49) −ins3−ins4 −ins3+ ins4 +ins3−ins4 +ins3+ins4 3′D52INS3 AGCAGGCTTGGCTCCTCC (SEQ ID NO:50) 105 117 144 156 D53 1 5′D53INS1 ATGGAGGCGCAGGCACAAGG (SEQ ID NO:51) −ins1 +ins1 3′D53INS1 CATGCTAGAGAAGTCAGC (SEQ ID NO:52)  90 120 2 5′D53INS2 ACGACAAGTTTTGTCAGC (SEQ ID NO:53) −ins2 +ins2 3′D53INS2 TTCTTGCTGATGGCAGTTCC (SEQ ID NO:54) 213 273 3&4 5′D53INS3 CCCTGAGCCACGCAGGGC (SEQ ID NO:55) −ins3−ins4 −ins3+ins4 +ins3−ins4 +ins3+ins4 3′D53INS3 CTGTGAGCTGGCGTGTGC (SEQ ID NO:56) 209 221 248 260 D54 1 5′D54INS1 ATGGACTCTGCTAGCC (SEQ ID NO:57) −ins1 +ins1 3′D54INS1 CCTGGCGCAGAGTGAC (SEQ ID NO:58) 166 196 2 5′D54INS2 GTCACTCTGCGCCAGG (SEQ ID NO:59) −ins2 +ins2 3′D54INS2 TCCAAGCTTCCTGCTG (SEQ ID NO:60) 228 288 3&4 5′D54INS3 AGCAGGAAGCTTGGAG (SEQ ID NO:61) −ins3−ins4 −ins3+ins4 +ins3−ins4 +ins3+ins4 3′D54INS3 CTCTGCCACCCACAACC (SEQ ID NO:62)  94 106 133 145

Coding Sequence Heterogeneity in D54 Transcripts in Rat Tissues

RT-PCR amplification of D54 coding sequences, as predicted from the results of cDNA cloning, indicated coding sequence heterogeneity within D54 transcripts. Whereas amplification of rat D54 sequences flanking those encoding ins1 resulted in a single 196 bp PCR product, which sequencing confirmed to contain sequences encoding ins1, in all tissue samples examined (FIG. 12A), amplification of rat D54 sequences flanking those encoding ins2 resulted in PCR products of 288 bp and/or 228 bp, which sequencing confirmed to contain sequences predicting the presence or absence of ins2, respectively (FIG. 12B). Both 228 and 288 bp PCR products were obtained from cardiac atrium, testis, skeletal muscle and brain, whereas only the 288 bp PCR product was obtained from liver, stomach and kidney (FIG. 12B).

Amplification of rat D54 sequences flanking those encoding ins3 and ins4 routinely resulted in PCR products of 94 and 139 bp in all tissues examined, except brain (FIG. 12C). Sequencing of the 94 bp PCR product confirmed the absence of sequences encoding ins3 and ins4 (FIG. 12C). Two PCR products of 139 and 163 bp were obtained in all brain samples, with the larger 163 bp PCR product encoding an ins3 sequence of 23 amino acids (FIG. 12C). The first 20 amino acids predicted by the partial-length 192334 cDNA were 90% identical to the C-terminal 20 amino acids of this ins3 sequence (FIG. 12C).

Coding Sequence Heterogeneity in D52 and D53 Transcripts in Rat Tissues

RT-PCR amplification of D52 and D53 sequences also indicated coding sequence heterogeneity within D52 and D53 transcripts. Whereas amplification of rat D52 sequences flanking those encoding ins1 or ins2 gave rise to single PCR products lacking sequences encoding ins1 or ins2 in all tissues examined (FIGS. 13A and B), amplification of sequences flanking those encoding ins3 and ins4 resulted in up to 3 PCR products (FIG. 13C). Sequencing of a 105 bp PCR product identified in all tissue samples confirmed the absence of sequences encoding ins3 or ins4 (FIGS. 13C and C-1). However, sequencing of a 147 bp PCR product identified in all brain samples indicated this to encode a 14 amino acid ins3 sequence (FIG. 13C), which was 93% identical to the 14 C-terminal residues of the quail D52 orthologue R10 ins3 sequence (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)). An additional 174 bp PCR product was detected in all brain samples other than 12.5 dpc fetal brain, and was the major PCR product identified within post-natal brain samples (FIG. 13C and C-1). Sequencing of this 174 bp product identified a 23 amino acid ins3 sequence, which was 96% identical to the 23 amino acid R10 ins3 sequence, and whose 14 C-terminal residues were identical to the ins3 sequence of the 147 bp PCR product (FIGS. 13C and C-1).

Amplification of rat D53 sequences flanking those encoding ins1 or ins2 also produced single PCR products lacking sequences encoding ins1 or ins2 (FIGS. 14A, B, and B-1). However, amplification of rat D53 sequences flanking those encoding ins3 and ins4 from adult cardiac atrium, stomach, liver, kidney, testis and brain resulted in a major 160 bp PCR product (FIG. 14A) whose size was not predicted from any combination ofthe presence or absence of sequences encoding ins3 and/or ins4 (Table 4). Sequencing of this 160 bp PCR product revealed a 100 bp internal deletion including sequences encoding ins3 and ins4 (FIG. 14B-1). This deletion was not produced in-frame, and thus a truncated protein is predicted 3 amino acids after the deletion point (FIG. 14B-1). In addition, sequencing of a 272 bp PCR product from 6 week and adult brain samples showed that this encodes an 18 amino acid ins3 sequence, in addition to ins4 (FIG. 14B-1). The 13 most C-terminal residues of this ins3 sequence were identical to the mD53 ins3 sequence (FIG. 14B-1), and the ins4 sequence was also identical to that of mD53 (FIG. 14B-1).

D52-like Coding Sequence Heterogeneity Indicated by EST Database Analyses

The EST divisions of nucleotide sequence databases provide a resource by which sequences of randomly-selected D52, D53 and D54 cDNAs from a diversity of cDNA libraries could be compared. We regularly performed TBLASTN searches to identify ESTs presenting significant homology with the coding sequences of DS2-like cDNAs. Fifty-nine mouse, rat and human ESTs were identified of which 11, 14 and 34 corresponded to D52, D53 and D54 cDNAs, respectively (Table 5).

TABLE 5 The status of D52-like expressed sequence tags with respect to sequences encoding ins1, ins2, ins3 and ins4. Numbers that appear in superscript after each entry indicate the cDNA library of origin: ¹human retina; ²human placenta; ³human fetal lung; ⁴human fetal heart; ⁵mouse pooled organs; ⁶human fetus (8-9 weeks); ⁷human pancreatic carcinoma; ⁸mouse embryo ectoplacental cone; ⁹HeLa; ¹⁰mouse adult brain; ¹¹mouse kidney; ¹²mouse; ¹³mouse skin; ¹⁴human fetal liver-spleen; ¹⁵human colon; ¹⁶human liver; ¹⁷human multiple sclerosis lesions; ¹⁸mouse embryo; ¹⁹human pregnant uterus; ²⁰mouse thymus; ²¹mouse liver; ²²mouse lymph node; ²³rat; ²⁴human adult brain; ²⁵human testis. ⁺Predicts a truncated D53 isoform due to a 61 bp deletion occurring after sequences encoding ins3; *Predicts a truncated D53 isoform due to a 100 bp deletion occurring before sequences encoding ins3. Gene Insert Insert Present Insert Absent D52 ins1 0/5 5/5 (AA016984¹, R27168², W25008³, W67735⁴, AA245630⁵) ins2 0/6 6/6 (AA016984¹, R64056², W25008³, W25876¹, W67735⁴, AA245630⁵) ins3 ¼ (W25876¹) ¾ (AA069079⁷, R64056², AA408435⁸) ins4 0/3 3/3 (AA069079⁷, R64056², AA408435⁸) D53 ins1 0/5 5/5 (AA182908⁹, W93489⁴, W49042¹⁰, AA240722¹¹, AA278103¹²) ins2 0/3 3/3 (AA066421¹³, W93489⁴, AA278103¹²) ins3 3/8 (T89899¹⁴, T93647¹⁴, W69680^(4,+)) 5/8 (AA055718^(15,)*, AA066421^(13,)*, T68402^(16,*), W11611^(12,)*, W14257^(12,)*) ins4 3/3 (T89899¹⁴, T93647¹⁴, N99206¹⁷) 0/3 D54 ins1 22/22 (AA004043¹⁸, AA008731¹⁸, AA031903¹⁹, AA071975¹⁰, 0/22 AA103819¹⁸, AA124904¹¹, W10501¹², W20813¹², W54810¹⁸, W66669¹⁸, W82290¹², W91446¹⁸, W97219¹⁸, AA218395¹², AA268015²¹, AA266320⁵, AA255184²², AA071975¹⁰, W75292¹⁸, AA048792¹⁸, H31879²³, AA277778⁵) ins2 1/9 (AA031903¹⁹) 8/9 (AA008731¹⁸, W20813¹², W82290¹², AA218395¹², AA268015²¹, AA266320⁵, W75292¹⁸, AA277778⁵) ins3 3/6 (W13944¹², H39077²⁴, AA277778⁵) 3/6 (W82290¹², AA218395¹², AA411964²⁵) ins4 0/9 9/9 (W13944¹², W82290¹², AA218395¹², AA124922²⁰, H39077²⁴, AA116313²⁰, W75408¹⁸, AA277778⁵, AA436748⁶)

The 11 D52 EST sequences (Table 5) were essentially in accordance with D52 cDNA sequences previously reported (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995); Chen, S-L., et al., Oncogene 12:741-751 (1996); Byrne, J. A., et al., Genomics 35:523-532 (1996); Parente (Jr), J A., et al., J. Biol. Chem. 271:20096-20101 (1996), Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)), as sequences encoding ins1, ins2, ins3 and ins4 were absent in 5/5, 6/6, 3/4 and 3/3 ESTs, respectively (Table 5). A single EST from an adult human retina cDNA library (GenBank Accession No. W25876) contained an additional 70 bp and 166 bp at the ins2 and ins3 insertion points, respectively, when compared with the hD52 sequence (FIG. 15). The 70 bp W25876 insertion occurred at a point at which sequences encoding ins2 might be inserted (FIG. 8), but shows no homology with hD54 sequences encoding ins2, and a continuation of the reading frame predicts a stop codon at nucleotides 130-132 (FIG. 15). Alignment of the W25876 sequence with that of the quail D52 orthologue R10 (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)), indicated that the 166 bp W25876 sequence insertion encodes a 24 residue ins3 sequence which is 91% identical to the R10 ins3 sequence (FIG. 15). The alignment between the 2 sequences was however interrupted twice by additional sequences present in W25876 (FIG. 15).

The 14 D53 EST sequences (Table 5) were also largely in accordance with D53 cDNA sequences previously reported (Byrne, J. A., et al., Genomics 35:523-532 (1996)). Sequences homologous to those encoding ins1 and ins2 were absent from 5/5 and 3/3 ESTs, respectively, and 2 ESTs (T89899 and T93647) contained sequences encoding both ins3 and ins4 (Table 5) as predicted from both hD53 and mD53 sequences (Byrne, J. A., et al., Genomics 35:523-532 (1996)). However, 5 ESTs showed evidence of a 100 bp deletion (corresponding to hD53 nucleotides 567-666), which had been previously identified in the sequence of the 83289 cDNA (corresponding to one of these 5 ESTs, Genbank Accession Nos. T68402 and U44429). This deletion is predicted to introduce a frame-shift after hD53 Met¹²⁸, resulting in a truncation after 3 amino acids (FIG. 14B-1). A single EST (GenBank Accession No. W69680) contained a similar deletion of 61 bp (corresponding to hD53 nucleotides 606-666) which is predicted to introduce an identical frame-shift after hD53 Met¹⁴¹ (FIGS. 8A and B).

Sequences of the 34 D54 ESTs identified (Table 5) were also largely in accordance with those of the hD54 cDNAs isolated from the human breast carcinoma cDNA library. A total of 22/22 ESTs included sequences encoding ins1, as identified in 5/5 breast carcinoma-derived hD54 cDNAs. The sequence region encoding ins2 was present in 1/9 D54 ESTs, and similarly in 1/5 breast carcinoma-derived hD54 cDNAs. Ins3 was predicted to be encoded by 3/6 ESTs identified, including that corresponding to the 192334 cDNA (FIGS. 8A and B). The remaining 2 ESTs predicted 14 residue ins3 sequences identical to the 14 most C-terminal residues of the 23 residue D54 ins3 sequence predicted by RT-PCR analyses (FIG. 12C). Ins4 was predicted to be absent from 9/9 D54 ESTs, as was the case for all hD54 cDNAs sequenced (FIGS. 8A and B and Table 5).

Discussion

We report the identification and cloning of a third member of the D52 gene family, which we have named D54. Using a strategy similar to that used to identify the second member of the D52 family, D53 (Byrne, J. A., et al., Genomics 35:523-532 (1996)), an EST was identified whose translated sequence showed homology to other D52-like sequences, and the corresponding 192334 cDNA was used to isolate full-length hD54 cDNAs from a human breast carcinoma cDNA library. Interestingly, the 192334 cDNA was subsequently shown to contain sequences (nucleotides 1-55 of SEQ ID NO:7) that were not present in 5 breast carcinoma-derived hD54 cDNAs. It might be hypothesized that these coding sequence differences could indicate that the 192334 and breast carcinoma-derived hD54 cDNAs derive from separate genes. However, this is unlikely, since sequence analysis of the 192334 and H11 3′-UTRs showed these to be virtually identical over 1588 bp. The assignment of a separate locus for hD54 on chromosome 20q13.2-q3.3, which is clearly independent of those previously demonstrated for hD52 and hD53 (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995); Byrne, J. A., et al., Genomics 35:523-532 (1996)), confirmed that D54 represents a unique member of the D52 gene family. We have thus showed, as have others (Allikmets, R., et al., Hum. Mol Genet 5:1649-1655 (1996)), that use of EST sequences is an effective strategy for characterizing members of a gene family.

A comparison of the coding sequences of hD54 cDNAs indicated heterogeneity with respect to sequences encoding 2 insertions in the global alignment of D52-like protein sequences. Due to the level of identity between D52-like protein sequences we examined using RT-PCR whether sequences encoding 4 such insertions exhibited heterogeneity in transcripts from all 3 D52-like genes. As a complement to this approach, we also conducted searches of the EST divisions of nucleotide databases, in order to identify ESTs deriving from known d52-like genes. The large number of ESTs deposited in public databases means that a certain level of redundancy exists (Gerhold, D. & Caskey, C. T., Bioessays 18:973-981 (1996)), despite the use in some instances, of normalized cDNA libraries (Bonaldo, M. F., et al., Genome Res. 6:791-806 (1996)). This fact has recently been exploited to obtain information about alternative splicing events occurring in gene transcripts deriving from a variety of tissue types (Wolfsberg, T. G. & Landsman, D., Nucleic Acids Res. 25:1626-1632 (1997)). In the present study, data from cDNA cloning, RT-PCR and EST sequence analyses have suggested that while certain insertions in the global alignment of D52-like sequences reflect constitutive differences between individual D52-like genes, others are likely to result from alternative exon splicing.

Sequences encoding ins1 and ins4, as identified in hD54 and D53 cDNA sequences (Byrne, J. A., et al., Genomics 35:523-532 (1996)), respectively, were uniquely and consistently identified in D54 or D53 transcripts only. When PCR primers encompassed sequences flanking the ins1 insertion point, single PCR products were obtained from all 3 D52-like genes in all rat tissue samples examined. In the case of D54 transcripts, PCR products encoded ins1, but in the case of D53 and D52 transcripts sequences encoding ins1 were absent. Similarly, all 22 D54 ESTs which included sequences flanking the ins1 insertion point encoded an ins1 sequence, whereas none of the D52 or D53 ESTs included homologous sequences. Thus ins1 is predicted to be encoded by a D54 coding region which represents a constitutive difference between D54, D52 and D53 genes. Similarly, RT-PCR and EST sequence analyses identified sequences encoding ins4 as a constitutive coding sequence difference between D53 transcripts, and D52 and D54 transcripts.

In contrast, ins2 and ins3 sequences appear to be encoded by alternatively-spliced exon(s) present in one or more D52-like genes. The results of cDNA cloning, RT-PCR, and EST sequence analyses indicated that sequences encoding ins2 were either present in or absent from D54 transcripts. However, these approaches did not identify homologous sequences encoding similar amino acid sequences in either D52 or D53 transcripts. One hD52 EST W25876 contained a 70 bp sequence insertion with respect to D52 cDNA sequences at the point at which sequences encoding ins2 might be inserted, but this sequence showed no homology with hD54 sequences encoding ins2. That a continuation of the W25876 reading frame predicts a stop codon suggests that this EST derives from an incompletely spliced transcript and that the 70 bp insertion represents intronic sequence. The point at which sequences encoding ins2 would be predicted to be inserted in the R10 gene has also been indicated to represent an exon-intron boundary (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)), indicating structural similarities between quail and human D52 genes. Thus, ins2 appears to be encoded by one or more alternatively-spliced D54 exons for which equivalents may not exist in D52 or D53. The presence of ins2 in D54 isoforms would not appear to pertain to any putative spatio- or temporally-specific D54 protein function, as the alternative splicing of sequences encoding ins2 did not seem to be regulated in an obviously tissue-specific or temporal fashion.

Sequence analyses predict that the significance of ins2 lies in the fact that its presence effectively duplicates hD54−ins2 residues Val¹⁰⁰-Ala¹⁰⁵ and Tyr¹⁰⁶-Leu¹¹³, found N- and C-terminal to the ins2 insertion point, respectively. The residues Val¹⁰⁰-Ala¹⁰⁵ are homologous to D52 residues Val⁹⁰-Ala⁹⁵ which map withing a larger regions (Gly⁷²-Ala⁹⁵), implicated as being involved in mediating protein-protein interactions of D52/N8 (Chen et al., Oncogene 15:2577-2588 (1997); Byrne et al., Oncogene 16:873-882 (1998)). In these studies, a truncated hD52/N8 protein N8LZ (Met¹-Ala⁹⁵) did not form homomeric interactions, unlike wild-type D52/N8, whereas a truncated mD52 bait protein (Met¹-Ala⁹⁵) formed interactions withing the yeast two-hybrid system. Therefore, whereas interactions mediated by D52 proteins had been previously attributed to the coiled-coil domain, residues Gly⁷²-Ala⁹⁵ may therefore also be necessary, or even sufficient, for certain interactions to occur. Since the corresponding D54 region (Gly⁸²-Ala¹⁰⁵) is well conserved, this implicated ins2, as potentially modulating interactions mediated by D54. The interactions mediated by the hD54 isoforms hD54+ins2 and hD54−ins2 and other D52-like proteins were recently examined, and while it was found that the presence of ins2 did not obviously alter interaction preferences, both hD54 isoforms interacted more strongly with hD54+ins2 than with hD54−ins2 (Byrne et al., Oncogene 16:873-882 (1998)).

Whereas alternatively-spliced coding sequences encoding ins2 were only identified in D54 transcripts, sequences encoding ins3 appeared to be subject to alternative splicing in all 3 D52-like genes. Sequences encoding a 13 residue ins3 sequence were initially identified in hD53 cDNAs from breast carcinoma and fetal liver-spleen, but not in D52 cDNAs from several tissues (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995); Chen, S-L., et al., Oncogene 12:741-751 (1996); Byrne, J. A., et al., Genomics 35:523-532 (1996); Parente, J. A. et al., J. Biol. Chem. 271:30790-30797 (1996)). However, the present study has indicated that sequences encoding ins3 can be present in D52 and D54 transcripts, particularly those expressed in neural tissues. The presence of sequences encoding ins3 in D54 transcripts was first indicated by the partial-length 192334 cDNA from adult human brain. The 20 predicted N-terminal 192334 residues were 90% identical to the C-terminal 20 residues of a 23 residue ins3 sequence predicted by the quail D52 orthologue R10 (Proux, V., et al., J. Biol. Chem. 271:30790-30797 (1996)), the R10 cDNA having been isolated from an embryonic neuroretina cDNA library. RT-PCR analyses subsequently predicted a 23 residue ins3 sequence in D54 transcripts from post-natal brain samples, which was 75% identical to the R10 ins3 sequence. A shorter 14 residue ins3 sequence predicted by 2 mouse D54 ESTs (Table 5) was identical to the C-terminal 14 amino acids of the longer D54 ins3 sequence. Similarly, RT-PCR analyses of D52 transcripts from post-natal rat brain samples indicated that the major PCR product encoded a 23 residue ins3 sequence which was 96% identical to the R10 ins3 sequence. A shorter PCR product obtained from both fetal and post-natal brain samples predicted a 14 residue ins3 sequence identical to the 14 C-terminal residues ofthe longer ins3 sequence. As a larger 18 residue ins3 sequence was also identified in rat D53 transcripts from 6 week and adult brain samples, the 13 most C-terminal residues of which were identical to the 13 residue D53 ins3 sequences previously reported (Byrne, J. A., et al., Genomics 35:523-532 (1996)), it appears that transcripts from all 3 D52 genes may encode long and short forms of ins3.

RT-PCR analysis of D54 and D52 transcripts indicated those encoding long ins3 sequences were only identified in brain samples, thus providing an example where alternative splicing of D52 and D54 sequences appears to be regulated in a tissue-specific fashion. In addition, since PCR products predicting 23 residue D52 or D54 ins3 sequences were also more abundant in post-natal brain samples, the alternative splicing of these sequences appears to be temporally regulated. This additionally suggests that the presence ofD52 and D54 transcript sequences encoding long ins3 sequences correlates with brain maturation processes.

The W25876 EST, deriving from an apparently incompletely-spliced D52 transcript from human retina, provides a possible explanation for the existence of short and long ins3 sequences in D52-like proteins. An alignment of the W25876 nucleotide sequence with those of hD52 and R10 indicates that the W25876 sequence encodes a 23 amino acid ins3 sequence which is 91% identical to that of R10. The position of non-aligned W25876 sequence with respect to the R10 sequence, combined with the absence of ins3 sequences in some D52 transcripts (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995); Chen, S-L., et al., Oncogene 12:741-751 (1996); Byrne, J. A., et al., Genomics 35:523-532 (1996); Parente, J. A. et al., J. Biol. Chem. 2 71:30790-30797 (1996)) suggests that the 23 residue hD52 ins3 sequence is contributed to by at least 3 separate exons, including a very small 4 bp exon. The use of multiple exons may thus determine the ultimate length of encoded ins3 sequences as reported for tissue-specific forms of the neural cell adhesion molecule (N-CAM), where 4 exons (including one of 3 bp) were found to encode a 93 bp insert in N-CAM mRNAs specific for chicken heart and skeletal muscle (Prediger, E. A., et al., Proc. Natl. Acad. Sci. USA 85:9616-9620 (1988)).

While sequences encoding ins3 regions were observed to be either present in or absent from D52 and D54 transcripts, the absence of such sequences from D53 transcripts was only produced by a 100 bp deletion predicted to introduce a frame-shift after Met¹²⁸, and resulting in a truncated D53 product. This 100 bp deletion does not appear to occur in a tissue-specific fashion, having been identified inD53 transcripts from 10 rat, mouse and human tissues using RT-PCR, EST sequence analyses, and a yeast two-hybrid screening approach. The fact that similarly-truncated proteins were not predicted by D52 or D54 sequences suggests functional differences between D53, and other D52-like proteins. However, the diversity of alternative splicing events affecting sequences encoding ins3 in all 3 genes strongly indicates that the presence or absence of ins3 sequences plays an important role in modulating D52-like protein function.

In summary, we have isolated and characterized a third member of the breast carcinoma-derived D52 gene family, and using a combination of approaches, have indicated that a wealth of protein isoforms may be produced from all 3 D52-like genes. In particular, alternative splicing events involving sequences encoding ins3 sequences appear to be regulated in a tissue-specific and temporal fashion in the case of D52 and D54 genes.

Materials and Methods

cDNA Library Screening

The cDNA 192334, originally isolated by the IMAGE consortium (Lennon, G., et al., Genomics 33:151-152 (1996)) was purchased from Genome Systems, Inc. (St. Louis, Mo.). A random-primed ³²P-labeled BamHI-EcoRI clone 192334 fragment (including nucleotides 1-188 of SEQ ID NO:7) was used to screen 600,000 plaque forming units from a breast carcinoma cDNA library, basically as described (Byrne, J. A., el al., Cancer Res. 55:2896-2903 (1995)).

Chromosomal Localization

Chromosomal localization of the hD54 gene was performed using chromosome preparations obtained from phytohemagglutinin-stimulated lymphocytes as previously described (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995)). The 192334 cDNA was ³H-labeled using nick-translation to a final specific activity of 1×10⁸ dpm/μg, and hybridized to metaphase spreads at a final concentration of 100 ng/ml of hybridization solution, as described (Mattei, M. G., et al., Hum. Genet. 69:268-271 (1985)). Autoradiography was performed using NTB2 emulsion (Kodak) for 18 days at 4° C.

RNA Extraction and Northern Blot Analyses

Brain, skeletal muscle and liver samples were dissected from 14.5 dpc and 16.5 dpc rat fetuses, and from neonatal., 3 week old and 6 week old female Sprague-Dawley rats. Only brain and liver samples were dissected from 12.5 dpc fetuses. Where tissues were dissected from multiple animals, these were pooled prior to RNA extraction. Total RNA was extracted from frozen tissue samples using TRizol reagent, according to instructions supplied by the manufacturer (Gibco BRL, Life Technologies, Inc, Australia). Total cellular RNA was isolated from 7 tissue samples (skeletal muscle, cardiac atrium, stomach, testis, liver, kidney and brain) obtained from adult rats using the guanidine hydrochloride procedure (Strohmann, R. C., et al., Cell 10:265-273 (1977)). Ten μg aliquots of total RNA were subjected to Northern blot analysis basically as described (Byrne, J. A., et al., Cancer Res. 55:2896-2903 (1995)). Filters were hybridized successively with ³²P-labeled cDNA fragments deriving from 192334 (including nucleotides 1-188 of SEQ ID NO:7), and 36B4 (Masiakowski, P., et al., Nucleic Acids Res. 10:7895-7903 (1982)) cDNAs, the latter representing a ubiquitously expressed gene. Filters were washed to final stringencies of 1×SSC, 0.1% SDS at 65° C. or 0.1×SSC, 0.1% SDS at 65° C. following hybridizations employing the 192334 or 36B4 probes, respectively.

cDNA synthesis and RT-PCR amplification

Ten μg samples of total RNA primed with random hexamers were reverse-transcribed using Superscript II Reverse Transcriptase in total reaction volumes of 50 μl, according to the manufacturers instructions (Gibco BRL, Life Technologies, Inc.). Control reactions were routinely included where the RNA template was omitted. One half μl of each cDNA synthesis reaction was subjected to RT-PCR amplification in 40 μl reaction volumes including 4 μl 10×PCR buffer containing magnesium (Boehringer Mannheim), 0.8 μl PCR nucleotide mix (10 mM each dNTP) (Boehringer Mannheim), 0.4 μl each primer (100 mM), and 0.2 μl Taq DNA polymerase (5 U/μl) (Boehringer Mannheim). Reactions were first denatured at 94° C. for 3 min, followed by 30 cycles of denaturation (94° C. for 45 s), annealing (55 or 60° C. for 1 min 30 s or 1 min), and elongation (72° C. for 1 min) in a DNA Engine PTC-200 (MJ Research). The final elongation step was performed at 72° C. for 5 min. PCR products were separated on 4-5% MetaPhor agarose gels (FMC BioProducts Corp.) run overnight at 30-40 V. PCR primers for RT-PCR analyses were based upon the human and/or mouse D52-like sequences (GenBank Accession Nos. U44426, AF004428, AF004430 and W82290). Three sets of primers were synthesized for each D52-like gene (see below). As a positive reaction control, and also to assist in sizing PCR products, PCR amplifications were also performed using an appropriate mouse or human D52, D53 or D54 cDNA template. Negative RT-PCR amplification controls consisted of those in which the cDNA template had been omitted and/or replaced by a control cDNA synthesis reaction in which the RNA template had been omitted.

Purification of PCR Products for Sequencing

PCR products of interest were excised from agarose gels, and following centrifugation through siliconized glass wool, 2 μl elutant was re-amplified using the previous PCR amplification conditions (see above). The sizes and purity of PCR products were reconfirmed using agarose gel electrophoresis. PCR products were then purified on PCR SPINCLEAN columns according to the manufacturer's instructions (Progen Industries Ltd, Australia).

DNA Sequencing

Mini-preparations of plasmid DNA were purified by NaCl and polyethylene glycol 6000 precipitation, and sequenced with Taq polymerase and T3 and T7 universal primers, or internal primers, and dye-labeled ddNTPs for detection on an Applied Biosystems 373A automated sequencer. Sequencing of PCR products was performed using internal primers and/or PCR primers, where suitable internal primers could not be designed.

Sequence Analyses

Searches of nucleotide databases were performed using the TBLASTN program (Altschul, S. F., et al., J. Mol. Biol. 215:403-410 (1990)), using D52, D53 and hD54+ins2 amino acid sequences as the query sequence. Multiple nucleotide or amino acid sequences were aligned using CLUSTAL (Thompson, J. D., et al., Nucleic Acids Res. 22:4673-4680 (1994)), with other analyses employing programs from the GCG package, including Pepcoil, for the identification of coiled-coil domains (Lupas, A., el al., Science 252:1162-1164 (1991)).

Example 4

Increased Copy Number of hD54 in Breast Carcinomas

Increased dosage of cellular oncogenes is a frequent genetic abnormality displayed by tumor cells (Schwab M. and Amler L. C., Genes Chromosome Cancer 1: 181-193 (1990); Schwab M. BioEssays, 20:473-479 (1998)), and the study of oncogene amplification has been of seminal importance in molecular oncology. The genome scanning technique of comparative genomic hybridization (CGH) has indicated that several regions apart from those classically studied can be gained in breast carcinoma, one such region being the long (q) arm of chromosome 8 (reviewed by Forozan et al., Trends Genet. 13:405-409 (1997); Knuutila et al.,. J. Am. Pathol., 152:1107-1123 (1998)). Chromosome 8q has been observed to be amongst the most frequently gained regions (Kallioniemi et al., Proc. Natl Acad. Sci. USA 91:2156-2160 (1994): Isola et al., Am. J. Pathol., 147:905-911 (1995); Reid et al.,. Cancer Res. 55:5415-5423 (1995); Nishizaki et al., J. Int. Cancer (Pred. Oncol). 74:513-517 (1997a); Nishizaki et al., Genes Chromosom. Cancer 19:267-272 (1997b); Tirkkonen et al., Genes Chromosom. Cancer 21:177-184 (1998)), or indeed the most frequently gained genomic region, in breast cancer (Muleris et al., Genes Chromosom. Cancer 10:160-170 (1994); Courjal et al., Cancer Res. 57:4360-4367 (1997)). Nishizaki et al., Genes Chromosom. Cancer 19:267-272 (1997b) reported that the gain of chromosome 8q was significantly more frequent in ductal than in lobular cancers, and similarly, Afify A. et al., Breast Cancer Res. Treat., 38:201-208 (1996), detected chromosome 8 gain in infiltrating ductal carcinomas and ductal carcinoma in situ but not in lobular or pillary card benign lesions. In a genome-wide screen to detect genetic changes associated with clinical outcome in node-negative breast cancer, Isola et al., Am. J. Pathol., 147:905-911 (1995) reported that a high-level gain of chromosome 8q was significantly associated with recurrence. These combined data suggest that chromosome 8q gain is a frequent event defining a subset of breast carcinomas, which is of potential prognostic significance.

That gain of the 8q chromosomal arm reflects the existence of more than one 8q target gene was suggested by the finding that the 8q24, 8q22-q23 and 8q21 regions could be gained separately in breast cancers or cell lines (Kallioniemi et al., Proc. Natl Acad Sci. USA 91:2156-2160 (1994)). Regions including chromosome bands 8q24, 8q23 and/or 8q22 have been observed to be separately gained in other breast cancer studies (Muleris et al., Genes Chromosom. Cancer 10: 160-170 (1994); Reid et al.,. Cancer Res. 55:5415-5423 (1995), Courjal et al.,.Cancer Res. 57:4368-4377 (1997); Nishizaki et al., J. Int. Cancer (Pred. Oncol). 74:513-517 (1997a); Nishizaki et al., Genes Chromosom. Cancer 19:267-272 (1997b)), and in other cancers such as bladder cancer (Kallioniemi A., et al., Genes Chromosom. Cancer 12:213-219 (1995); Richter et al., Cancer Res. 57:2860-2864 (1997)), hepatocellular carcinoma (Fujiwara et al., Cancer Res. 53:857-860 (1993)), lung cancer (Balsara et al., Cancer Res. 57:2116-2120 (1997), Petersen et al., Cancer Res. 57:2331-2335 (1997)), osteosarcoma (Tarkkanen et al., Cancer Res. 55:1334-1338 (1995)), ovarian cancer (Sonoda et al., Genes Chromosom. Cancer 20:320-328), and prostate cancer (Cher et al., Genes Chromosom. Cancer 11: 153-162 (1994), Visakorpi et al., Cancer Res. 55:342-347 (1995), Van Den Berg et al., Clin. Cancer Res. 1:11-1 8 (1995)). The c-myc gene may represent a target gene where gains include chromosome 8q24 (Jenkins et al., Cancer Res. 57:524-531 (1997)), although data exist to suggest that q-Myc represents a surrogate marker in some cases (Sauter et al., Am. J. Pathol. 146:1131-1139(1995); Visscher et al., Genes Chromosom Cancer 18:1-7 (1997)). The E2F5 gene at chromosome 8q22 was found to be present at ICN, albeit at low levels, in 4.2% of breast cancers (Courjal et al., Cancer Res. 57:4360-4367 (1997); Courjal et al., Cancer Res. 57:4368-4377 (1997)); but its status as a target gene was not investigated.

The chromosome 8q21 band was separately gained in the SK-BR-3 breast cancer cell line (Kallioniemi et al., Proc. Natl. Acad. Sci. USA 91:2156-2160 (1994)), and also either represented, or was included within, a minimal commonly-gained chromosome 8q region in prostate cancer (Cher et al., Genes Chromosom. Cancer 11:153-162 (1994); Cher et al., Cancer Res. 56:3091-3102 (1996)), bladder cancer (Kallioniemi A., et al., Genes Chromosom. Cancer 12:213-219 (1995); Richter et al., Cancer Res. 57:2860-2864 (1997)) and osteosarcoma (Tarkkanen et al., Cancer Res. 55:1334-1338 (1995)). This suggests that one or more target genes are located at 8q21, which could have a role in the initiation or progression of multiple cancers. However, a comparative lack of candidate molecular probes to this region has meant that no candidate 8q21 target gene has been proposed in breast or any other cancer.

Determination of D52-like Gene Copy Number in Breast Carcinomas Using Southern Analyses

As both hD52 and hD54 genes map to genomic regions which are frequently present at ICN in human breast carcinoma (chromosomes 8q21 and 20q1 3.2-q1 3.3, respectively), RCN at the hD52 and hD54 loci was determined in a panel of human breast carcinomas using Southern blot analyses. Southern blot analyses were performed using EcoRI restricted genomic DNA samples, and a doublet of 2.1 kb and 2.2 kb were the major restriction fragments detected by a hD52 cDNA probe. A hD54 cDNA probe detected a doublet of approximately 20 kb and 23 kb on the same filters, whereas a hD53 cDNA probe detected a single 2.4 kb EcoR I fragment. The signal intensities of these bands were measured densitometrically, and used to calculate RCN at hD52 and hD54 loci, using the hD53 locus as a control locus. The hD53 gene maps to chromosome 6q22-q23, which is not (Reid et al., Cancer Res. 55:5415-5423 (1995)) or only infrequently (Kallioniemi et al., Proc. Natl. Acad. Sci. USA 91:2156-2160 (1994); Muleris et al., Genes Chromosom. Cancer 10:160-170 (1994)) present at ICN in human breast carcinomas, and therefore represents a suitable control. Signal intensities obtained with the hD53 probe were also compared with those obtained at a second control locus, fibronectin-1 (FN-1), located at chromosome 2q34, which is also not (Muleris et al., Genes Chromosom. Cancer 10:160-170 (1994); Reid et al., Cancer Res. 55:5415-5423 (1995)) or infrequently (Kallioniemi et al., Proc. Natl. Acad. Sci. USA 91:2156-2160 (1994); Nishizaki et al., Genes Chromosom. Cancer 19:267-272 (1997b)) present at ICN in human breast cancer, and with the intensity of ethidium bromide staining within restricted DNA samples following electrophoresis, in order to verify that hD53 represented a suitable control locus.

Three tumors (9% of cases) showed ICN (RCN>2.0) at the hD52 locus, and 3 different tumors showed ICN at the hD54 locus (Table 6). Of the 6 tumors showing ICN at hD52 or hD54 loci, measured increases in copy number were low (2.1- to 2.8-fold increases) in 4 cases, whereas the remaining 2 cases showed higher (4.9- or 7.8-fold) increases. All tumors showing ICN at hD52 or hD54 loci were infiltrating ductal carcinomas. This indicates that hD52 and hD54 loci are present at ICN in some 9% of breast carcinomas, which are in turn primarily infiltrating ductal carcinomas.

Immunohistochemical Analysis of hD52 Protein Expression in Paraffin-embedded Breast Carcinoma Sections

Increases in hD52 RCN (2.4- and 2.8-fold) or hD54 RCN (2.3- and 4.9-fold) were measured in 4 of 10 tumors which exhibited overall moderate intensity of hD52 staining in cancer cells (cases 28 and 25, and cases 3 and 17, respectively) (Table 6). In the tumors, hD52 staining of cancer cells was weak (Table 6), presenting as diffuse cytoplasmic staining. Increases in hD52 RCN were not found in these tumors, although case 4 was indicated to have a low-level (2.1-fold) increase in hD54 RCN (Table 6). In the 3 tumors examined where hD52 was undetectable, no increases in hD52 or hD54 RCN were found (Table 6).

TABLE 6 Relative copy number (RCN) at hD52 and hD54 loci in 32 breast carcinomas, compared with hD52 protein expression, as determined using immunohistochemistry. hD52 hD54 Tumor RCN RCN hD52 expression^(a) 1 0.9 1.7 ND 2 7.8 1.5 +++ 3 1.9 2.3 ++ 4 0.8 2.1 + 5 0.8 1.4 ++ 6 1.4 1.2 ND 7 1.1 1.0 + 8 1.1 1.0 ++ 9 1.1 1.8 ND 10 0.9 1.7 0 11 0.7 1.4 ++ 12 1.0 1.4 0 13 0.8 1.4 + 14 0.7 1.2 0 15 0.7 1.1 ND 16 0.9 1.1 + 17 0.8 4.9 ++ 18 1.2 1.1 ++ 19 1.9 1.0 ND 20 1.6 0.8 ++ 21 1.6 0.7 ND 22 0.9 0.7 ND 23 1.0 0.6 + 24 1.3 0.7 ND 25 2.8 0.7 ++ 26 1.8 ND b ND 27 1.5 ND ND 28 2.4 1.4 ++ 29 1.9 0.8 ++ 30 0.9 0.8 ND 31 1.5 0.8 ND 32 0.8 0.5 ND ^(a)hD52 protein levels are shown according to the following scale: 0 = not detected, + = weakly detected, ++ = moderately detected, +++ = strongly detected b ND = not done

DISCUSSION

In the present study, we have investigated whether the chromosome 8q21hQ52 (TPD52) locus represents a target gene within chromosomal gains or amplifications emcopassing this region in human breast cancer. Alterations in copy number at hD52 and hD54 were investigated using Southern blot analyses in a panel of 32 breast carcinomas. The hD54 locus has been mapped to chromosome 20113.2-q13.3 (Nourse et al., Biochim. Biophys. Acta 1443:155-168 (1998)), another region which is frequently gained in breast (Kallioniemi et al., Proc. Natl. Acad. Sci. USA 91:2156-2160 (1994); Courjal et al., Cancer Res. 57:4360-4367 (1997); Courjal et al., Cancer Res. 57:4368-4377 (1997); Tirkkonen et al., Genes Chromosom. Cancer 21:177-184 (1998)) and other carcinomas (Solinas-Toldo et al., Cancer Res. 56:3803-3807 (1996), Sonoda et al., Genes Chromosom. Cancer 20:320-328 (1997)). Three tumors (9% of cases) showed ICN at the hD52 locus, and 3 different tumors showed ICN at the hD54 locus. In each group of tumors showing ICN at hD52 or hD54 loci, one tumor showed copy number increases indicating regional amplification encompassing hD52 or hD54, whereas in the remaining cases, increases in copy number were low, and possibly consistent with the gain of an entire chromosome or chromosomal arm (Schwab and Amler., Genes Chromosom. Cancer 1:181-193 (1990)). However, since cancer cells are typically diluted two-fold by stromal and other cell types in human breast carcinoma (Visscher et al., Genes Chromosom Cancer 18:1-7 (1997)), the use of Southern blot analyses to measure changes in hD52 and hD54 dosage may have lead to both an underestimation of the extent to which copy number was increased, and of the number of tumors harboring ICN at hD52 or hD54 loci. That this was indeed the case is suggested by a comparison of the results obtained in the present study with those of a past study, where FISH showed YAC 936B3 (containing hD52) to be present at ICN relative to the chromosome 8 centromere in 5/8 breast cancer cell lines and 6/10 primary breast tumors analyzed (Schoenberg et al., Genes Chromosom. Cancer 22:105-113 (1998)).

Materials and Methods

Human Cell Lines and Tissues

The MCF7 and BT474 breast cancer cell lines, the HL60 myelocytic leukemia cell line, and the HFL1 foet al lung fibroblast cell line, are described in the American Type Culture Collection Catalogue (8th Edition). Paraffin-embedded tissue sections and surgical breast carcinoma specimens were obtained from Westmead Hospital, Australia. Surgical specimens were stored in liquid nitrogen prior to genomic DNA extraction, which was performed using standard techniques (Ausubel et al., Current Protocols in Molecular Biology Vol. 1, John Wiley & Sons, Inc. New York (1997)). Of the 32 breast carcinomas examined, the tumor type was known in 31 cases, of which 24 cases represented infiltrating ductal carcinomas. The remaining 7 cases represented carcinomas of other types (3 lobular, 2 mucinous, and 1 each of carcinoid and tubular types). Thirty and 22 tumors were positive for the presence of estrogen or progesterone receptors, respectively, with only one tumorbeing both estrogen- and progesterone receptor-negative. The mean patient age was 63 years. The 6 normal breast samples examined showed no signs of epithelial hyperplasia or malignancy, and the mean patient age was 39 years.

Southern Blot Analyses and Quantification of Hybridization Signals

Approximately 10 μg genomic DNA from each of 32 primary breast cancers, and samples of DNA from a healthy female control subject, were digested with EcoR I overnight at 37° C. Samples were electrophoresed through 1% agarose gels, with a sample of restricted control DNA being included on each gel, and transferred to nylon membranes (HybondN+, Amersham). Southern blot hybridizations were performed successively with ³²P-1 labelled inserts from hD52, hD53, hDS4 and FN-1 (Byrne et al., 1995) cDNAs. Hybridizations and subsequent washing steps followed standard procedures, and filters were exposed to Kodak AR film for 8-23 h, to obtain exposures of varying intensity for each probe.

Hybridization signals were quantitated using a computing densitometer (Molecular Dynamics). To calculate RCN, signals obtained in tumor samples were divided by that obtained in a control DNA sample loaded on the same gel from a healthy female volunteer, to correct for lane loading discrepancies. Corrected signals at test (hD52 or hD54) loci were then divided by the corrected signal obtained at the control hQ53 locus. The overall formula used to calculate RCN was therefore (tumor signal_(hD52) or _(hD54)/control signal_(hD52) or _(hD54))/(tumor signal_(hD53)/control signal_(hD53)), and a RCN>2.0 was considered to indicate ICN (Courjal el al., 1997).

108 1 1097 DNA Homo sapiens CDS (2)..(433) 1 a tcc agt tgg ctc ccc tgg agt gaa gtt cta cac aga ccc tgg agg aac 49 Ser Ser Trp Leu Pro Trp Ser Glu Val Leu His Arg Pro Trp Arg Asn 1 5 10 15 cac ccc atc tgt ttg ttg gag act gaa ccg ttg caa gga aca gac gaa 97 His Pro Ile Cys Leu Leu Glu Thr Glu Pro Leu Gln Gly Thr Asp Glu 20 25 30 gat gca gta gcc agt gct gac ttc tct agc atg ctc tct gag gag gaa 145 Asp Ala Val Ala Ser Ala Asp Phe Ser Ser Met Leu Ser Glu Glu Glu 35 40 45 aag gaa gag tta aaa gca gag tta gtt cag cta gaa gac gaa att aca 193 Lys Glu Glu Leu Lys Ala Glu Leu Val Gln Leu Glu Asp Glu Ile Thr 50 55 60 aca cta cga caa gtt ttg tca gcg aaa gaa agg cat cta gtt gag ata 241 Thr Leu Arg Gln Val Leu Ser Ala Lys Glu Arg His Leu Val Glu Ile 65 70 75 80 aaa caa aaa ctc ggc atg aac ctg atg aat gaa tta aaa cag aac ttc 289 Lys Gln Lys Leu Gly Met Asn Leu Met Asn Glu Leu Lys Gln Asn Phe 85 90 95 agc aaa agc tgg cat gac atg cag act acc act gcc tac aag aaa aca 337 Ser Lys Ser Trp His Asp Met Gln Thr Thr Thr Ala Tyr Lys Lys Thr 100 105 110 cat gaa acc ctg agt cac gca ggg caa aag gca act gca gct ttc agc 385 His Glu Thr Leu Ser His Ala Gly Gln Lys Ala Thr Ala Ala Phe Ser 115 120 125 aac gtt gga acg gcc atc agc aag aag ttc gga gac atg aga cga aag 433 Asn Val Gly Thr Ala Ile Ser Lys Lys Phe Gly Asp Met Arg Arg Lys 130 135 140 taggcggtac gaaccctaat ggaggcagtt ttgaggaggt cctcagctcc acggcccatg 493 ccagtgccca gagcttggca ggaggctccc ggcggaccaa ggaggaggag ctgcagtgct 553 aagtccagcc agcgtgcagc tgcatccaga aaccggccac tacccagccc atctctgcct 613 gtgcttatcc agataagaag accaaaatcc cgctgggaaa aacccaggcc ttgacattgt 673 tattcaaatg gcccctccag aaagtttaat gatttccatt tgtatttgtg ttgatgatgg 733 accacttgac catcacattt cagtattcat agatgactgt cacattttaa aatgttccca 793 cttgagcagg tacacaactg gtcataattc ctgtctgtgt aattcgatgt atatttttcc 853 aaacatgtag ctattgtttg ctttgatttt tgcttggcct cctttatgat gtgcatgtcc 913 ttgaaggctg aatgaacagt ccctttcagt tcagcagatc aacaggatgg agctcttcat 973 gactgtctcc agcaatagga tgatttacta taaatttcat ccaactactt gtgatctctc 1033 tcacctacat caattatgta tgttaatttc agcaattaaa agaattgatt ttaaaaaaaa 1093 aaaa 1097 2 144 PRT Homo sapiens 2 Ser Ser Trp Leu Pro Trp Ser Glu Val Leu His Arg Pro Trp Arg Asn 1 5 10 15 His Pro Ile Cys Leu Leu Glu Thr Glu Pro Leu Gln Gly Thr Asp Glu 20 25 30 Asp Ala Val Ala Ser Ala Asp Phe Ser Ser Met Leu Ser Glu Glu Glu 35 40 45 Lys Glu Glu Leu Lys Ala Glu Leu Val Gln Leu Glu Asp Glu Ile Thr 50 55 60 Thr Leu Arg Gln Val Leu Ser Ala Lys Glu Arg His Leu Val Glu Ile 65 70 75 80 Lys Gln Lys Leu Gly Met Asn Leu Met Asn Glu Leu Lys Gln Asn Phe 85 90 95 Ser Lys Ser Trp His Asp Met Gln Thr Thr Thr Ala Tyr Lys Lys Thr 100 105 110 His Glu Thr Leu Ser His Ala Gly Gln Lys Ala Thr Ala Ala Phe Ser 115 120 125 Asn Val Gly Thr Ala Ile Ser Lys Lys Phe Gly Asp Met Arg Arg Lys 130 135 140 3 1307 DNA Homo sapiens CDS (192)..(803) 3 aggtaaccag cagcggccag tggtggccgc cgccagtacc ccgccccctc cacgaatgct 60 cgcgacacgc gcgccgggag agggcacggg cggcggggct agctgtcttc cgagctcggg 120 aatcgctacc atctgctgct ctgcgaggag tccgcgtgtt ctccgcggtg ctcagctcca 180 aaccggccac c atg gag gcg cag gca caa ggc ttg ttg gag acg gaa ccg 230 Met Glu Ala Gln Ala Gln Gly Leu Leu Glu Thr Glu Pro 1 5 10 cta caa gga aga gat ggg gat gca gta ggc agt gct gac ttc tct agc 278 Leu Gln Gly Arg Asp Gly Asp Ala Val Gly Ser Ala Asp Phe Ser Ser 15 20 25 atg ctc tct gag gag gag aag gaa gag cta aag gca gag tta att cag 326 Met Leu Ser Glu Glu Glu Lys Glu Glu Leu Lys Ala Glu Leu Ile Gln 30 35 40 45 cta gaa gac gaa atc aca aca tta cga caa gtt ttg tca gca aaa gaa 374 Leu Glu Asp Glu Ile Thr Thr Leu Arg Gln Val Leu Ser Ala Lys Glu 50 55 60 aga cat ctg gtt gag atc aaa cag aaa ctc ggc atg aat ctg atg aat 422 Arg His Leu Val Glu Ile Lys Gln Lys Leu Gly Met Asn Leu Met Asn 65 70 75 gag tta aag cag aac ttc agc agg agc tgg cac gac atg cag acc acg 470 Glu Leu Lys Gln Asn Phe Ser Arg Ser Trp His Asp Met Gln Thr Thr 80 85 90 act gcg tac aag aaa acg cac gaa acc ctg agc cac gca ggg cag aag 518 Thr Ala Tyr Lys Lys Thr His Glu Thr Leu Ser His Ala Gly Gln Lys 95 100 105 gca aca gca gct ttc aat aac gtg gga act gcc atc agc aag aag ttt 566 Ala Thr Ala Ala Phe Asn Asn Val Gly Thr Ala Ile Ser Lys Lys Phe 110 115 120 125 gga gat atg agg tac tcc atc cgc cat tcc ata agt atg cct gcc atg 614 Gly Asp Met Arg Tyr Ser Ile Arg His Ser Ile Ser Met Pro Ala Met 130 135 140 agg aat tct tct act ttc aaa tca ttt gag gag agg gtt gag aca act 662 Arg Asn Ser Ser Thr Phe Lys Ser Phe Glu Glu Arg Val Glu Thr Thr 145 150 155 gtt gca agc ctc aag acg aaa gta ggt ggg aca aac cac ggt ggt ggc 710 Val Ala Ser Leu Lys Thr Lys Val Gly Gly Thr Asn His Gly Gly Gly 160 165 170 agt ttt gag gag gtc ctg aac tcc aca gca cac gcc agc tca cag aat 758 Ser Phe Glu Glu Val Leu Asn Ser Thr Ala His Ala Ser Ser Gln Asn 175 180 185 gct tca gca ggc tcc cgg cag acc aag gac gag gag ctg cag tgc 803 Ala Ser Ala Gly Ser Arg Gln Thr Lys Asp Glu Glu Leu Gln Cys 190 195 200 taggtcccgc ctgggctgct gctggtcaat ctgcctgctc atcctctgat atgaagacca 863 aaatcccact gggaacccca agttttgaca ttgatattta aatggggtct ccaaaaagct 923 taataaaatg atttcttttt gcatttgtgt tgatgaccac tactctggag tatttacaaa 983 tgtcatcttt aaaaatagac aacctggagc agggtcataa ttgttctgaa ttcttgtctg 1043 cggaactcaa tgtatttccc aatcatgcag atactgatta ttagctttgg ttttgacttg 1103 gtctccaaac caatatgcat gtctcagagt gcacctgcca gtctgtagat cgacaggtga 1163 cactatttat gacggtctcc agcagggcgc aaatcctaca aacttcacca aattgcttgt 1223 gatttttatg tgcatttatt taagtcatta aaataattca ttttaaaaaa aaaaaaaaaa 1283 aaaaaaaaaa aaaaaaaaaa aaaa 1307 4 204 PRT Homo sapiens 4 Met Glu Ala Gln Ala Gln Gly Leu Leu Glu Thr Glu Pro Leu Gln Gly 1 5 10 15 Arg Asp Gly Asp Ala Val Gly Ser Ala Asp Phe Ser Ser Met Leu Ser 20 25 30 Glu Glu Glu Lys Glu Glu Leu Lys Ala Glu Leu Ile Gln Leu Glu Asp 35 40 45 Glu Ile Thr Thr Leu Arg Gln Val Leu Ser Ala Lys Glu Arg His Leu 50 55 60 Val Glu Ile Lys Gln Lys Leu Gly Met Asn Leu Met Asn Glu Leu Lys 65 70 75 80 Gln Asn Phe Ser Arg Ser Trp His Asp Met Gln Thr Thr Thr Ala Tyr 85 90 95 Lys Lys Thr His Glu Thr Leu Ser His Ala Gly Gln Lys Ala Thr Ala 100 105 110 Ala Phe Asn Asn Val Gly Thr Ala Ile Ser Lys Lys Phe Gly Asp Met 115 120 125 Arg Tyr Ser Ile Arg His Ser Ile Ser Met Pro Ala Met Arg Asn Ser 130 135 140 Ser Thr Phe Lys Ser Phe Glu Glu Arg Val Glu Thr Thr Val Ala Ser 145 150 155 160 Leu Lys Thr Lys Val Gly Gly Thr Asn His Gly Gly Gly Ser Phe Glu 165 170 175 Glu Val Leu Asn Ser Thr Ala His Ala Ser Ser Gln Asn Ala Ser Ala 180 185 190 Gly Ser Arg Gln Thr Lys Asp Glu Glu Leu Gln Cys 195 200 5 2285 DNA Homo sapiens CDS (77)..(694) 5 acgcggcgag cttctcccgg cgccgcccgc tcggctccca tagcgcccgc gacagcggtc 60 cggacgccgc ccgaac atg gac tcc gcc ggc caa gat atc aac ctg aat tct 112 Met Asp Ser Ala Gly Gln Asp Ile Asn Leu Asn Ser 1 5 10 cct aac aaa ggt ctg ctg tct gac tcc atg acg gat gtt cct gtc gac 160 Pro Asn Lys Gly Leu Leu Ser Asp Ser Met Thr Asp Val Pro Val Asp 15 20 25 aca ggt gtg gct gcc cgg act cct gct gtt gag ggt ctg aca gag gct 208 Thr Gly Val Ala Ala Arg Thr Pro Ala Val Glu Gly Leu Thr Glu Ala 30 35 40 gag gag gag gag ctc agg gct gag ctt acc aag gtg gaa gag gaa att 256 Glu Glu Glu Glu Leu Arg Ala Glu Leu Thr Lys Val Glu Glu Glu Ile 45 50 55 60 gtc act ctg cgc cag gtc ctg gca gcc aag gag aag cac tgt gga gag 304 Val Thr Leu Arg Gln Val Leu Ala Ala Lys Glu Lys His Cys Gly Glu 65 70 75 ctc aag agg agg ctg ggc ctc tcc acc ctg ggg gag ctg aaa cag aac 352 Leu Lys Arg Arg Leu Gly Leu Ser Thr Leu Gly Glu Leu Lys Gln Asn 80 85 90 ctg tcc agg agc tgg cat gac gtg cag gtc tct agc gcc tat gtg aaa 400 Leu Ser Arg Ser Trp His Asp Val Gln Val Ser Ser Ala Tyr Val Lys 95 100 105 act tct gag aaa ctt gga gag tgg aat gag aaa gtg acc cag tca gac 448 Thr Ser Glu Lys Leu Gly Glu Trp Asn Glu Lys Val Thr Gln Ser Asp 110 115 120 ctc tac aag aag act cag gaa act ctt tca cag gca gga cag aag act 496 Leu Tyr Lys Lys Thr Gln Glu Thr Leu Ser Gln Ala Gly Gln Lys Thr 125 130 135 140 tca gct gcc ctg tcc aca gtg ggc tct gcc atc agc agg aag ctt gga 544 Ser Ala Ala Leu Ser Thr Val Gly Ser Ala Ile Ser Arg Lys Leu Gly 145 150 155 gac atg agg aac tct gcg acc ttc aag tcg ttt gag gac cga gtt ggg 592 Asp Met Arg Asn Ser Ala Thr Phe Lys Ser Phe Glu Asp Arg Val Gly 160 165 170 acc ata aag tct aag gtt gtg ggt gac aga gag aac ggc agt gac aac 640 Thr Ile Lys Ser Lys Val Val Gly Asp Arg Glu Asn Gly Ser Asp Asn 175 180 185 ctc cct tcc tca gcg ggg agt ggt gac aag ccc ctg tcg gat ccc gca 688 Leu Pro Ser Ser Ala Gly Ser Gly Asp Lys Pro Leu Ser Asp Pro Ala 190 195 200 cct ttc taagcctgtg gttgcttcac ccgctgcaga gcacacgcaa cccagcctca 744 Pro Phe 205 gcatcacagc cgcagctctg ttcagcggag cagccagcca gggcggatga gcagagccgg 804 ccctgaggac agtcctgccc atccacgcgg agatgtggct gccgcgtttg catgaatttg 864 aagaacacag gcttgtacac agatgtttta cactcacgtt tgtagatgaa acagatcact 924 gtgctgtcct tcctaggggt gcaggaagtg gacagggcgg agggtttgaa agaatattga 984 gccaaagccc aggctccctt tgggaatcat gttagcccat cagaatgttg aaggattgaa 1044 gagttctaag cataaaataa gtggcatttt ctgacttctt cctcctcctc cttccctgac 1104 tcacagaagg aatgcaatca cccagcaagt cctacctgtt acgcaatttt ttatctcaaa 1164 atgccgaacg agaaaactgt ccattttctg agacccccag aaaggaaact gaccctcagc 1224 agctgcctga ttgttacgcg aatctagctt taacggaagc aaattcatta ttttttaaat 1284 gcagtggact tttcaaaaag tttaaattag gcaaagcagc tttagcctca tagaatatta 1344 tttctttgga ctcaagctga aatacaagcc ttacattgcc ttatgcttta tttctttcta 1404 atttttatat gtatatagat gagggttcct taatggttgt gagcattgtg tggaatttta 1464 cacctggcct gcgtggcagc ctcttccagt tgaggtgttt tatgtcacgc acactccatc 1524 ccagtgtaca aaacctgctt ctcttctcaa ccgtggcagc tcccgctggc tcctatgccc 1584 tgccctaaag ggctcttgag cctctgggaa tgggaggggc caagagaagg aaaaccctgt 1644 ctttagcacc ctttaaaaga actgtgcccc ccttctcagt gctgcctttg catgggcctg 1704 gcccggctca cattcgtcag tgactccaac cctcctgctt gctgtacttg ggatgaaacg 1764 accccacagg tcaggtggag ggtggggcgt gggcatcagc caggattgcc gttacagtct 1824 ttttctcagg agctacaaag atctcttcct gttactaaat agtcgcaccc cagcagcctc 1884 tctcgcacac cggggccctg catgtcagat ggcgtggtct gcagggggag ctctgtgcct 1944 tagtggctct tggcaggaca ctgagggcct gcctgtggtg tgcccggctc tgccactccc 2004 gggaggggaa gggctgctca gctcaaggtg tcctgttcgg tagagcaagt gtcctctgac 2064 agccgtgtcc ccggacagtt cagacaccct tggggatggc actccacaca cgacagagat 2124 gcaggggcca gggaagccca gcgctcggtg cccttcgtcc agggttaaaa tcggcctgtg 2184 gggtgtggtg agaaggcagg ttgtgcgggt gttgaccgat gtatcttttc cttaaagtta 2244 ttataataat gggtaatttg tcaataaagc attcctttgg g 2285 6 206 PRT Homo sapiens 6 Met Asp Ser Ala Gly Gln Asp Ile Asn Leu Asn Ser Pro Asn Lys Gly 1 5 10 15 Leu Leu Ser Asp Ser Met Thr Asp Val Pro Val Asp Thr Gly Val Ala 20 25 30 Ala Arg Thr Pro Ala Val Glu Gly Leu Thr Glu Ala Glu Glu Glu Glu 35 40 45 Leu Arg Ala Glu Leu Thr Lys Val Glu Glu Glu Ile Val Thr Leu Arg 50 55 60 Gln Val Leu Ala Ala Lys Glu Lys His Cys Gly Glu Leu Lys Arg Arg 65 70 75 80 Leu Gly Leu Ser Thr Leu Gly Glu Leu Lys Gln Asn Leu Ser Arg Ser 85 90 95 Trp His Asp Val Gln Val Ser Ser Ala Tyr Val Lys Thr Ser Glu Lys 100 105 110 Leu Gly Glu Trp Asn Glu Lys Val Thr Gln Ser Asp Leu Tyr Lys Lys 115 120 125 Thr Gln Glu Thr Leu Ser Gln Ala Gly Gln Lys Thr Ser Ala Ala Leu 130 135 140 Ser Thr Val Gly Ser Ala Ile Ser Arg Lys Leu Gly Asp Met Arg Asn 145 150 155 160 Ser Ala Thr Phe Lys Ser Phe Glu Asp Arg Val Gly Thr Ile Lys Ser 165 170 175 Lys Val Val Gly Asp Arg Glu Asn Gly Ser Asp Asn Leu Pro Ser Ser 180 185 190 Ala Gly Ser Gly Asp Lys Pro Leu Ser Asp Pro Ala Pro Phe 195 200 205 7 74 DNA Homo sapiens 7 cattttcaca ctcctttagc agctactcca tccgccactc aataagtatg ccagccatga 60 ggaactctgc gacc 74 8 67 PRT Homo sapiens 8 Phe Ser His Ser Phe Ser Ser Tyr Ser Ile Arg His Ser Ile Ser Met 1 5 10 15 Pro Ala Met Arg Asn Ser Ala Thr Phe Lys Ser Phe Glu Asp Arg Val 20 25 30 Gly Thr Ile Lys Ser Lys Val Val Gly Asp Arg Glu Asn Gly Ser Asp 35 40 45 Asn Leu Pro Ser Ser Ala Gly Ser Gly Asp Lys Pro Leu Ser Asp Pro 50 55 60 Ala Pro Phe 65 9 204 PRT Homo sapiens 9 Met Glu Ala Gln Ala Gln Gly Leu Leu Glu Thr Glu Pro Leu Gln Gly 1 5 10 15 Thr Asp Glu Asp Ala Val Ala Ser Ala Asp Phe Ser Ser Met Leu Ser 20 25 30 Glu Glu Glu Lys Glu Glu Leu Lys Ala Glu Leu Val Gln Leu Glu Asp 35 40 45 Glu Ile Thr Thr Leu Arg Gln Val Leu Ser Ala Lys Glu Arg His Leu 50 55 60 Val Glu Ile Lys Gln Lys Leu Gly Met Asn Leu Met Asn Glu Leu Lys 65 70 75 80 Gln Asn Phe Ser Lys Ser Trp His Asp Met Gln Thr Thr Thr Ala Tyr 85 90 95 Lys Lys Thr His Glu Thr Leu Ser His Ala Gly Gln Lys Ala Thr Ala 100 105 110 Ala Phe Ser Asn Val Gly Thr Ala Ile Ser Lys Lys Phe Gly Asp Met 115 120 125 Ser Tyr Ser Ile Arg His Ser Ile Ser Met Pro Ala Met Arg Asn Ser 130 135 140 Pro Thr Phe Lys Ser Phe Glu Glu Arg Val Glu Thr Thr Val Thr Ser 145 150 155 160 Leu Lys Thr Lys Val Gly Gly Thr Asn Pro Asn Gly Gly Ser Phe Glu 165 170 175 Glu Val Leu Ser Ser Thr Ala His Ala Ser Ala Gln Ser Leu Ala Gly 180 185 190 Gly Ser Arg Arg Thr Lys Glu Glu Glu Leu Gln Cys 195 200 10 168 DNA Homo sapiens 10 acagagccgg tggccgagga aggagaggat gctgttacca tgctcagtgc tccagaggcg 60 gccaaagggt ggcaagacgt gacggcaacc aatgcataca agaagacctc tgaagtgaaa 120 aactccccaa ctttcaagtc atttgaagaa aaagttgaaa atttaaag 168 11 185 PRT Homo sapiens 11 Met Asp Arg Gly Glu Gln Gly Leu Leu Lys Thr Glu Pro Val Ala Glu 1 5 10 15 Glu Gly Glu Asp Ala Val Thr Met Leu Ser Ala Pro Glu Ala Leu Thr 20 25 30 Glu Glu Glu Gln Glu Glu Leu Arg Arg Glu Leu Thr Lys Val Glu Glu 35 40 45 Glu Ile Gln Thr Leu Ser Gln Val Leu Ala Ala Lys Glu Lys His Leu 50 55 60 Ala Glu Leu Lys Arg Lys Leu Gly Ile Ser Ser Leu Gln Glu Phe Lys 65 70 75 80 Gln Asn Ile Ala Lys Gly Trp Gln Asp Val Thr Ala Thr Asn Ala Tyr 85 90 95 Lys Lys Thr Ser Glu Thr Leu Ser Gln Ala Gly Gln Lys Ala Ser Ala 100 105 110 Ala Phe Ser Ser Val Gly Ser Val Ile Thr Lys Lys Leu Glu Asp Val 115 120 125 Lys Asn Ser Pro Thr Phe Lys Ser Phe Glu Glu Lys Val Glu Asn Leu 130 135 140 Lys Ser Lys Val Gly Gly Ala Lys Pro Ala Gly Gly Asp Phe Gly Glu 145 150 155 160 Val Leu Asn Ser Thr Ala Asn Ala Thr Ser Thr Met Thr Thr Glu Pro 165 170 175 Pro Pro Glu Gln Met Thr Glu Ser Pro 180 185 12 149 DNA Homo sapiens 12 aaagggtggc aagacgtgac agcaacatct gcttacaaga agacatctga aaccttatcc 60 caggctggac agaaggcctc agctgctttt tcgtctgttg gctcagtcat caccaaaaag 120 ctggaagatg taaaaaactc cccaacttt 149 13 184 PRT Homo sapiens 13 Met Asp Arg Gly Glu Gln Gly Leu Leu Arg Thr Asp Pro Val Pro Glu 1 5 10 15 Glu Gly Glu Asp Val Ala Ala Thr Ile Ser Ala Thr Glu Thr Leu Ser 20 25 30 Glu Glu Glu Gln Glu Glu Leu Arg Arg Glu Leu Ala Lys Val Glu Glu 35 40 45 Glu Ile Gln Thr Leu Ser Gln Val Leu Ala Ala Lys Glu Lys His Leu 50 55 60 Ala Glu Ile Lys Arg Lys Leu Gly Ile Asn Ser Leu Gln Glu Leu Lys 65 70 75 80 Gln Asn Ile Ala Lys Gly Trp Gln Asp Val Thr Ala Thr Ser Ala Tyr 85 90 95 Lys Lys Thr Ser Glu Thr Leu Ser Gln Ala Gly Gln Lys Ala Ser Ala 100 105 110 Ala Phe Ser Ser Val Gly Ser Val Ile Thr Lys Lys Leu Glu Asp Val 115 120 125 Lys Asn Ser Pro Thr Phe Lys Ser Phe Glu Glu Lys Val Glu Asn Leu 130 135 140 Lys Ser Lys Val Gly Gly Thr Lys Pro Ala Gly Gly Asp Phe Gly Glu 145 150 155 160 Val Leu Asn Ser Ala Ala Asn Ala Ser Ala Thr Thr Thr Glu Pro Leu 165 170 175 Pro Glu Lys Thr Gln Glu Ser Leu 180 14 84 DNA Homo sapiens CDS (1)..(84) 14 cag aac ctg tcc agg agc tgg cat gac gtg cag gtc tct agc gcc tac 48 Gln Asn Leu Ser Arg Ser Trp His Asp Val Gln Val Ser Ser Ala Tyr 1 5 10 15 aag aag act cag gaa act ctt tca cag gca gga cag 84 Lys Lys Thr Gln Glu Thr Leu Ser Gln Ala Gly Gln 20 25 15 186 PRT Homo sapiens 15 Met Asp Ser Ala Gly Gln Asp Ile Asn Leu Asn Ser Pro Asn Lys Gly 1 5 10 15 Leu Leu Ser Asp Ser Met Thr Asp Val Pro Val Asp Thr Gly Val Ala 20 25 30 Ala Arg Thr Pro Ala Val Glu Gly Leu Thr Glu Ala Glu Glu Glu Glu 35 40 45 Leu Arg Ala Glu Leu Thr Lys Val Glu Glu Glu Ile Val Thr Leu Arg 50 55 60 Gln Val Leu Ala Ala Lys Glu Lys His Cys Gly Glu Leu Lys Arg Arg 65 70 75 80 Leu Gly Leu Ser Thr Leu Gly Glu Leu Lys Gln Asn Leu Ser Arg Ser 85 90 95 Trp His Asp Val Gln Val Ser Ser Ala Tyr Lys Lys Thr Gln Glu Thr 100 105 110 Leu Ser Gln Ala Gly Gln Lys Thr Ser Ala Ala Leu Ser Thr Val Gly 115 120 125 Ser Ala Ile Ser Arg Lys Leu Gly Asp Met Arg Asn Ser Ala Thr Phe 130 135 140 Lys Ser Phe Glu Asp Arg Val Gly Thr Ile Lys Ser Lys Val Val Gly 145 150 155 160 Asp Arg Glu Asn Gly Ser Asp Asn Leu Pro Ser Ser Ala Gly Ser Gly 165 170 175 Asp Lys Pro Leu Ser Asp Pro Ala Pro Phe 180 185 16 84 DNA Homo sapiens CDS (1)..(84) 16 cag aac ctg tcc agg agc tgg cat gac gtg cag cta caa gaa gac tca 48 Gln Asn Leu Ser Arg Ser Trp His Asp Val Gln Leu Gln Glu Asp Ser 1 5 10 15 gga aac tct ttc aca ggc agg aca gaa gac ttc agc 84 Gly Asn Ser Phe Thr Gly Arg Thr Glu Asp Phe Ser 20 25 17 143 PRT Homo sapiens 17 Met Asp Ser Ala Gly Gln Asp Ile Asn Leu Asn Ser Pro Asn Lys Gly 1 5 10 15 Leu Leu Ser Asp Ser Met Thr Asp Val Pro Val Asp Thr Gly Val Ala 20 25 30 Ala Arg Thr Pro Ala Val Glu Gly Leu Thr Glu Ala Glu Glu Glu Glu 35 40 45 Leu Arg Ala Glu Leu Thr Lys Val Glu Glu Glu Ile Val Thr Leu Arg 50 55 60 Gln Val Leu Ala Ala Lys Glu Lys His Cys Gly Glu Leu Lys Arg Arg 65 70 75 80 Leu Gly Leu Ser Thr Leu Gly Glu Leu Lys Gln Asn Leu Ser Arg Ser 85 90 95 Trp His Asp Val Gln Leu Gln Glu Asp Ser Gly Asn Ser Phe Thr Gly 100 105 110 Arg Thr Glu Asp Phe Ser Cys Pro Val His Ser Gly Leu Cys His Gln 115 120 125 Gln Glu Ala Trp Arg His Glu Glu Leu Cys Asp Leu Gln Val Val 130 135 140 18 216 DNA Homo sapiens 18 aaaagctggc aagatgtgac atcaactgca gcgtacaaga aaacatcaga aaccctgtct 60 caggcaggtc agaaggcttc tgctgcgttt tcctctgtcg gttcagtcct atccaagaag 120 tttgaagacg tcaaactaca ggcattttca cattccttta gtacgctcca tacaacattc 180 gattagcatg cctattatga gaaattctcc tacttt 216 19 73 PRT Homo sapiens 19 Lys Ser Trp Gln Asp Val Thr Ser Thr Ala Ala Tyr Lys Lys Thr Ser 1 5 10 15 Glu Thr Leu Ser Gln Ala Gly Gln Lys Ala Ser Ala Ala Phe Ser Ser 20 25 30 Val Gly Ser Val Leu Ser Lys Lys Phe Glu Asp Val Lys Leu Gln Ala 35 40 45 Phe Ser His Ser Phe Ser Ile Arg Ser Ile Gln His Ser Ile Ser Met 50 55 60 Pro Ile Met Arg Asn Ser Pro Thr Phe 65 70 20 14 PRT Homo sapiens 20 Val Thr Ala Thr Ser Ala Tyr Lys Lys Thr Ser Glu Thr Leu 1 5 10 21 11 PRT Homo sapiens UNSURE (1)..(2) May be any amino acid 21 Xaa Xaa Ala Tyr Lys Lys Thr Xaa Glu Thr Leu 1 5 10 22 54 DNA Homo sapiens 22 gtgctgtctg actttatgac tgacgtccct gttgacccag gtgtggtcca ccgg 54 23 24 DNA Homo sapiens 23 gtctctactg cctacaagaa gact 24 24 84 DNA Homo sapiens 24 gtctctactg cctatgtgaa aacgtctgag aaacttggag agtggaatga gaaagtgacg 60 cagtctgacc tctacaagaa gact 84 25 18 DNA Homo sapiens 25 atgaggaatt cagccacc 18 26 87 DNA Homo sapiens 26 atgagggctt atccgttctc ccaatccttt agcagctact ccatccgcca ctcgataagt 60 atgcctgtca tgaggaactc agccacc 87 27 24 DNA Homo sapiens 27 cgagtgggga ctataaagtc taag 24 28 24 DNA Homo sapiens 28 cgagtgggga ccataaagtc taag 24 29 60 DNA Homo sapiens 29 acagagccgg tggccgagga aggagaggat gctgttacca tgctcagtgc tccagaggcg 60 30 54 DNA Homo sapiens 30 gccaaagggt ggcaagacgt gacggcaacc aatgcataca agaagacctc tgaa 54 31 54 DNA Homo sapiens 31 gtgaaaaact ccccaacttt caagtcattt gaagaaaaag ttgaaaattt aaag 54 32 96 DNA Homo sapiens 32 gtaaatatcc gctccattca gcattcgatt agcatgcctg ctatgagaaa ctctccaact 60 ttcaagtcat ttgaagaaaa agttgaaaat ttaaag 96 33 123 DNA Homo sapiens 33 gtgaaattgc aagctttctc acattcattt agtatccgct ccattcagca ttcgattagc 60 atgcctgcta tgagaaactc cccaactttc aagtcatttg aagaaaaagt tgaaaattta 120 aag 123 34 42 DNA Homo sapiens 34 agagatgggg atgcagtagg cagtgctgac ttctctagca tg 42 35 66 DNA Homo sapiens 35 tggcacgaca tgcagaccac gactgcgtac aagaaaacgc acgaaaccct gagccacgca 60 gggcag 66 36 54 DNA Homo sapiens 36 gccatcagca agaagtttgg agatatgaga cgaaagtagg tgggacaaac cacg 54 37 138 DNA Homo sapiens 37 ggagatatga ggtctcactc tattgggtac tccatccgcc attccataag tatgcctgcc 60 atgaggaatt cttctacttt caaatcattt gaggagaggg ttgagacaac tgttgcaagc 120 ctcaagacga aagtaggt 138 38 385 DNA Homo sapiens 38 aaagggtggc aagacgtgac agcaacatct gcgaggagca agcttctagc agcagaaacc 60 gaactgctct gtcttctgta ttgagagcca tctgcagagc tgttacaaga agacatctga 120 aaccttatcc caggctggac agaaggcctc agctgctttt tcgtctgttg gctcagtcat 180 caccaaaaag ctggaagatg taaaattgca agccttttca cattcctagg taaggagagt 240 ttganccatc actgcagtcc agcagttgtn tnagaaaagt gtgctgagat tagattacca 300 tgctacgttg gatgatcgtg tttgnccata tncgttccat tcagcattca attagcatgc 360 ctgctatgag aaactcccca acttt 385 39 18 PRT Homo sapiens 39 Val Leu Ser Asp Phe Met Thr Asp Val Pro Val Asp Pro Gly Val Val 1 5 10 15 His Arg 40 29 PRT Homo sapiens 40 Met Arg Ala Tyr Pro Phe Ser Gln Ser Phe Ser Ser Tyr Ser Ile Arg 1 5 10 15 His Ser Ile Ser Met Pro Val Met Arg Asn Ser Ala Thr 20 25 41 41 PRT Homo sapiens 41 Val Lys Leu Gln Ala Phe Ser His Ser Phe Ser Ile Arg Ser Ile Gln 1 5 10 15 His Ser Ile Ser Met Pro Ala Met Arg Asn Ser Pro Thr Phe Lys Ser 20 25 30 Phe Glu Glu Lys Val Glu Asn Leu Lys 35 40 42 46 PRT Homo sapiens 42 Gly Asp Met Arg Ser His Ser Ile Gly Tyr Ser Ile Arg His Ser Ile 1 5 10 15 Ser Met Pro Ala Met Arg Asn Ser Ser Thr Phe Lys Ser Phe Glu Glu 20 25 30 Arg Val Glu Thr Thr Val Ala Ser Leu Lys Thr Lys Val Gly 35 40 45 43 51 PRT Homo sapiens 43 Ala Ile Ser Lys Lys Phe Gly Asp Met Arg Tyr Ser Ile Arg His Ser 1 5 10 15 Ile Ser Met Pro Ala Met Arg Asn Ser Ser Thr Phe Lys Ser Phe Glu 20 25 30 Glu Arg Val Glu Thr Thr Val Ala Ser Leu Lys Thr Lys Val Gly Gly 35 40 45 Thr Asn His 50 44 14 PRT Homo sapiens UNSURE (1) May be Valine or Methionine 44 Xaa Xaa Xaa Xaa Xaa Ala Tyr Lys Lys Thr Xaa Glu Thr Leu 1 5 10 45 20 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 45 atggaccgcg gcgagcaagg 20 46 20 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 46 tgggacagag tctggatttc 20 47 19 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 47 gccaaagggt ggcaagacg 19 48 18 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 48 tttggtgatg actgagcc 18 49 19 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 49 gtcatcacca aaaagctgg 19 50 18 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 50 agcaggcttg gctcctcc 18 51 20 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 51 atggaggcgc aggcacaagg 20 52 18 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 52 catgctagag aagtcagc 18 53 18 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 53 acgacaagtt ttgtcagc 18 54 20 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 54 ttcttgctga tggcagttcc 20 55 18 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 55 ccctgagcca cgcagggc 18 56 18 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 56 ctgtgagctg gcgtgtgc 18 57 16 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 57 atggactctg ctagcc 16 58 16 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 58 cctggcgcag agtgac 16 59 16 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 59 gtcactctgc gccagg 16 60 16 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 60 tccaagcttc ctgctg 16 61 16 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 61 agcaggaagc ttggag 16 62 17 DNA Artificial Sequence Description of Artificial Sequence PCR Primer 62 ctctgccacc cacaacc 17 63 347 DNA Homo sapiens unsure (29) May be any nucleic acid 63 cggggcagca tgcgttctga gcctgggcnc agtgccatct gctctgggaa gcaccagggt 60 gtccccgccg ccctcagctc gaagtcagcc accatggagg cgcaggcaca aggtttgttg 120 gagactgaac cngttgcaag gaacagacga agatgcagta gccagtgctg acttctctag 180 catgctctct gaggaggaaa aggaagagtt aaaagcagag ttagttcagc tagaagacga 240 aattacaaca ctacngacaa gttttgtcag ccgaaagaaa ggcatctagt tgagataaaa 300 caaaaactcg gcatgaacct gatgaatgaa ttaaaaccag aacttca 347 64 400 DNA Homo sapiens unsure (174) May be any nucleic acid 64 gcccaagccc tcagctcgaa gtcagccacc atggaggcgc aggacaaggt ttgttggaga 60 ctgaaccgtt gcaaggaaca gacgaagatg cagtagccag tgctgacttc tctagcatgc 120 tctctgagga ggaaaaggaa gagttaaaag cagagttagt tcagctagaa gacngaaatt 180 acaacactac gacaagtttt gtcagcgaaa gaaaggcatc tagttgagat aaaacaaaaa 240 ctcggcatga acctgatgaa tganttaaaa cagaacttca gcaaaagctg gcactgacag 300 tgcagactac cactgcctac aagagaacac atgataccct gagtcacgca gggcagaang 360 gcaactgcag ctttcagcaa cngttggaac ggccatcngc 400 65 319 DNA Homo sapiens 65 taccatctgc tgctctgcga ggagtccgcg tgttctccgc ggtgctcagc tccaaaccgg 60 ccaccatgga ggcgcagcac aaggcttgtt ggagacggaa ccgctacaag gaagagatgg 120 ggatgcagta ggcagtgctg acttctctag catgctctct gaggaggaga aggaagagct 180 aaaggcagag ttaattcagc tagaagacga aatcacaaca ttacgacaag ttttgtcagc 240 aaaagaaaga catctggttg agatcaaaca gaaactcggc atgaatctga tgaatgagtt 300 aaagcagaac ttcagcagg 319 66 331 DNA Homo sapiens 66 accacaacgg ttgttcgaca cggaacccgt acaacgaaga catcccgatg gagtaccgag 60 tggtcagttg tgtacgatgg tgtgtgacca cgagaacgaa gacgtaaacg gagagttaat 120 tgaggtagaa gacgaaatga gaagattacg agaagttttg tgaggaaaac aaacacatct 180 cgttgagatc gaagagaaag tcccgatgaa tgtgatcgat gagttaaacg agaacttgac 240 gacgacgtcc gacgagatgc agacgaggag tgggtagaac aaaaccgacg aaagcctcac 300 ggaccgaccg cagcaacgca acacgaggtt t 331 67 197 DNA Homo sapiens unsure (123) May be any nucleic acid 67 gcagaccacg actgcgtaca agaaaacgca cgaaaccctg agccacgcag ggtcagaagg 60 caacagcagc tttcaataac gtgggaactg ccatcagcaa gaagtttgga gatatgagac 120 ganagtaggt gggacaacca cggtggtggc agttttgagg aggtctgaac tcacagcaca 180 cgcagctcac agatgct 197 68 417 DNA Homo sapiens unsure (21) May be any nucleic acid 68 gcagggcaaa aggcaactga ngctttcaga acgttggaac ggccatcagc aagaagttcg 60 gagacatgag ttactccatt cgccattcca taagtatgcc tgctatgagg aattctccta 120 ctttcaaatc atttgaggag agggttgaga caactgtcac aagcctcaag acgaaagtag 180 ggcggtacga accctaatgg aggcagtttt gaggaggtcc tcagctccac ggcccatgcc 240 agtgcccaga gcttggcagg aggctcccgg cggaccaagg agggaggagc tgcagtgtta 300 agtccagcca gcntgcagtt cattccagga aaccgggcca ttaccccagc ccntttttgc 360 ctgtggttta ttccttttaa ggaaggacca aattcccgtt ggggnaaaaa cccaggg 417 69 171 DNA Homo sapiens unsure (41) May be any nucleic acid 69 tactccattc gccattccat aagtatgcct gctatgagga nttctcctac tttcaaatca 60 tttgaggaga gggttgagac anctgtcaca agcctcaaga cgaaantagg cggtacgacc 120 cctantggag gcagttttta gggaggtcct cagnttccac gggcccnttc c 171 70 434 DNA Homo sapiens unsure (1) May be any nucleic acid 70 ngagttactc cattcgccat tccataagta tgcctgctat gagacgaaag taggcggtac 60 gaaccctaat ggaggcagtt ttgaggaggt cctcagctcc acggcccatg ccagtgccca 120 gagcttggca ggaggctccc ggcggaccaa ggaggaggag ctgcagtgct aagtccagcc 180 agcgtgcagc tgcatccaga aaccggccac tacccagccc atctctgcct gtgcttatcc 240 agataagaag accaaaatcc cgctgggaaa aacccaggcc ttgacattgt tattcaaatg 300 gcccctccag aaagtttaat gatttccatt tgtatttgtg ttgatgatgg accacttgac 360 catcacattt cagtattcat agatgactgt cacattttaa aatgttccca cttgagcagg 420 tacacaactg gtca 434 71 365 DNA Homo sapiens unsure (132) May be any nucleic acid 71 gacgaagatg cagtagccag tgctgacttc tctagcatgc tctctgagga ggaaaaggaa 60 gagttaaaag cagagttagt tcagctagaa gacgaaatta caacactacg acaagttttg 120 tcagcgaaag anaggcatct agttgagata aaacaaaaac tcggcatgaa cctgatgaat 180 ganttanaac agaacttcag caaaagctgg catgacatgc agactaccac tgcctacaag 240 acaacacatg anaccctgag tcacgcaggg caaaaggcaa ctgcaagctt tcagcaacgt 300 ttggaacggc catcagcaag angttcggag acatgagacg aaagtaggcg gtacgaaccc 360 taatg 365 72 323 DNA Homo sapiens unsure (12) May be any nucleic acid 72 tcggcacgag cntgcagctt tcagcaacgt tggaacggcc atcagcaaga agttcggaga 60 catgagacga aagtaggcgg tacgaaccct aatggaggca gttttgagga ggtcctcagc 120 tccacggccc atgccagtgc ccagagcttg gcaggaggct cccggcggac caaggaggag 180 gagctgcagt gcttaagtcc agccagcgtg cagtgcattc cagaaaccgg ccattaccca 240 gcccattttt gcctgtgntt attccagata aggaaggacc aaantcccgt tngggaaaaa 300 acccagggnt ttgacattgt tta 323 73 242 DNA Homo sapiens 73 gccatcagca agaagtttgg agatatgaga cgaaagtagg tgggacaaac cacggtggtg 60 gcagttttga ggaggtcctg aactccacag cacacgccag ctcacagaat gcttcagagg 120 ctcccggcag accaaggacg aggagctgca gtgctaggtc ccgcctgggc tgctgctggt 180 caatctgcct gctcatcctc tgatatgaag accaaaatcc cactgggaac cccaagtttt 240 ga 242 74 396 DNA Homo sapiens 74 attcggcacg acgggggaac tgccatcagc aagaagtttg gagatatgag acgaaagtag 60 gtgggacaaa ccacggtggt ggcagttttg aggaggtcct gaactccaca gcacacgcca 120 gctcacagaa tgcttcagca ggctcccggc agaccaagga cgaggagctg cagtgctagg 180 tcccgcctgg gctgctgctg gtcaatctgc ctgctcatcc tctgatatga agaccaaaat 240 cccactggga accccaagtt ttgacattga tatttaaatg gggtctccaa aaagcttaat 300 aaaatgattt ctttttgcat ttgtgttgat gaccactact ctggagtatt tacaaatgtc 360 atctttaaaa atagacaacc tggagcaggg tcataa 396 75 376 DNA Homo sapiens unsure (1) May be any nucleic acid 75 ntgaggaatt ctcctactnt caaatcattt gaggagaggg ttgagacaac tgtcacaagc 60 ctcaagacga aagtaggcgg tacgaaccct aatggaggca gttttgagga ggtcctcagc 120 tccacggccc atgccagtgc ccagagcttg gcaggaggct cccggcggac caaggaggag 180 gagctgcagt gctaagtcca gccagcgtgc agctgcatcc agaaaccggn cactacccag 240 cccatctctg cctgtgctta tccagataag aagaccaaaa tcccgctggg aaaaacccag 300 gccttgacaa ttgttattca aatggncccc ccagaaagtt taatgatttc cattttgtat 360 ttgtgttgat gatgga 376 76 264 DNA Homo sapiens 76 cgaacgtgcc agcttgcagt cctcggggct gggctcctgt aggacctgcg atcccagcac 60 cgacgccagc tacacccagc tgccgcctga acatggactc tgctagccaa gatatcaacc 120 tgaattctcc taacaaaggt gtgctgtctg actttatgac tgacgtccct gttgacccag 180 gtgtggtcca ccggactcca gttgtagaag gcctgacaga gggggaggaa gatgagcttc 240 gggctgagct tgctaaggtg gaag 264 77 424 DNA Homo sapiens 77 gtgtgtacga agctgccagc ttgcagtcct cggggctggg ctcctgtagg acctgcgatc 60 ccagcaccga cgccagctac acccagctgc cgcctgaaca tggactctgc tagccaagat 120 atcaacctga attctcctaa caaaggtgtg ctgtctgact ttatgactga cgtccctgtt 180 gacccaggtg tggtccaccg gactccagtt gtagaaggcc tgacagatgg ggaggaagaa 240 gagcttcggg ctgagcttgc taaggtggaa gaagaaattg tcactctgcg ccaggtgctg 300 gcagccaaag agaggcactg tggagagctg aaaaggaggc tgggctctcc acattagggg 360 agctgaagca gaacctgtct aggagctggc atgatgtgca ggtctctact gcctacaaga 420 agac 424 78 388 DNA Homo sapiens 78 gacaagcggt ccggacgccg cccgaacatg gactccgccg gccaagatat caacctgaat 60 tctcctaaca aaggtctgct gtctgactcc atgacggatg ttcctgtcga cacaggtgtg 120 gctgcccgga ctcctgctgt tgagggtctg acagaggctg aggaggagga gctcagggct 180 gagcttacca aggtggaaga ggaaattgtc actctgcgcc aggtcctggc agccaaggag 240 aggcactgtg gagagctcaa gaggaggctg ggcctctcca ccctggggga gctgaaacag 300 aacctgtcca ggagctggca tgacgtgcag gtctctagcg cctatgtgaa aacttctgag 360 aaacttggag agtggaatga gaaagtga 388 79 339 DNA Homo sapiens 79 acgaagctgc cagcttgcag tcctcggggc tgggctcctg taggacctgc gatcccagca 60 ccgacgccag ctacacccag ctgccgcctg aacatgggct ctgctagcca agatatcaac 120 ctgaattctc ctaacaaagg tgtgctgtct gactttatga ctgacgtccc tgttgaccca 180 ggtgtggtcc accggactcc agttgtagaa ggcctgacag agggggagga agattagctt 240 cgggctgagc ttgctaaggt ggaagaagaa attgtcactc tgcgccaggt gctggcagcc 300 aaagagaggc actgtggaga gctgaaaagg aggctgggc 339 80 364 DNA Homo sapiens 80 cgacatgcca gcttgcagtc ctcggggctg ggctcctgta ggacctgcga tcccagcacc 60 gacgccagct acacccagct gccgcctgaa catggactct gctagccaag atatcaacct 120 gaattctcct aacaaaggtg tgctgtctga ctttatgact gacgtccctg ttgacccagg 180 tgtggtccac cggactccag ttgtagaagg cctgacagat ggggaggtag atgagcttcg 240 ggctgagctt gctaaggtgg aagaagaaat tgtcactctg cgccaggtgc tggcagccaa 300 agagaggcac tgtggagagc tgaaaaggag gctgggctct ccacattagg ggagctgaag 360 caga 364 81 248 DNA Homo sapiens 81 ctgccagctt gcagtcctcg gggctgggct cctgtaggac ctgcgatccc agcaccgacg 60 ccagctacac ccagctgccg cctgaacatg gactctgcta gccaagatat caacctgaat 120 tctcctaaca aaggtgtgct gtctgacttt atgactgacg tccctgttga cccaggtgtg 180 gtccaccgga ctccagttgt agaaggcctg acagaggggg aggaagaaga gcttcgggct 240 gagcttgc 248 82 379 DNA Homo sapiens 82 cgaactgcca gcttgcagtc ctcggggctg ggctcctgta ggacctgcga tcccagcacc 60 gacgccagct acacccagct gccgcctgaa catggactct gctagccaag atatcaacct 120 gaattctcct aacaaaggtg tgctgtctga ctttatgact gacgtccctg ttgacccagg 180 tgtggtccac cggactccag ttgtagaagg cctgacagag ggggaggaag aaattgtcac 240 tctgcgccag gtgctggcag ccaaagagag gcactgtgga gagctgaaaa ggaggctggg 300 ctctccacat taggggagct gaagcagaac ctgtctagga gctggcatga tgtgcaggtc 360 tctactgcct acaagaaga 379 83 347 DNA Homo sapiens 83 cgactgcggc cctacagttc cactggctcg tgtgtacgaa gctgccagct tgcagtcctc 60 ggggctgggc tcctgtagga cctgcgatcc cagcaccgac gccagctaca cccagctgcc 120 gcctgaacat ggactctgct agccaagata tcaacctgaa ttctcctaac aaaggtgtgc 180 tgtctgactt tatgactgac gtccctgttg acccaggtgt ggtccaccgg actccagttg 240 tagaaggcct gacagacggg gaggaagaag agcttcgggc tgagcttgct aaggtggaag 300 aagaaattgt cactctgcgc caggtgctgg cagccaaaga gaggcac 347 84 444 DNA Homo sapiens 84 cgactgtcca gcttgcagtc ctcggggctg ggctcctgta ggacctgcga tcccagcacc 60 gacgccagct acacccagct gccgcctgaa catggactct gctagccaag atatcaacct 120 gaattctcct aacaaaggtg tgctgtctga ctttatgact gacgtccctg ttgacccagg 180 tgtggtccac cggactccag ttgtagaagg cctgacagat ggggaggttt attagcttcg 240 ggctgagctt gctaaggtgg aagaagaaat tgtcactctg cgccaggtgc tggcagccaa 300 agagaggcac tgtggagagc tgaaaaggag gctgggctct ccacattagg ggagctgaag 360 cagaacctgt ctaggagctg gcatgatgtg caggtctcta ctgcctacaa gaagactcaa 420 gaaactcttt cacaggctgg acag 444 85 503 DNA Homo sapiens 85 ctggctcgtg tgtacgaagc tgccagcttg cagtcctcgg ggctgggctc ctgtaggacc 60 tgcgatccca gcaccgacgc cagctacacc cagctgccgc ctgaacatgg actctgctag 120 ccaagatatc aacctgaatt ctcctaacaa aggtgtgctg tctgacttta tgactgacgt 180 ccctgttgac ccaggtgtgg tccaccggac tccagttgta gaaggcctga cagatgggga 240 gggagaggag cttcgggctg agcttgctaa ggtggaagaa gaaattgtca ctctgcgcca 300 ggtgctggca gccaaagaga ggcactgtgg agagctgaaa aggaggctgg gctctccaca 360 ttaggggagc tgaagcagaa cctgtctagg agctggcatg atgtgcaggt ctctactgcc 420 tacaagaaga ctcaagaaac tctttcacag gctggacaga aaacatcagc tgccctgtgt 480 cacatgggct ctgcatcagc agg 503 86 258 DNA Homo sapiens 86 gcggccctac agttccactg gctcgtgtgt acgaagctgc cagcttgcag tcctcggggc 60 tgggctcctg taggacctgc gatcccagca ccgacgccag ctacacccag ctgccgcctg 120 aacatggact ctgctagcca agatatcaac ctgaattctc ctaacaaagg tgtgctgtct 180 gactttatga ctgacgtccc tgttgaccca ggtgtggtcc accggactcc agttgtagaa 240 ggcctgacag agggggag 258 87 273 DNA Homo sapiens 87 tgggctcctg taggacctgc gatcccagca ccgacgccag ctacacccag ctgccgcctg 60 aacatggact ctgctagcca agatatcaac ctgaattctc ctaacaaagg tgtgctgtct 120 gactttatga ctgacgtccc tgttgaccca ggtgtggtcc accggactcc agttgtagaa 180 ggcctgacag acggggaggc cgactatctt cgggctgatc ttgctattgt ggaagttgat 240 attttcactc tgcgccaggt gctggagcca aag 273 88 529 DNA Homo sapiens 88 cgacatgcca gcttgcagtc ctcggggctg ggctcctgta ggacctgcga tcccagcacc 60 gacgccagct acacccagct gccgcctgaa catggactct gctagccaag atatcaacct 120 gaattctcct aacaaaggtg tgctgtctga ctttatgact gacgtccctg ttgacccagg 180 tgtggtccac cggatccagt tgtagaaggc ctgacagagg gggagtaaga agagcttcgg 240 gctgagcttg ctaagctaca agaagactca agaaactctt tcacaggctg gacagaaaac 300 atcagctgcc ctgtccacca tgggctctgc tatcagcagg aagcttggag acatgaggaa 360 ctcagccacc ttcaagtcat ttgaagaccg agtggggacc ataaagtcta aggttgtggg 420 tggcagagag aatggcagcg ataacctccc tccctctcct ggaagtggtg accagacatt 480 gccggatcat gcgcctttct aagcctgtcc tagcttgcca gccacagag 529 89 420 DNA Homo sapiens 89 cgaatgccag cttgcagtcc tcggggctgg gctcctgtag gacctgcgat cccagcaccg 60 acgccagcta cacccagctg ccgcctgaac atggactctg ctagccaaga tatcaacctg 120 aattctccta acaaaggtgt gctgtctgac tttatgactg acgtccctgt tgacccaggt 180 gtggtccacc ggactccagt tgtagaaggc ctgacagagg gggaggaaga agagcttcgg 240 gctgagcttg ctaaggtgga agaagaaatt gtcactctgc gccaggtgct ggcagccaaa 300 gagaggcact gtggagagct gaaaaggagg ctgggctctc cacattaggg gagctgaagc 360 agaacctgtc taggagctgg catgatgtgc aggtctctac tgcctatgtg aaaacgtctg 420 90 471 DNA Homo sapiens 90 attcggatcc aacgtacgaa gctgccagct tgcagtcctc ggggctgggc tcctgtagga 60 cctgcgatcc cagcaccgac gccagctaca cccagctgcc gcctgaacat ggactctgct 120 agccaagata tcaacctgaa ttctcctaac aaaggtgtgc tgtctgactt tatgactgac 180 gtccctgttg acccaggtgt ggtccaccgg actccagttg tagaaggcct gacagagggg 240 gaggaagaag agcttcgggc tgagcttgct aaggtggaag aagaaattgt cactctgcgc 300 caggtgctgg cagccaaaga gaggcactgt ggagagctga aaaggaggct gggcctctcc 360 acattagggg agctgaagca gaacctgtct aggagctggc atgatgtgca ggtctctact 420 gagtatgtga aaacgtctga gaaacttgga gagtggaatg agaaagtgac g 471 91 399 DNA Homo sapiens 91 ctgccagctt gcagtcctcg gggctgggct cctgtaggac ctgcgatccc agcaccgacg 60 ccagctacac ccagctgccg cctgaacatg gactctgcta gccaagatat caacctgaat 120 tctcctaaca aaggtgtgct gtctgacttt atgactgacg tccctgttga cccaggtgtg 180 gtccaccgga ctccagttgt agaaggcctg acagattggg aggaagaaga gcttcgggct 240 gagcttgcta aggtggaaga agaaattgtc actctgcgcc aggtgctggc agccaaagag 300 aggcactgtg gagagctgaa aaggaggctg ggctctccac attaggggag ctgaagcaga 360 acctgtctag gagctggcat gatgtgcagg tctctactg 399 92 466 DNA Homo sapiens 92 gcggccctac agttccactg gctcgtgtgt acgaagctgc cagcttgcag tcctcggggc 60 tgggctcctg taggacctgc gatcccagca ccgacgccag ctacacccag ctgccgcctg 120 aacatggact ctgctagcca agatatcaac ctgaattctc ctaacaaagg tgtgctgtct 180 gactttatga ctgacgtccc tgttgaccca ggtgtggtcc accggactcc agttgtagaa 240 ggcctgacag acggggaggc agaccagctt cgggctgagc ttgctaaggt ggaagaagat 300 attgtcactc tgcgccaggt gctggcagcc aaagagaggc actgtggaga gctgaaaagg 360 aggctgggct ctccacatta ggggagctga agcagaacct gtctaggagc tggcatgatg 420 tgcaggtctc tactgcctac aagaagactc aagaaactct ttcaca 466 93 232 DNA Homo sapiens 93 gattcggcac tagggcggcc ctacagttcc actggctcgt gtgtacgaag ctgccagctt 60 gcagtcctcg gggctgggct cctgtaggac ctgcgatccc agcaccgacg ccagctacac 120 ccagctgccg cctgaacatg gactctgcta gccaagatat caacctgaat tctcctaaca 180 aaggtgtgct gtctgacttt atgactgacg tccctgttga cccaggtgtg gt 232 94 284 DNA Homo sapiens unsure (3) May be any nucleic acid 94 ctngtgtgta ccaagctgcc agcttgcagt tctcggggct tggctcctgt agtacctgca 60 atcccagcac cgacgncagc tacacccagc tgccgnctga acatggattc tgatagccaa 120 gatatcaacc tganttctcc taacaaaggt ttgctgtctg attttatgac tgatgtccct 180 gttgacccag gtgtggtcca ccggactcca gctgtagagg gcctgaccga ggtggaggaa 240 gaagagctcc gggntngagc ttgntaaggt ggaagaggaa attt 284 95 540 DNA Homo sapiens 95 attcggatcc aacgacttta tgactgacgt ccctgttgac ccaggtgtgg tccaccggac 60 tccagttgta gaaggcctga cagatgggga ggaagaagag cttcgggctg agcttgctaa 120 ggtggaagaa gaaattgtca ctctgcgcca ggtgctggca gccaaagaga ggcactgtgg 180 agagctgaaa aggaggctgg gcctctccac attaggggag ctgaagcaga acctgtctag 240 gagctggcat gatgtgcagg tctctactgc ctacaagaag actcaagaaa ctctttcaca 300 ggctggacag aaaacatcag ctgccctgtc caccatgggc tctgcatcag caggaagctt 360 ggagacatga gcagctactc catccgccac tcgataagta tgcctgtcat gaggaactca 420 gccaccttca agtcatttga agaccgagtg gggaccataa agtctaaggt tgtgggtggc 480 agagagaatg gcagcgataa cctccctccc tctcctggaa gtggtgacca gacattgccg 540 96 235 DNA Homo sapiens 96 gctggacaga aaacatcagc tgccctgtcc accatgggct ctgcatcagc aggaagcttg 60 gagacatgag cagctactcc atccgccact cgataagtat gcctgtcatg aggaactcag 120 ccaccttcaa gtcatttgaa gaccgagtgg ggaccataaa gtctaaggtt gtgggtggca 180 gagagaatgg cagcgataac ctccctccct ctcctggaag tggtgaccag acatt 235 97 224 DNA Homo sapiens unsure (144) May be any nucleic acid 97 cattttcaca ctcctttagc agctactcca tccgccactc aataagtatg ccagccatga 60 ggaactctgc gaccttcaag tcgtttgagg accgagttgg gaccataaag tctaaggttg 120 tgggtgacag agagaacggc agtnaccaac ctcccttcct cagcggggag tggtgacaag 180 cccctgtcgg atcccgganc tttctaagcc tttggttgct tnac 224 98 344 DNA Homo sapiens 98 ccaacaccat atgtgaaaca gaagacatca gctgctctgt ccaccatggg cactctcatc 60 tgcaggaagc ttggaggcgt gaagaagtcg gccacactca gatcttttga aggattgatc 120 ttcaataaat acacgttaaa tcaaggaagg aattaacatc atatacttca gacatcaaat 180 atggaatcca agagactatc aacaacatga acttgttcac aagttccttc tgcttttaaa 240 caaaaatatc gtgtttattc aaagccaatc tgagacccta ctctgtatca agaactgtcc 300 caggttctga aagcatagaa ttagacatcg tatgtgccct ctag 344 99 516 DNA Homo sapiens 99 atttgaagac cgagtgggga ccataaagtc taaggttgtg ggtggcagag agaatggcag 60 cgataacctc cctccctctc ctggaagtgg tgaccagaca ttgccggatc atgcgccttt 120 ctaagcctgt cctagcttgc cagccacaga gtacagaagc acacgctcat catcacagct 180 gcaactctgc atgacagagc caccagccag agacagtgaa gagctggttt tgaagacagt 240 catacccatg ttcatgcaga tgtggctgcc ttggcatgaa ttagagaaca gtcttgtaca 300 taaatgtttt acactaaagt tcgtagatga agcagaccac tgtgccatcc tttcaagggc 360 cacaggaaat ggacagggtg gcggggcact caggcctgag gagcactgaa ccaggagccc 420 tgctcccttt gaaggtctca gcagagtgct gagggaagaa gtgtgagtat tgagtgaaca 480 gtatttcctt cctgacctcc tcccctagct caggag 516 100 354 DNA Homo sapiens 100 atttgaagac cgagtgggga ccataaagtc taaggttgtg ggtggcagag agaatggcag 60 cgataacctc cctccctctc ctggaagtgg tgaccagaca ttgccggatc atgcgccttt 120 ctaagcctgt cctagcttgc cagccacaga gtacagaagc acacgctcat catcacagct 180 gcaactctgc atgacagagc caccagccag agacagtgaa gagctggttt tgaagacagt 240 catacccatg ttcatgcaga tgtggctgcc ttggatgaat tagagaacag tcttgtacat 300 aaatgtttta cactaaagtt cgtagatgaa gcagaccact gtgccatcct ttca 354 101 425 DNA Homo sapiens 101 gtcatttgaa gaccgagtgg ggaccataaa gtctaaggtt gtgggtggca gagagaatgg 60 cagcgataac ctccctccct ctcctggaag tggtgaccag acattgccgg atcatgcgcc 120 tttctaagcc tgtcctagct tgccagccac agagtacaga agcacacgct catcatcaca 180 gctgcaactc tgcatgacag agccaccagc cagagacagt gaagagctgg ttttgaagac 240 agtcataccc atgttcatgc agatgtggct gccttggagt gaattagaga acagtcttgt 300 acataaatgt tttacactaa agttcgtaga tgaagcagac cactgtgcca tcctttcaag 360 ggccacagga aatggacagg gtggcggggc actcaggcct gaggagcact gaaccaggag 420 cctgc 425 102 441 DNA Homo sapiens unsure (209) May be any nucleic acid 102 aggaactctg cgaccttcaa gtcgtttgag gaccgagttg ggaccataaa gtctaaggtt 60 gtgggtgaca gagagaacgg cagtgacaac ctcccttcct cagcggggag tggtgacaag 120 cccctgtcgg atcccgcacc tttctaagcc tgtggttgct tcacccgctg cagagcacac 180 gcaacccagc ctcagcatca cagccgcang ctcgtgttca gcggacgagc nncagccagg 240 cgcggatgag cagagccggc cctgaggaca gtcctgccca tccacgcgga gatgtggctg 300 ccgcgtttgc atgaatttga agaacacagg cttgtacaca gatgttttac actcacgttt 360 gtagatgaaa cagatcactg tgctgtcctt cctaggggtg caggaagtgg acagggcgga 420 gggtttgaaa gaatattgag c 441 103 23 DNA Artificial Sequence Description of Artificial Sequence DNA Primer 103 cgcatgccat ggactccgcc ggc 23 104 30 DNA Artificial Sequence Description of Artificial Sequence DNA Primer 104 tcccccgggg gattagaaag gtgcgggatc 30 105 37 DNA Artificial Sequence Description of Artificial Sequence DNA Primer 105 gcgggagcga ggtggcgcta gcatggaccg cggcgag 37 106 37 DNA Artificial Sequence Description of Artificial Sequence DNA Primer 106 gatgacagag agcccctcta gagccgacct gtgtcct 37 107 17 DNA Artificial Sequence Description of Artificial Sequence DNA Primer 107 tcatcggaag agagtag 17 108 17 DNA Artificial Sequence Description of Artificial Sequence DNA Primer 108 taccactaca atggatg 17 

What is claimed is:
 1. An isolated nucleic acid molecule comprising a polynucleotide at least 90% identical to a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding amino acids 1 to 206 of SEQ ID NO:6; (b) a nucleotide sequence encoding amino acids 2 to 206 of SEQ ID NO:6; (c) a nucleotide sequence encoding amino acids 1 to 186 of SEQ ID NO:15; (d) a nucleotide sequence encoding amino acids 1 to 143 of SEQ ID NO:17; and (e) a nucleotide sequence complementary to the entire sequence of (a), (b), (c) or (d); wherein said isolated nucleic acid molecule is selected from the group consisting of mRNA and cDNA; and wherein said polynucleotide is a prognostic marker for breast cancer.
 2. The isolated nucleic acid molecule of claim 1, comprising a polynucleotide at least 90% identical to a nucleotide sequence encoding amino acids 1 to 206 of SEQ ID NO:6.
 3. The isolated nucleic acid molecule of claim 2, comprising a polynucleotide encoding amino acids 1 to 206 of SEQ ID NO:6.
 4. The isolated nucleic acid molecule of claim 3, comprising nucleotides 77 to 694 of SEQ ID NO:5.
 5. The isolated nucleic acid molecule of claim 1, comprising a polynucleotide at least 90% identical to a nucleotide sequence encoding amino acids 2 to 206 of SEQ ID NO:6.
 6. The isolated nucleic acid molecule of claim 5, comprising a polynucleotide encoding amino acids 2 to 206 of SEQ ID NO:6.
 7. The isolated nucleic acid molecule of claim 6, comprising nucleotides 80 to 694 of SEQ ID NO:5.
 8. The isolated nucleic molecule of claim 1, comprising a polynucleotide at least 90% identical to a nucleotide sequence encoding amino acids 1 to 186 of SEQ ID NO:15.
 9. The isolated nucleic acid molecule of claim 8, comprising a polynucleotide encoding amino acids 1 to 186 of SEQ ID NO:15.
 10. The isolated nucleic acid molecule of claim 1, comprising a polynucleotide at least 90% identical to a nucleotide sequence encoding amino acids 1 to 143 of SEQ ID NO:17.
 11. The isolated nucleic acid molecule of claim 10, comprising a polynucleotide encoding amino acids 1 to 143 of SEQ ID NO:17.
 12. The isolated nucleic acid molecule of claim 1, comprising a polynucleotide at least 90% identical to a nucleotide sequence which is complementary to an entire nucleotide sequence selected from the group consisting of: (a) a polynucleotide encoding amino acids 1 to 206 of SEQ ID NO:6; (b) a polynucleotide encoding amino acids 2 to 206 of SEQ ID NO:6; (c) a polynucleotide encoding amino acids 1 to 186 of SEQ ID NO:15; and (d) a polynucleotide encoding amino acids 1 to 143 of SEQ ID NO:17.
 13. The isolated nucleic acid molecule of claim 1, comprising a polynucleotide complementary to an entire nucleotide sequence selected from the group consisting of: (a) a polynucleotide encoding amino acids 1 to 206 of SEQ ID NO:6; (b) a polynucleotide encoding amino acids 2 to 206 of SEQ ID NO:6; (c) a polynucleotide encoding amino acids 1 to 186 of SEQ ID NO:15; and (d) a polynucleotide encoding amino acids 1 to 143 of SEQ ID NO:17.
 14. The isolated nucleic acid molecule of claim 1, which is cDNA.
 15. The isolated nucleic acid molecule of claim 1, which is mRNA.
 16. A method for making a recombinant vector comprising inserting the isolated nucleic acid molecule of claim 1 into a vector.
 17. A vector comprising the isolated nucleic acid molecule of claim
 1. 18. A method of making are recombinant host cell comprising introducing the recombinant vector of claim 17, into a host cell.
 19. A host cell comprising the isolated nucleic acid molecule of claim
 1. 20. A method for producing a polypeptide comprising culturing the host cell of claim 19 under conditions to produce said polypeptide, and recovering said polypeptide.
 21. An isolated nucleic acid molecule consisting of 15 or more contiguous nucleotides of the coding region of SEQ ID NO:5 or the complement thereof, wherein said isolated polynucleotide is a prognostic marker for breast cancer.
 22. The isolated nucleic acid molecule of claim 21, consisting of 50 or more contiguous nucleotides of the coding region of SEQ ID NO:5 or the complement thereof.
 23. An isolated nucleic acid molecule comprising 200 contiguous nucleotides of the coding region of SEQ ID NO:5 or the complement thereof, wherein said isolated polynucleotide is a prognostic marker for breast cancer.
 24. The isolated nucleic acid molecule of claim 23, comprising 500 contiguous nucleotides of SEQ ID NO:5 or the complement thereof. 